{
  "drug": "Rituximab",
  "fetched_at": "2026-01-16T12:31:35.206975+00:00",
  "drug_class_search": {
    "fetched_at": "2026-01-16T12:31:35.206975+00:00",
    "results": [
      {
        "title": "Mechanism of action of rituximab",
        "url": "https://pubmed.ncbi.nlm.nih.gov/12710585/",
        "content": "Rituximab, the humanized chimeric anti-CD20 monoclonal antibody, represents a powerful tool for treating B-cell malignancies and is licensed for the treatment of relapsed or chemorefractory low-grade or follicular non-Hodgkin's lymphoma (NHL). It has a unique mode of action and can induce killing of CD20+ cells via multiple mechanisms. The direct effects of rituximab include complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity, and the indirect effects include structural changes, apoptosis, and sensitization of cancer cells to chemotherapy. In vitro studies have made a significant contribution to the understanding of these mechanisms of action and have led to the development of innovative and effective treatment strategies to optimize patient response. The [...] Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation\n\n\n\n Search:  Search\n\nAdvancedClipboard\n\nUser Guide\n\n Save  Email \n\nSend to\n\n   Clipboard\n   My Bibliography\n   Collections\n   Citation manager\n\nDisplay options\n\n Display options \n\n Format \n\nSave citation to file\n\n Format:  \n\n Create file  Cancel \n\nEmail citation\n\n Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. \n\n To: \n\n Subject:  \n\n Body:  \n\n Format:  \n\n- [x]  MeSH and other data  \n\n Send email  Cancel \n\n### Add to Collections\n\n   Create a new collection \n   Add to an existing collection \n\n Name your collection:  \n\n Name must be less than 100 characters \n\n Choose a collection:  \n\n Unable to load your collection due to an error\n\nPlease try again",
        "raw_content": "Mechanism of action of rituximab - PubMed\n===============\n\n Clipboard, Search History, and several other advanced features are temporarily unavailable. \n\n[Skip to main page content](https://pubmed.ncbi.nlm.nih.gov/12710585/#article-details)\n\n![Image 1: U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png)\nAn official website of the United States government\n\nHere's how you know\n\n![Image 2: Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg)\n\n**The .gov means it’s official.**\n\n Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.\n\n![Image 3: Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg)\n\n**The site is secure.**\n\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n[![Image 4: NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg)](https://www.ncbi.nlm.nih.gov/)\n\n[Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F12710585%2F)Show account info\n\nClose\n#### Account\n\n Logged in as:\n\n**username**\n\n*   [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/)\n*   [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/)\n*   [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/)\n*   [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/12710585/)\n\n[Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys)[NCBI Homepage](https://www.ncbi.nlm.nih.gov/)[MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/)[Main Content](https://pubmed.ncbi.nlm.nih.gov/12710585/#maincontent)[Main Navigation](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n[](https://pubmed.ncbi.nlm.nih.gov/12710585/)\n\n[![Image 5: pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/2e313790-2c09-494d-b7cb-04cb0d03ced3/core/images/pubmed-logo-blue.svg)](https://pubmed.ncbi.nlm.nih.gov/)[](https://pubmed.ncbi.nlm.nih.gov/12710585/# \"Show search bar\")\n\n Search:  [](https://pubmed.ncbi.nlm.nih.gov/12710585/# \"Clear search input\")Search\n\n[Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/)[Clipboard](https://pubmed.ncbi.nlm.nih.gov/clipboard/)\n\n[User Guide](https://pubmed.ncbi.nlm.nih.gov/help/)\n\n Save  Email \n\nSend to\n\n*   [Clipboard](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n*   [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F12710585%2F%23open-bibliography-panel)\n*   [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F12710585%2F%23open-collections-panel)\n*   [Citation manager](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\nDisplay options\n\n Display options \n\n Format \n\nSave citation to file\n---------------------\n\n Format:  \n\n Create file  Cancel \n\nEmail citation\n--------------\n\n Email address has not been verified. Go to [My NCBI account settings](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. \n\n To: \n\n Subject:  \n\n Body:  \n\n Format:  \n\n- [x]  MeSH and other data  \n\n Send email  Cancel \n\n### Add to Collections\n\n*   Create a new collection \n*   Add to an existing collection \n\n Name your collection:  \n\n Name must be less than 100 characters \n\n Choose a collection:  \n\n Unable to load your collection due to an error\n\n[Please try again](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n Add  Cancel \n\n### Add to My Bibliography\n\n*   My Bibliography \n\n Unable to load your delegates due to an error\n\n[Please try again](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n Add  Cancel \n\nYour saved search\n-----------------\n\n Name of saved search:  \n\n Search terms:  \n\n[Test search terms](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n Would you like email updates of new search results? Saved Search Alert Radio Buttons\n*   Yes \n*   No \n\n Email:   ([change](https://www.ncbi.nlm.nih.gov/account/settings/))\n\n Frequency:  \n\n Which day?  \n\n Which day?  \n\n Report format:  \n\n Send at most:  \n\n- [x]  Send even when there aren't any new results  \n\n Optional text in email:  \n\n Save  Cancel \n\nCreate a file for external citation management software\n-------------------------------------------------------\n\n Create file  Cancel \n\nYour RSS Feed\n-------------\n\n Name of RSS Feed:  \n\n Number of items displayed:  \n\n Create RSS  Cancel \n\nRSS Link  Copy \n\n### Full text links\n\n[![Image 6: Wolters Kluwer full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--static.lww.com-pubmed-wolters-kluwer-non-oa-articles.png) Wolters Kluwer](https://doi.org/10.1097/00001813-200211002-00002 \"See full text options at Wolters Kluwer\")\n\n[Full text links](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n### Actions\n\nCite\n\nCollections\n\nAdd to Collections\n\n*   Create a new collection \n*   Add to an existing collection \n\n Name your collection:  \n\n Name must be less than 100 characters \n\n Choose a collection:  \n\n Unable to load your collection due to an error\n\n[Please try again](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n Add  Cancel \n\nPermalink\n\nPermalink\n\nCopy\n\nDisplay options\n\n Display options \n\n Format \n\n### Page navigation\n\n*   [Title & authors](https://pubmed.ncbi.nlm.nih.gov/12710585/#heading)\n*   [Abstract](https://pubmed.ncbi.nlm.nih.gov/12710585/#abstract)\n*   [Similar articles](https://pubmed.ncbi.nlm.nih.gov/12710585/#similar)\n*   [Cited by](https://pubmed.ncbi.nlm.nih.gov/12710585/#citedby)\n*   [Publication types](https://pubmed.ncbi.nlm.nih.gov/12710585/#publication-types)\n*   [MeSH terms](https://pubmed.ncbi.nlm.nih.gov/12710585/#mesh-terms)\n*   [Substances](https://pubmed.ncbi.nlm.nih.gov/12710585/#substances)\n*   [Related information](https://pubmed.ncbi.nlm.nih.gov/12710585/#related-links)\n*   [LinkOut - more resources](https://pubmed.ncbi.nlm.nih.gov/12710585/#linkout)\n\nReview\n\n Anticancer Drugs \n\nActions\n\n*   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anticancer+Drugs%22%5Bjour%5D&sort=date&sort_order=desc)\n*   [Search in NLM Catalog](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Anticancer+Drugs%22%5BTitle+Abbreviation%5D)\n*   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n. 2002 Nov:13 Suppl 2:S3-10.\n\n doi: 10.1097/00001813-200211002-00002. \n\nMechanism of action of rituximab\n================================\n\n[Thomas Cerny](https://pubmed.ncbi.nlm.nih.gov/?term=Cerny+T&cauthor_id=12710585)[1](https://pubmed.ncbi.nlm.nih.gov/12710585/#full-view-affiliation-1 \"Division of Oncology/Hematology, Department of Internal Medicine, Kantonsspital St Gallen, Switzerland. mcca@ms1.kssg.ch\"),[Bettina Borisch](https://pubmed.ncbi.nlm.nih.gov/?term=Borisch+B&cauthor_id=12710585),[Martino Introna](https://pubmed.ncbi.nlm.nih.gov/?term=Introna+M&cauthor_id=12710585),[Peter Johnson](https://pubmed.ncbi.nlm.nih.gov/?term=Johnson+P&cauthor_id=12710585),[Andrea L Rose](https://pubmed.ncbi.nlm.nih.gov/?term=Rose+AL&cauthor_id=12710585)\n\n Affiliations  Expand \n\n### Affiliation\n\n*   1 Division of Oncology/Hematology, Department of Internal Medicine, Kantonsspital St Gallen, Switzerland. mcca@ms1.kssg.ch\n\n*    PMID: **12710585**\n*    DOI: [10.1097/00001813-200211002-00002](https://doi.org/10.1097/00001813-200211002-00002)\n\n Item in Clipboard \n\nReview\n\nMechanism of action of rituximab\n================================\n\nThomas Cerny et al. Anticancer Drugs.2002 Nov.\n\nShow details\n\nDisplay options\n\n Display options \n\n Format \n\n Anticancer Drugs \n\nActions\n\n*   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Anticancer+Drugs%22%5Bjour%5D&sort=date&sort_order=desc)\n*   [Search in NLM Catalog](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Anticancer+Drugs%22%5BTitle+Abbreviation%5D)\n*   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n. 2002 Nov:13 Suppl 2:S3-10.\n\n doi: 10.1097/00001813-200211002-00002. \n\n### Authors\n\n[Thomas Cerny](https://pubmed.ncbi.nlm.nih.gov/?term=Cerny+T&cauthor_id=12710585)[1](https://pubmed.ncbi.nlm.nih.gov/12710585/#short-view-affiliation-1 \"Division of Oncology/Hematology, Department of Internal Medicine, Kantonsspital St Gallen, Switzerland. mcca@ms1.kssg.ch\"),[Bettina Borisch](https://pubmed.ncbi.nlm.nih.gov/?term=Borisch+B&cauthor_id=12710585),[Martino Introna](https://pubmed.ncbi.nlm.nih.gov/?term=Introna+M&cauthor_id=12710585),[Peter Johnson](https://pubmed.ncbi.nlm.nih.gov/?term=Johnson+P&cauthor_id=12710585),[Andrea L Rose](https://pubmed.ncbi.nlm.nih.gov/?term=Rose+AL&cauthor_id=12710585)\n\n### Affiliation\n\n*   1 Division of Oncology/Hematology, Department of Internal Medicine, Kantonsspital St Gallen, Switzerland. mcca@ms1.kssg.ch\n\n*    PMID: **12710585**\n*    DOI: [10.1097/00001813-200211002-00002](https://doi.org/10.1097/00001813-200211002-00002)\n\n Item in Clipboard \n\n Full text links Cite\n\nDisplay options\n\n Display options \n\n Format \n\nAbstract\n--------\n\nRituximab, the humanized chimeric anti-CD20 monoclonal antibody, represents a powerful tool for treating B-cell malignancies and is licensed for the treatment of relapsed or chemorefractory low-grade or follicular non-Hodgkin's lymphoma (NHL). It has a unique mode of action and can induce killing of CD20+ cells via multiple mechanisms. The direct effects of rituximab include complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity, and the indirect effects include structural changes, apoptosis, and sensitization of cancer cells to chemotherapy. In vitro studies have made a significant contribution to the understanding of these mechanisms of action and have led to the development of innovative and effective treatment strategies to optimize patient response. The most significant of these strategies is the combination of rituximab and CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone), which is proving a highly effective combination in the treatment of NHL. However, all patients do not respond equally well to rituximab, and in vitro studies have identified a possible mechanism of resistance involving the anti-complement inhibitors CD55 and CD59. Neutralizing antibodies to CD55 and CD59 can overcome resistance to rituximab-mediated complement-mediated cytotoxicity in vitro. This paper overviews our understanding of the mechanisms of action of rituximab and identifies how this knowledge could be applied in a clinical setting to maximize response in both sensitive and resistant patients.\n\n[PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/)\n\nSimilar articles\n----------------\n\n*   [The therapeutic use of rituximab in non-Hodgkin's lymphoma.](https://pubmed.ncbi.nlm.nih.gov/17206982/)Marcus R, Hagenbeek A.Marcus R, et al.Eur J Haematol Suppl. 2007 Jan;(67):5-14. doi: 10.1111/j.1600-0609.2006.00789.x.Eur J Haematol Suppl. 2007.PMID: 17206982 Review.  \n*   [Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.](https://pubmed.ncbi.nlm.nih.gov/17335294/)Fanale MA, Younes A.Fanale MA, et al.Drugs. 2007;67(3):333-50. doi: 10.2165/00003495-200767030-00002.Drugs. 2007.PMID: 17335294 Review.  \n*   [An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.](https://pubmed.ncbi.nlm.nih.gov/12649096/)Boye J, Elter T, Engert A.Boye J, et al.Ann Oncol. 2003 Apr;14(4):520-35. doi: 10.1093/annonc/mdg175.Ann Oncol. 2003.PMID: 12649096 Review.  \n*   [Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.](https://pubmed.ncbi.nlm.nih.gov/19662541/)Dzietczenia J, Wróbel T, Mazur G, Poreba R, Jaźwiec B, Kuliczkowski K.Dzietczenia J, et al.Med Oncol. 2010 Sep;27(3):743-6. doi: 10.1007/s12032-009-9278-9. Epub 2009 Aug 7.Med Oncol. 2010.PMID: 19662541  \n*   [Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.](https://pubmed.ncbi.nlm.nih.gov/15042528/)Coiffier B.Coiffier B.Semin Oncol. 2004 Feb;31(1 Suppl 2):7-11.Semin Oncol. 2004.PMID: 15042528 Review.  \n\n[See all similar articles](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=12710585)\n\nCited by\n--------\n\n*   [Immune infiltrate diversity confers a good prognosis in follicular lymphoma.](https://pubmed.ncbi.nlm.nih.gov/33929583/)Tsakiroglou AM, Astley S, Dave M, Fergie M, Harkness E, Rosenberg A, Sperrin M, West C, Byers R, Linton K.Tsakiroglou AM, et al.Cancer Immunol Immunother. 2021 Dec;70(12):3573-3585. doi: 10.1007/s00262-021-02945-0. Epub 2021 Apr 30.Cancer Immunol Immunother. 2021.PMID: 33929583 Free PMC article.  \n*   [Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias.](https://pubmed.ncbi.nlm.nih.gov/35011701/)Panuciak K, Margas M, Makowska K, Lejman M.Panuciak K, et al.Cells. 2022 Jan 2;11(1):139. doi: 10.3390/cells11010139.Cells. 2022.PMID: 35011701 Free PMC article.Review.  \n*   [Advances in B Cell Targeting for Treating Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis.](https://pubmed.ncbi.nlm.nih.gov/39678139/)Hu G, Zhao X, Wang Y, Zhu X, Sun Z, Yu X, Wang J, Liu Q, Zhang J, Zhang Y, Yang J, Chang T, Ruan Z, Lv J, Gao F.Hu G, et al.Immunotargets Ther. 2024 Dec 11;13:707-720. doi: 10.2147/ITT.S492062. eCollection 2024.Immunotargets Ther. 2024.PMID: 39678139 Free PMC article.Review.  \n*   [The Role of Novel Immunomodulators in the Treatment of Autoimmune Hepatitis.](https://pubmed.ncbi.nlm.nih.gov/40474885/)Li J, Wang H, Lin J, Wang A, Miao S, Liu H.Li J, et al.J Clin Transl Hepatol. 2025 Jun 28;13(6):493-503. doi: 10.14218/JCTH.2025.00008. Epub 2025 May 13.J Clin Transl Hepatol. 2025.PMID: 40474885 Free PMC article.Review.  \n*   [Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy.](https://pubmed.ncbi.nlm.nih.gov/27579294/)Al-Shammari AM, Rameez H, Al-Taee MF.Al-Shammari AM, et al.Oncolytic Virother. 2016 Apr 20;5:27-34. doi: 10.2147/OV.S95250. eCollection 2016.Oncolytic Virother. 2016.PMID: 27579294 Free PMC article.  \n\n[See all \"Cited by\" articles](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed_citedin&from_uid=12710585)\n\nPublication types\n-----------------\n\n*   \n Review \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Review)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\nMeSH terms\n----------\n\n*   \n Antibodies, Monoclonal / pharmacology* \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Monoclonal%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Antibodies%2C+Monoclonal)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n*   \n Antibodies, Monoclonal / therapeutic use \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Monoclonal%2Ftherapeutic+use%22%5BMeSH%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Antibodies%2C+Monoclonal)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n*   \n Antibodies, Monoclonal, Murine-Derived \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Monoclonal%2C+Murine-Derived%22%5BMeSH%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Antibodies%2C+Monoclonal%2C+Murine-Derived)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n*   \n Antineoplastic Agents / pharmacology* \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Fpharmacology%22%5BMAJR%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n*   \n Antineoplastic Agents / therapeutic use \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%2Ftherapeutic+use%22%5BMeSH%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Agents)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n*   \n Antineoplastic Combined Chemotherapy Protocols / pharmacology \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Combined+Chemotherapy+Protocols%2Fpharmacology%22%5BMeSH%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Combined+Chemotherapy+Protocols)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n*   \n Antineoplastic Combined Chemotherapy Protocols / therapeutic use \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Combined+Chemotherapy+Protocols%2Ftherapeutic+use%22%5BMeSH%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Antineoplastic+Combined+Chemotherapy+Protocols)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n*   \n Apoptosis \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Apoptosis%22%5BMeSH%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Apoptosis)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n*   \n Drug Resistance, Neoplasm \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Drug+Resistance%2C+Neoplasm%22%5BMeSH%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Drug+Resistance%2C+Neoplasm)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n*   \n Humans \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Humans%22%5BMeSH%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Humans)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n*   \n Lymphoma, Non-Hodgkin / drug therapy \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Lymphoma%2C+Non-Hodgkin%2Fdrug+therapy%22%5BMeSH%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Lymphoma%2C+Non-Hodgkin)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n*   \n Rituximab \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Rituximab%22%5BMeSH%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=Rituximab)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\nSubstances\n----------\n\n*   \n Antibodies, Monoclonal \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Monoclonal%22%5Bnm%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=%22Antibodies%2C+Monoclonal%22)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n*   \n Antibodies, Monoclonal, Murine-Derived \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antibodies%2C+Monoclonal%2C+Murine-Derived%22%5Bnm%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=%22Antibodies%2C+Monoclonal%2C+Murine-Derived%22)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n*   \n Antineoplastic Agents \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Antineoplastic+Agents%22%5Bnm%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=%22Antineoplastic+Agents%22)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n*   \n Rituximab \n\nActions \n\n    *   [Search in PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=%22Rituximab%22%5Bnm%5D&sort=date&sort_order=desc)\n    *   [Search in MeSH](https://www.ncbi.nlm.nih.gov/mesh?term=%22Rituximab%22)\n    *   [Add to Search](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\nRelated information\n-------------------\n\n*   [PubChem Compound](https://www.ncbi.nlm.nih.gov/pccompound?linkname=pubmed_pccompound&from_uid=12710585 \"Related PubChem Compound\")\n*   [PubChem Substance](https://www.ncbi.nlm.nih.gov/pcsubstance?linkname=pubmed_pcsubstance&from_uid=12710585 \"Related PubChem Substance\")\n\nLinkOut - more resources\n------------------------\n\n*   ### Full Text Sources\n\n    *   [Ovid Technologies, Inc.](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=12710585.ui)\n    *   [Wolters Kluwer](https://doi.org/10.1097/00001813-200211002-00002)\n\n*   ### Other Literature Sources\n\n    *   [The Lens - Patent Citations Database](https://www.lens.org/lens/search/patent/list?q=reference_cited.npl.ids.pmid:12710585)\n\n*   ### Research Materials\n\n    *   [NCI CPTC Antibody Characterization Program](https://antibodies.cancer.gov/detail/CPTC-DDIT3-1)\n\n*   ### Miscellaneous\n\n    *   [NCI CPTAC Assay Portal](https://assays.cancer.gov/CPTAC-43)\n\n**Full text links**[x]\n\n[![Image 7: Wolters Kluwer full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--static.lww.com-pubmed-wolters-kluwer-non-oa-articles.png) Wolters Kluwer](https://doi.org/10.1097/00001813-200211002-00002 \"See full text options at Wolters Kluwer\")\n\n[x]\n\nCite\n\n Copy Download .nbib.nbib\n\nFormat: \n\n**Send To**\n*   [Clipboard](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n*   [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F12710585%2F%23open-email-panel)\n*   [Save](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n*   [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F12710585%2F%23open-bibliography-panel)\n*   [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F12710585%2F%23open-collections-panel)\n*   [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/12710585/#)\n\n[x]\n\nNCBI Literature Resources\n\n[MeSH](https://www.ncbi.nlm.nih.gov/mesh/)[PMC](https://www.ncbi.nlm.nih.gov/pmc/)[Bookshelf](https://www.ncbi.nlm.nih.gov/books)[Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/)\n\nThe PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.\n\nFollow NCBI\n\n[](https://twitter.com/ncbi)[](https://www.facebook.com/ncbi.nlm)[](https://www.linkedin.com/company/ncbinlm)[](https://github.com/ncbi)[](https://ncbiinsights.ncbi.nlm.nih.gov/)\n\n[Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html)\n\n*   [](https://twitter.com/NLM_NIH)\n*   [](https://www.facebook.com/nationallibraryofmedicine)\n*   [](https://www.youtube.com/user/NLMNIH)\n\nNational Library of Medicine\n\n[8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323)\n\n[Web Policies](https://www.nlm.nih.gov/web_policies.html)\n\n[FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office)\n\n[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n[Help](https://support.nlm.nih.gov/?pagename=pubmed%3Apubmed%3Aabstract%3ANONE)\n\n[Accessibility](https://www.nlm.nih.gov/accessibility.html)\n\n[Careers](https://www.nlm.nih.gov/careers/careers.html)\n\n*   [NLM](https://www.nlm.nih.gov/)\n*   [NIH](https://www.nih.gov/)\n*   [HHS](https://www.hhs.gov/)\n*   [USA.gov](https://www.usa.gov/)"
      },
      {
        "title": "Rituximab - PubChem - NIH",
        "url": "https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab",
        "content": "DrugBank\n\nRituximab is a CD20-directed Cytolytic Antibody. The mechanism of action of rituximab is as a CD20-directed Antibody Interaction. \n\nFDA Pharm Classes\n\nRituximab is a chimeric mouse/human monoclonal antibody to CD20 a cell surface antigen found on pre-B and mature B lymphocytes and which is approved for use in non-Hodgkin lymphoma and chronic lymphocytic leukemia as well as in several autoimmune conditions, including rheumatoid arthritis and Wegener granulomatous. Rituximab has been linked to many cases of severe and even fatal liver injury as a result of reactivation of inactive or previously resolved hepatitis B. \n\nLiverTox\n\nView More...\n\nSee also: Rituximab-Abbs (has subclass); Rituximab-Arrx (has subclass); Rituximab-Pvvr (has subclass).\n\n1 Synonyms [...] Pharmacological Classes\n\nEstablished Pharmacologic Class [EPC] - CD20-directed Cytolytic Antibody \n\nFDA Pharmacology Summary\n\nRituximab is a CD20-directed Cytolytic Antibody. The mechanism of action of rituximab is as a CD20-directed Antibody Interaction. \n\nFDA Pharm Classes\n\n2 of 2 items\n\nNon-Proprietary Name\n\nRITUXIMAB \n\nPharmacological Classes\n\nCD20-directed Antibody Interactions [MoA]; CD20-directed Cytolytic Antibody [EPC] \n\nNational Drug Code (NDC) Directory\n\n### 7.4 ATC Code\n\nL01FA01 \n\nEuropean Medicines Agency (EMA); WHO Model Lists of Essential Medicines\n\nL01XC02 \n\nEuropean Medicines Agency (EMA)\n\nL - Antineoplastic and immunomodulating agents\n\nL01 - Antineoplastic agents\n\nL01F - Monoclonal antibodies and antibody drug conjugates [...] Rituximab is a monoclonal antibody that targets CD20, an antigen expressed on the surface of pre-B and mature B-lymphocytes. About 85% of non-Hodgkin’s lymphoma (NHL) cases are B-cell lymphomas, characterized by the high expression of CD19, CD20 and CD22 cell surface antigens. CD20 is involved in cell cycle regulation, apoptosis and calcium signaling. By targeting CD20, rituximab promotes cell lysis while sparing hematopoietic and plasma cells without this surface antigen. It has been suggested that cell lysis mechanisms triggered by rituximab include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Rituximab is part of the immunoglobulin G1 (IgG1) subclass of antibodies, and is formed by a murine variable region (Fab region) and a human",
        "raw_content": "Rituximab - PubChem\n===============\n\nAn official website of the United States government\n\nHere is how you know\n\n**The .gov means it’s official.**\nFederal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.\n\n**The site is secure.**\nThe **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n[NIH National Library of Medicine NCBI](https://www.ncbi.nlm.nih.gov/)\n\n[PubChem](https://pubchem.ncbi.nlm.nih.gov/)\n*   [About](https://pubchem.ncbi.nlm.nih.gov/docs/about)\n*   [Docs](https://pubchem.ncbi.nlm.nih.gov/docs)\n*   [Submit](https://pubchem.ncbi.nlm.nih.gov/submit/)\n*   [Contact](https://pubchem.ncbi.nlm.nih.gov/docs/contact)\n*   Theme Settings \n\nSearch PubChem \n\nDraw\n\nID File\n\nSubmit search\n\nAdvanced Search\n\n[Search History](https://pubchem.ncbi.nlm.nih.gov/history)\n\n[Help](https://pubchem.ncbi.nlm.nih.gov/docs/quick-search)\n\n[refchem](https://pubchem.ncbi.nlm.nih.gov/refchem/)\nRituximab\n=========\n\nPubChem Reference Collection SID\n\n[481101830](https://pubchem.ncbi.nlm.nih.gov/substance/481101830)\n\nPubChem CID\n\nNot available and might not be a discrete structure.\n\nPrimary Hazards\n\n[![Image 2: Health Hazard](https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS08.svg)](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=GHS-Classification)\n\n[Laboratory Chemical Safety Summary (LCSS) Datasheet](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#datasheet=LCSS)\n\nDescription\n\nRituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences,. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL), however, has now been approved for a variety of conditions. On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab).\n\nDrugBank\n\nRituximab is a CD20-directed Cytolytic Antibody. The mechanism of action of rituximab is as a CD20-directed Antibody Interaction. \n\nFDA Pharm Classes\n\nRituximab is a chimeric mouse/human monoclonal antibody to CD20 a cell surface antigen found on pre-B and mature B lymphocytes and which is approved for use in non-Hodgkin lymphoma and chronic lymphocytic leukemia as well as in several autoimmune conditions, including rheumatoid arthritis and Wegener granulomatous. Rituximab has been linked to many cases of severe and even fatal liver injury as a result of reactivation of inactive or previously resolved hepatitis B. \n\nLiverTox\n\nView More...\n\nSee also: [Rituximab-Abbs](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab%2DAbbs) (has subclass); [Rituximab-Arrx](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab%2DArrx) (has subclass); [Rituximab-Pvvr](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab%2DPvvr) (has subclass).\n\n1 Synonyms[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Synonyms&fullscreen=true \"Open this section in a new browser window\")\n----------------------------------------------------------------------------------------------------------------------------------------------\n\n*   Rituximab \n*   RefChem:490 \n*   174722-31-7 \n*   4F4X42SYQ6 \n*   IDEC-C2B8 \n*   HSDB 7455 \n*   IDEC-102 \n*   PF-05280586 \n*   UNII-4F4X42SYQ6 \n*   ABP 798 \n*   BI 695500 \n*   C2B8 Monoclonal Antibody \n*   CD20 Antibody, Rituximab \n*   CHEBI:64357 \n*   Chimeric Anti-CD20 Antibody \n*   DTXSID5040910 \n*   IDEC-C2B8 Monoclonal Antibody \n*   L01XC02 \n*   Mab Thera \n*   Monoclonal Antibody IDEC-C2B8 \n*   NSC687451 \n*   PF 05280586 \n*   RG-105 \n*   RITUXAN HYCELA COMPONENT RITUXIMAB \n*   RITUXIMAB (MART.) \n*   RITUXIMAB (PURPLE BOOK CDER) \n*   RITUXIMAB COMPONENT OF RITUXAN HYCELA \n*   RTXM83 \n*   Rituximab Biosimilar ABP 798 \n*   Rituximab Biosimilar BI 695500 \n*   Rituximab Biosimilar CT-P10 \n*   Rituximab Biosimilar GB241 \n*   Rituximab Biosimilar IBI301 \n*   Rituximab Biosimilar JHL1101 \n*   Rituximab Biosimilar PF-05280586 \n*   Rituximab Biosimilar RTXM83 \n*   Rituximab Biosimilar SAIT101 \n*   Rituximab Biosimilar SIBP-02 \n*   Rituximab CD20 Antibody \n*   Truximab \n*   USP MAB 001, MONOCLONAL IGG1 (USP-RS) \n*   rituximab biosimilar TQB2303 \n*   rituximabum \n\nPubChem\n\n2 MeSH Entry Terms[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=MeSH-Entry-Terms&fullscreen=true \"Open this section in a new browser window\")\n--------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n*   Rituximab \n*   CD20 Antibody, Rituximab \n\nMedical Subject Headings (MeSH)\n\n3 Names and Identifiers[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Names-and-Identifiers&fullscreen=true \"Open this section in a new browser window\")\n------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 3.1 Other Identifiers[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Other-Identifiers&fullscreen=true \"Open this section in a new browser window\")\n\n#### 3.1.1 CAS[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=CAS&fullscreen=true \"Open this section in a new browser window\")\n\n174722-31-7 \n\nEuropean Chemicals Agency (ECHA); Hazardous Substances Data Bank (HSDB); CAS Common Chemistry; ChemIDplus; DrugBank; EPA DSSTox; FDA Global Substance Registration System (GSRS)\n\nDTP/NCI\n\n#### 3.1.2 European Community (EC) Number[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=European-Community-EC-Number&fullscreen=true \"Open this section in a new browser window\")\n\n[695-706-4](https://chem.echa.europa.eu/100.224.382)\n\nEuropean Chemicals Agency (ECHA)\n\n#### 3.1.3 UNII[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=UNII&fullscreen=true \"Open this section in a new browser window\")\n\n[4F4X42SYQ6](https://gsrs.ncats.nih.gov/ginas/app/beta/substances/4F4X42SYQ6)\n\nFDA Global Substance Registration System (GSRS)\n\n#### 3.1.4 DrugBank ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=DrugBank-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[DB00073](https://www.drugbank.ca/drugs/DB00073)\n\nDrugBank\n\n#### 3.1.5 DSSTox Substance ID[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=DSSTox-Substance-ID&fullscreen=true \"Open this section in a new browser window\")\n\n[DTXSID5040910](https://comptox.epa.gov/dashboard/DTXSID5040910)\n\nEPA DSSTox\n\n#### 3.1.6 NCI Thesaurus Code[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=NCI-Thesaurus-Code&fullscreen=true \"Open this section in a new browser window\")\n\n[C1702](https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1702)\n\nNCI Thesaurus (NCIt)\n\n#### 3.1.7 Nikkaji Number[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Nikkaji-Number&fullscreen=true \"Open this section in a new browser window\")\n\n[J1.653.613J](http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J1.653.613J)\n\nJapan Chemical Substance Dictionary (Nikkaji)\n\n#### 3.1.8 NSC Number[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=NSC-Number&fullscreen=true \"Open this section in a new browser window\")\n\n[687451](https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=687451)\n\nDTP/NCI\n\n#### 3.1.9 RXCUI[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=RXCUI&fullscreen=true \"Open this section in a new browser window\")\n\n[121191](https://rxnav.nlm.nih.gov/id/rxnorm/121191)\n\nNLM RxNorm Terminology\n\n4 Chemical and Physical Properties[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Chemical-and-Physical-Properties&fullscreen=true \"Open this section in a new browser window\")\n----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 4.1 Experimental Properties[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Experimental-Properties&fullscreen=true \"Open this section in a new browser window\")\n\n#### 4.1.1 Melting Point[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Melting-Point&fullscreen=true \"Open this section in a new browser window\")\n\n61 °C (FAB fragment)\n\n[http://crdd.osdd.net/raghava/thpdb/display_thppid_sub.php?details=Th1062](http://crdd.osdd.net/raghava/thpdb/display_thppid_sub.php?details=Th1062)\n\nDrugBank\n\n#### 4.1.2 Hydrophobicity[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Hydrophobicity&fullscreen=true \"Open this section in a new browser window\")\n\n-0.414 \n\n[http://crdd.osdd.net/raghava/thpdb/display_thppid_sub.php?details=Th1062](http://crdd.osdd.net/raghava/thpdb/display_thppid_sub.php?details=Th1062)\n\nDrugBank\n\n#### 4.1.3 Isoelectric Point[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Isoelectric-Point&fullscreen=true \"Open this section in a new browser window\")\n\n8.68 \n\n[http://crdd.osdd.net/raghava/thpdb/display_thppid_sub.php?details=Th1062](http://crdd.osdd.net/raghava/thpdb/display_thppid_sub.php?details=Th1062)\n\nDrugBank\n\n#### 4.1.4 Other Experimental Properties[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Other-Experimental-Properties&fullscreen=true \"Open this section in a new browser window\")\n\nComposed of 2 heavy chains of 451 amino acids and 2 light chains of 213 amino acids \n\nO'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 10\n\nHazardous Substances Data Bank (HSDB)\n\nFormulation is a sterile, clear, colorless, preservative-free liquid concentrate \n\nPhysicians Desk Reference 60th ed, Thomson PDR, Montvale, NJ 2006., p. 1251\n\nHazardous Substances Data Bank (HSDB)\n\n### 4.2 Chemical Classes[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Chemical-Classes&fullscreen=true \"Open this section in a new browser window\")\n\n#### 4.2.1 Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Drugs&fullscreen=true \"Open this section in a new browser window\")\n\n##### 4.2.1.1 Human Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Human-Drugs&fullscreen=true \"Open this section in a new browser window\")\n\nBreast Feeding; Lactation; Milk, Human; Antibodies, Monoclonal; Antirheumatic Agents; Antineoplastic Agents \n\nDrugs and Lactation Database (LactMed)\n\nHuman drug -> Active ingredient (RITUXIMAB) \n\nDrugs@FDA\n\nHuman drugs -> Antineoplastic agents -> Human pharmacotherapeutic group -> EMA Drug Category \n\nEuropean Medicines Agency (EMA)\n\nPaediatric drug \n\nEuropean Medicines Agency (EMA)\n\nRare disease (orphan) drug \n\nEuropean Medicines Agency (EMA)\n\nMedicines for multiple sclerosis\n\nTargeted therapies\n\nWHO Model Lists of Essential Medicines\n\n##### 4.2.1.2 Biologics[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Biologics&fullscreen=true \"Open this section in a new browser window\")\n\nBiologic product () -> Rx -> FDA Purple Book \n\nFDA Purple Book\n\nBiologic product () -> Disc -> FDA Purple Book \n\nFDA Purple Book\n\n5 Related Records[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Related-Records&fullscreen=true \"Open this section in a new browser window\")\n------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 5.1 Substances[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Substances&fullscreen=true \"Open this section in a new browser window\")\n\n#### 5.1.1 PubChem Reference Collection SID[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=PubChem-Reference-Collection-SID&fullscreen=true \"Open this section in a new browser window\")\n\n[481101830](https://pubchem.ncbi.nlm.nih.gov/substance/481101830)\n\nPubChem\n\n### 5.2 Other Relationships[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Other-Relationships&fullscreen=true \"Open this section in a new browser window\")\n\n*   [Rituximab-Abbs](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab%2DAbbs) (has subclass)\n*   [Rituximab-Arrx](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab%2DArrx) (has subclass)\n*   [Rituximab-Pvvr](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab%2DPvvr) (has subclass)\n\nPubChem\n\n6 Drug and Medication Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Drug-and-Medication-Information&fullscreen=true \"Open this section in a new browser window\")\n--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 6.1 Drug Indication[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Drug-Indication&fullscreen=true \"Open this section in a new browser window\")\n\nRituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Additionally, rituximab is indicated for the treatment of adult patients with non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy; and previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. Rituximab, in combination with fludarabine and cyclophosphamide (FC), is indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL). In combination with methotrexate, rituximab is indicated for the treatment of adult patients with moderately-to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. Additionally, rituximab, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA). RITUXAN (rituximab injection for intravenous use) is indicated for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy; as well as the treatment of adult patients with moderate to severe pemphigus vulgaris. These indications for RITUXAN are not included in the labels of rituximab biosimilar products (rituximab-arrx, rituximab-abbs, rituximab-pvvr). The combination product RITUXAN HYCELA (rituximab and hyaluronidase human injection, for subcutaneous use) is not indicated for the treatment of non-malignant conditions. \n\nDrugBank\n\n[FDA Label](http://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00073.pdf?1543595004)\n\nDrugBank\n\nRiximyo is indicated in adults for the following indications: Non-Hodgkin's lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy. Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL). Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy. See section 5. 1 for further information. Rheumatoid arthritis Riximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies. Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA). Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener's) and MPA. Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV). \n\nEuropean Medicines Agency (EMA)\n\nView More...\n\n### 6.2 LiverTox Summary[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=LiverTox-Summary&fullscreen=true \"Open this section in a new browser window\")\n\nRituximab is a chimeric mouse/human monoclonal antibody to CD20 a cell surface antigen found on pre-B and mature B lymphocytes and which is approved for use in non-Hodgkin lymphoma and chronic lymphocytic leukemia as well as in several autoimmune conditions, including rheumatoid arthritis and Wegener granulomatous. Rituximab has been linked to many cases of severe and even fatal liver injury as a result of reactivation of inactive or previously resolved hepatitis B. \n\nLiverTox\n\n### 6.3 Drug Classes[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Drug-Classes&fullscreen=true \"Open this section in a new browser window\")\n\nBreast Feeding; Lactation; Milk, Human; Antibodies, Monoclonal; Antirheumatic Agents; Antineoplastic Agents \n\nDrugs and Lactation Database (LactMed)\n\nAntineoplastic Agents \n\nLiverTox\n\n### 6.4 FDA Medication Guides[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=FDA-Medication-Guides&fullscreen=true \"Open this section in a new browser window\")\n\n1 of 2 items\n\nDrug\n\nActive Ingredient\n\nForm;Route\n\nCompany\n\nDate\n\nDrug\n\n[RITUXAN](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5465lbl.pdf#page=56)\n\nActive Ingredient\n\nRituximab \n\nForm;Route\n\nSOLUTION;INTRAVENOUS \n\nCompany\n\nGENENTECH \n\nDate\n\n12/17/2021 \n\nFDA Medication Guides\n\n2 of 2 items\n\nDrug\n\nActive Ingredient\n\nForm;Route\n\nCompany\n\nDate\n\nDrug\n\n[RITUXAN HYCELA](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761064s013lbl.pdf#page=28)\n\nActive Ingredient\n\nRituximab; Hyaluronidase (Human Recombinant) \n\nForm;Route\n\nSOLUTION;SUBCUTANEOUS \n\nCompany\n\nGENENTECH INC \n\nDate\n\n6/10/2021 \n\nFDA Medication Guides\n\n### 6.5 WHO Essential Medicines[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=WHO-Essential-Medicines&fullscreen=true \"Open this section in a new browser window\")\n\nDrug\n\nDrug Classes\n\nFormulation\n\nIndication\n\nDrug\n\n[Rituximab](https://list.essentialmeds.org/medicines/104)\n\nDrug Classes\n\nMedicines for multiple sclerosis \n\nFormulation\n\nParenteral - General injections - IV: 500 mg per 50 mL in 50 mL vial \n\nIndication\n\nMultiple sclerosis \n\nDrug\n\n[Rituximab](https://list.essentialmeds.org/medicines/104)\n\nDrug Classes\n\nTargeted therapies \n\nFormulation\n\nParenteral - General injections - IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial \n\nIndication\n\n(1) Follicular lymphoma; (2) Chronic lymphocytic leukaemia or small lymphocytic lymphoma; (3) Diffuse large B-cell lymphomas; (4) Burkitt lymphoma including Burkitt leukaemia \n\nWHO Model Lists of Essential Medicines\n\n### 6.6 FDA Approved Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=FDA-Approved-Drugs&fullscreen=true \"Open this section in a new browser window\")\n\nDrugs@FDA\n\n### 6.7 FDA Purple Book[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=FDA-Purple-Book&fullscreen=true \"Open this section in a new browser window\")\n\n1 of 2 items\n\n[View All](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=FDA-Purple-Book&fullscreen=true \"Open this section in a new browser window\")\n\nApplication Number\n\n[103705](https://purplebooksearch.fda.gov/productdetails?query=103705)\n\nProper Name\n\nrituximab \n\nStatus\n\nRx \n\nDosage Form\n\nInjection \n\nRoute of Administration\n\nIntravenous \n\nProduct Presentation\n\nSingle-Dose Vial \n\nBLA Type\n\n351(a) \n\nLicensure\n\nLicensed No. 1048 \n\nDate\n\nNovember 26, 1997 \n\nCompany\n\nGenentech, Inc. \n\nFDA Purple Book\n\n### 6.8 FDA National Drug Code Directory[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=FDA-National-Drug-Code-Directory&fullscreen=true \"Open this section in a new browser window\")\n\nNational Drug Code (NDC) Directory\n\n### 6.9 Drug Labels[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Drug-Labels&fullscreen=true \"Open this section in a new browser window\")\n\nDrug and label\n\nDailyMed\n\nView More...\n\n### 6.10 Cancer Drugs[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Cancer-Drugs&fullscreen=true \"Open this section in a new browser window\")\n\nDrug Name\n\nRiabni (Rituximab) \n\nBrand Name(s)\n\nRiabni\n\nRituxan\n\nRuxience\n\nTruxima\n\nFDA Approved\n\nYes \n\nDrug Use\n\nRituximab is approved to be used alone or with other drugs to treat:\n\n• B-cellacute leukemia that is advanced and CD20positive. Rituximab is used with chemotherapy in children aged 6 months and older whose cancer has not been treated. This use is approved for the Rituxan brand of rituximab.\n\n• B-cell non-Hodgkin lymphoma (NHL) that is CD20 positive. Rituximab is used:\n\n• alone in adults with follicular lymphoma or low-grade lymphoma that has relapsed or is refractory (doesn’t respond to treatment)\n\n• with first-line chemotherapy in adults whose NHL has not been treated\n\n• alone as maintenance therapy in adults who are having a complete or partial response to rituximab and chemotherapy\n\n• alone in adults with low-grade NHL that has not progressed after first-line therapy with cyclophosphamide, vincristine sulfate, and prednisone (CVP)\n\n• with anthracyclinecombination chemotherapy in adults with diffuse large B-cell NHL (DLBCL) that has not been treated\n\n• with chemotherapy in children aged 6 months and older with DLBCL or Burkitt lymphoma that is advanced and has not been treated Use in adults is approved for the Riabni, Rituxan, Ruxience, and Truxima brands of rituximab. Use in children is approved for the Rituxan brand of rituximab.\n\n• Chronic lymphocytic leukemia (CLL) that is CD20 positive. Rituximab is used with fludarabine phosphate and cyclophosphamide in adults. This use is approved for the Riabni, Rituxan, Ruxience, and Truxima brands of rituximab.\n\nRituximab is also being studied in the treatment of other conditions and types of cancer.Rituximab is also available in a different form, combined with hyaluronidase.\n\nNCI Cancer Drugs\n\n### 6.11 EMA Drug Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=EMA-Drug-Information&fullscreen=true \"Open this section in a new browser window\")\n\n1 of 11 items\n\n[View All](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=EMA-Drug-Information&fullscreen=true \"Open this section in a new browser window\")\n\nMedicine\n\n[Riximyo](https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo)\n\nCategory\n\nHuman drugs \n\nTherapeutic area\n\nLymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Microscopic Polyangiitis; Wegener Granulomatosis \n\nActive Substance\n\nrituximab \n\nINN/Common name\n\nrituximab \n\nPharmacotherapeutic Classes\n\nAntineoplastic agents \n\nStatus\n\nThis medicine is authorized for use in the European Union \n\nCompany\n\nSandoz GmbH \n\nMarket Date\n\n2017-06-15 \n\nEuropean Medicines Agency (EMA)\n\n2 of 11 items\n\n[View All](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=EMA-Drug-Information&fullscreen=true \"Open this section in a new browser window\")\n\nMedicine\n\n[Blitzima](https://www.ema.europa.eu/en/medicines/human/EPAR/blitzima)\n\nCategory\n\nHuman drugs \n\nTherapeutic area\n\nLymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell \n\nActive Substance\n\nrituximab \n\nINN/Common name\n\nrituximab \n\nPharmacotherapeutic Classes\n\nAntineoplastic agents \n\nStatus\n\nThis medicine is authorized for use in the European Union \n\nCompany\n\nCelltrion Healthcare Hungary Kft. \n\nMarket Date\n\n2017-07-13 \n\nEuropean Medicines Agency (EMA)\n\n### 6.12 Therapeutic Uses[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Therapeutic-Uses&fullscreen=true \"Open this section in a new browser window\")\n\nAntineoplastic Agents; Antirheumatic Agents; Immunologic Factors \n\nNational Library of Medicine's Medical Subject Headings. Rituximab. Online file (MeSH, 2014). Available from, as of January 30, 2014: [https://www.nlm.nih.gov/mesh/2014/mesh_browser/MBrowser.html](https://www.nlm.nih.gov/mesh/2014/mesh_browser/MBrowser.html)\n\nHazardous Substances Data Bank (HSDB)\n\nRituximab is used alone or in combination with other chemotherapy regimens for the treatment of B-cell non-Hodgkin's lymphoma (NHL) and is designated an orphan drug by the US Food and Drug Administration (FDA) for the treatment of this cancer. /Included in the US product label/ \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1181\n\nHazardous Substances Data Bank (HSDB)\n\nRituxan (rituximab) is indicated for the treatment of patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) as a single agent; Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as single-agent maintenance therapy; Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line CVP chemotherapy; Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens. /Included in the US product label/ \n\nUS Natl Inst Health; DailyMed. Current Medication Information for RITUXAN (rituximab) injection, solution (September 2013). Available from, as of January 31, 2014: [https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563)\n\nHazardous Substances Data Bank (HSDB)\n\nRituxan (rituximab), in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA). /Included in the US product label/ \n\nUS Natl Inst Health; DailyMed. Current Medication Information for RITUXAN (rituximab) injection, solution (September 2013). Available from, as of January 31, 2014: [https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563)\n\nHazardous Substances Data Bank (HSDB)\n\nFor more Therapeutic Uses (Complete) data for RITUXIMAB (13 total), please visit the [HSDB record page](https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7455#section=Therapeutic-Uses-(Complete)).\n\nHazardous Substances Data Bank (HSDB)\n\n### 6.13 Drug Warnings[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Drug-Warnings&fullscreen=true \"Open this section in a new browser window\")\n\n/BOXED WARNING/ WARNING: FATAL INFUSION REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY. Infusion Reactions: Rituxan administration can result in serious, including fatal infusion reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions. Severe, Including Fatal, Mucocataneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan. Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation. Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving Rituxan. \n\nUS Natl Inst Health; DailyMed. Current Medication Information for RITUXAN (rituximab) injection, solution (September 2013). Available from, as of January 31, 2014: [https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563)\n\nHazardous Substances Data Bank (HSDB)\n\nSevere infusion-related effects, sometimes fatal, have been reported in patients receiving rituximab. Severe reactions typically occurred during the first infusion, with time to onset of 30-120 minutes. Fatal reactions have occurred within 24 hours of infusion, approximately 80% of which was associated with the first infusion. Manifestations and sequelae of an infusion-related reaction include urticaria, hypotension, angioedema, hypoxia, bronchospasm, pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, cardiogenic shock, anaphylactoid events, or death. Acute infusion-related reactions observed with rituximab result from the release and/or activation of cytokines during B-cell depletion, often referred to as cytokine-release syndrome. Reported risk factors for cytokine-release syndrome and subsequent infusion-related reactions induced by rituximab include older age, high tumor burden, elevated cytokine or complement levels, and B-lymphocyte aggregation or tumor cell agglutination at baseline. \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1185\n\nHazardous Substances Data Bank (HSDB)\n\nSevere mucocutaneous reactions, sometimes fatal, have been reported in patients receiving rituximab. Severe mucocutaneous reactions associated with rituximab therapy include paraneoplastic pemphigus (an uncommon disorder which is a manifestation of the underlying malignancy), Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis. The onset of severe mucocutaneous reactions has ranged from 1-13 weeks following rituximab administration. ... In the event of a severe mucocutaneous reaction, rituximab therapy should be discontinued, and the patient should undergo prompt medical evaluation. Skin biopsy may be useful to diagnose the mucocutaneous reaction and to guide treatment.... Adverse effects involving the skin or appendages were reported in 44% of patients receiving rituximab in clinical studies and were grade 3 or 4 in severity in 2% of patients. Rash, night sweats, pruritus, and urticaria were reported in 15, 15, 14, and 8% of patients, respectively. \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1186\n\nHazardous Substances Data Bank (HSDB)\n\nMyocardial infarction, ventricular fibrillation, cardiogenic shock, and/or hypotension have occurred as severe manifestations and sequelae of infusion-related reactions and sometimes led to death in patients receiving rituximab. Other severe adverse cardiac effects, including rare instances of fatal cardiac failure with onset of manifestations weeks after rituximab therapy, have been reported. Cardiac arrhythmias and angina also have been reported. \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1186\n\nHazardous Substances Data Bank (HSDB)\n\nFor more Drug Warnings (Complete) data for RITUXIMAB (20 total), please visit the [HSDB record page](https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7455#section=Drug-Warnings-(Complete)).\n\nHazardous Substances Data Bank (HSDB)\n\n7 Pharmacology and Biochemistry[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Pharmacology-and-Biochemistry&fullscreen=true \"Open this section in a new browser window\")\n----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 7.1 Pharmacodynamics[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Pharmacodynamics&fullscreen=true \"Open this section in a new browser window\")\n\nRituximab is a chimeric murine/human monoclonal antibody that binds to the CD20 antigen. CD20 is predominantly expressed on the surface of pre-B and mature B-lymphocytes, allowing rituximab to target and promote lysis in this specific type of cells.. In Non-Hodgkin's Lymphoma patients, rituximab treatment depleted circulating and tissue-based B-cells. In a study that included 166 patients, CD19-positive B-cells were depleted within three weeks, and in 83% of patients, cell depletion lasted up to 6-9 months. B-cell levels started to recover at approximately 6 months and returned to normal 12 months after treatment was completed. Approximately 14% of Non-Hodgkin's Lymphoma patients had IgM or IgG serum levels below the normal range. Most rheumatoid arthritis (RA) patients treated with rituximab showed a near-complete depletion of peripheral B lymphocytes within 2 weeks after the first dose. Peripheral B-cell depletion was sustained for at least 6 months, and in approximately 4% of RA patients, peripheral B-cell depletion was sustained for more than 3 years after a single course of rituximab treatment. Total IgG, IgA, and, more specifically, IgM levels were lower 24 weeks after the first cycle of rituximab treatment (2.8%, 0.8% and 10% below the lower limit of normal, respectively). However, the clinical consequences of this decrease in immunoglobulin levels in RA patients are not clear at this time. Treatment with rituximab in patients with RA was also associated with a decreased level of inflammation markers. In patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) treated with rituximab, CD19 B-cells in peripheral blood were depleted to less than 10 cells/μl after the first two infusions. By month 6, approximately 84% of patients had the same level of peripheral blood CD19 B-cells, and by month 12, 81% of patients demonstrated signs of B-cell return with counts >10 cells/μL. By Month 18, the majority of patients (87%) had counts >10 cells/μL. \n\nDrugBank\n\n### 7.2 MeSH Pharmacological Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=MeSH-Pharmacological-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nAntineoplastic Agents, Immunological\n\nAntineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS. \n\nMedical Subject Headings (MeSH)\n\nImmunologic Factors\n\nBiologically active substances whose activities affect or play a role in the functioning of the immune system. \n\nMedical Subject Headings (MeSH)\n\nAntirheumatic Agents\n\nDrugs that are used to treat RHEUMATOID ARTHRITIS. \n\nMedical Subject Headings (MeSH)\n\n### 7.3 FDA Pharmacological Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=FDA-Pharmacological-Classification&fullscreen=true \"Open this section in a new browser window\")\n\n1 of 2 items\n\nFDA UNII\n\n4F4X42SYQ6 \n\nActive Moiety\n\nRITUXIMAB \n\nPharmacological Classes\n\nMechanisms of Action [MoA] - CD20-directed Antibody Interactions \n\nPharmacological Classes\n\nEstablished Pharmacologic Class [EPC] - CD20-directed Cytolytic Antibody \n\nFDA Pharmacology Summary\n\nRituximab is a CD20-directed Cytolytic Antibody. The mechanism of action of rituximab is as a CD20-directed Antibody Interaction. \n\nFDA Pharm Classes\n\n2 of 2 items\n\nNon-Proprietary Name\n\nRITUXIMAB \n\nPharmacological Classes\n\nCD20-directed Antibody Interactions [MoA]; CD20-directed Cytolytic Antibody [EPC] \n\nNational Drug Code (NDC) Directory\n\n### 7.4 ATC Code[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=ATC-Code&fullscreen=true \"Open this section in a new browser window\")\n\nL01FA01 \n\nEuropean Medicines Agency (EMA); WHO Model Lists of Essential Medicines\n\nL01XC02 \n\nEuropean Medicines Agency (EMA)\n\n[L](https://atcddd.fhi.no/atc_ddd_index/?code=L) - Antineoplastic and immunomodulating agents\n\n[L01](https://atcddd.fhi.no/atc_ddd_index/?code=L01) - Antineoplastic agents\n\n[L01F](https://atcddd.fhi.no/atc_ddd_index/?code=L01F) - Monoclonal antibodies and antibody drug conjugates\n\n[L01FA](https://atcddd.fhi.no/atc_ddd_index/?code=L01FA) - Cd20 (clusters of differentiation 20) inhibitors\n\n[L01FA01](https://atcddd.fhi.no/atc_ddd_index/?code=L01FA01) - Rituximab\n\nWHO Anatomical Therapeutic Chemical (ATC) Classification\n\nATCvet Code\n\n[QL](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QL) - Antineoplastic and immunomodulating agents\n\n[QL01](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QL01) - Antineoplastic agents\n\n[QL01F](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QL01F) - Monoclonal antibodies and antibody drug conjugates\n\n[QL01FA](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QL01FA) - Cd20 (clusters of differentiation 20) inhibitors\n\n[QL01FA01](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QL01FA01) - Rituximab\n\nWHO ATCvet - Classification of Veterinary Medicines\n\n### 7.5 Absorption, Distribution and Excretion[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Absorption-Distribution-and-Excretion&fullscreen=true \"Open this section in a new browser window\")\n\nRituximab at a dose of 375 mg/sq m was administered as an IV infusion at weekly intervals for 4 doses to 203 patients naive to rituximab. The mean Cmax following the fourth infusion was 486 ug/mL (range, 77.5 to 996.6 ug/mL). The peak and trough serum levels of rituximab were inversely correlated with baseline values for the number of circulating CD20-positive B cells and measures of disease burden. Median steady-state serum levels were higher for responders compared with nonresponders ... Serum levels were higher in patients with International Working Formulation (IWF) subtypes B, C, and D as compared with those with subtype A. Rituximab was detectable in the serum of patients 3 to 6 months after completion of treatment. \n\nPhysicians Desk Reference 60th ed, Thomson PDR, Montvale, NJ 2006., p. 845\n\nHazardous Substances Data Bank (HSDB)\n\nRituximab at a dose of 375 mg/sq m was administered as an IV infusion at weekly intervals for 8 doses to 37 patients. The mean Cmax after 8 infusions was 550 ug/mL (range, 171 to 1177 ug/mL). The mean Cmax increased with each successive infusion through the eighth infusion. \n\nPhysicians Desk Reference 60th ed, Thomson PDR, Montvale, NJ 2006., p. 845\n\nHazardous Substances Data Bank (HSDB)\n\nFollowing IV infusion, binding of rituximab has been observed on lymphoid cells in the thymus, the white pulp of the spleen, and a majority of B lymphocytes in peripheral blood and lymph nodes. Little or no binding has been observed upon examination of non-lymphoid tissues. \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1189\n\nHazardous Substances Data Bank (HSDB)\n\nIt is not known whether rituximab crosses the placenta or distributes into milk; however, human IgG is known to cross the placenta and distributes into human milk. \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1189\n\nHazardous Substances Data Bank (HSDB)\n\nAbsorption of monoclonal antibodies (mAbs) after sc injection results from the interplay among several kinetic processes. The aims of this study were to investigate the absorption mechanisms of rituximab in rats by using slow sc infusion and coadministration with nonspecific IgG or hyaluronidase, and to evaluate the predictive performance of the pharmacokinetic model previously developed to describe the nonlinear absorption behavior of mAbs. Rituximab serum concentrations were measured after sc coadministration with nonspecific IgG and hyaluronidase to rats. Several dose levels and different injection sites were evaluated. For the back site, 6.5- and 2.6-fold decreases in the area under the concentration-time curve were obtained after coadministration with IgG for 1 and 10 mg/kg doses compared with administration of rituximab alone. For the abdomen, only a minor reduction in concentrations was observed. Hyaluronidase increased the rate of sc absorption and the bioavailability (1.9- and 1.6-fold for the back and the abdomen injection of 10 mg/kg). ... Previously established pharmacokinetic model provided excellent predictions of the effect of nonspecific IgG on rituximab absorption. In conclusion, the magnitude of the effect of absorption modifiers is dependent on the site of injection and the dose level of rituximab. Pharmacokinetic profiles further support the hypothesis that neonatal Fc receptor-mediated transport is a major determinant of sc absorption of mAbs. \n\n[PMID:23129212](https://pubmed.ncbi.nlm.nih.gov/23129212)\n\nKagan L, Mager DE; Drug Metab Dispos 41 (1): 248-55 (2013)\n\nHazardous Substances Data Bank (HSDB)\n\nAbsorption\n\nRituximab follows a linear pharmacokinetic model. In patients with non-Hodgkin’s lymphoma (NHL) administered 4 doses of 375 mg/m 2 of rituximab (IV) weekly, detectable levels were observed 3-6 months after treatment completion. The pharmacokinetic profile of rituximab administered in combination with 6 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy was similar to the one observed when administered alone. In patients with rheumatoid arthritis (RA) administered 2 doses of 500 mg of rituximab, the C max of the first and second infusions were 157 (SD ± 46) and 183 (SD ± 55) mcg/mL. In patients administered 2 doses of 1,000 mg of rituximab, the C max of the first and second infusions were 318 (SD ± 86) and 381 (SD ± 98) mcg/mL. In pediatric patients (6-17 years old) with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) given four doses of 375 mg/m 2 of rituximab intravenously once a week, the AUC 0-180 was 9787 µg/mL⋅day (range from 4838 to 20446 µg/mL⋅day). In adult patients given the same dose, the AUC 0-180 of rituximab was 10302 µg/mL⋅day (range from 3653 to 21874 µg/mL⋅day). The bioavailability of rituximab administered intravenously is expected to be close to 100%. Compared to rituximab administered intravenously, the bioavailability of RITUXAN HYCELA, a combination product of rituximab and hyaluronidase (human recombinant), is 64.6% in patients with follicular lymphoma and 63.4% in patients with chronic lymphocytic leukemia (CLL).\n\nDrugBank\n\nRoute of Elimination\n\nMonoclonal antibodies (mAb) such as rituximab trigger the formation of antidrug antibodies (ADAs) that form ADA-mAb immune complexes. The endogenous elimination of these immune complexes is mediated by the reticuloendothelial system, most likely via fragment crystallizable-gamma (Fcγ)-mediated endocytosis. \n\nDrugBank\n\nVolume of Distribution\n\nBased on a pharmacokinetic analysis that included 2005 patients with rheumatoid arthritis (RA), the volume of distribution of rituximab is 3.1 L. In pediatric patients (6-17 years old) with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) given four doses of 375 mg/m<sup>2</sup> of rituximab intravenously once a week, the volume of distribution was 2.28 L (range from 1.43 to 3.17 L). In adult patients given the same dose, the volume of distribution was 3.12 L (range from 2.42 to 3.91 L). In patients with pemphigus vulgaris given an intravenous infusion of 1000 mg of rituximab on days 1, 15, 168, and 182, the volume of distribution was 3.49 L (range from 2.48 to 5.22 L). \n\nDrugBank\n\nClearance\n\nIn patients with non-Hodgkin’s lymphoma (NHL), those with higher CD19-positive cell counts or larger measurable tumor lesions at pretreatment had higher rituximab clearance. Based on a pharmacokinetic analysis that included 2005 patients with rheumatoid arthritis (RA), the clearance of rituximab is 0.335 L/day. In pediatric patients (6-17 years old) with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) given four doses of 375 mg/m<sup>2</sup> of rituximab intravenously once a week, clearance was 0.222 L/day (range from 0.0996 to 0.381 L/day). In adult patients given the same dose, clearance was 0.279 L/day (range from 0.113 to 0.653 L/day). In patients with pemphigus vulgaris given an intravenous infusion of 1000 mg of rituximab, clearance was 0.30 L/day (range from 0.16 to 1.51 L/day) in the first infusion cycle (days 1 and 15), and 0.24 L/day (range from 0.13 to 0.45 L/day) in the second infusion cycle (days 168 and 182). \n\nDrugBank\n\n### 7.6 Metabolism / Metabolites[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Metabolism-Metabolites&fullscreen=true \"Open this section in a new browser window\")\n\nAs a monoclonal antibody, rituximab is expected to be metabolized by proteases throughout the body. \n\nDrugBank\n\n### 7.7 Biological Half-Life[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Biological-Half-Life&fullscreen=true \"Open this section in a new browser window\")\n\nBased on a population pharmacokinetic analysis of data in 2005 patients with rheumatoid arthritis ... the mean terminal elimination half-life was 18 days (range: 5-78 days). \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1189\n\nHazardous Substances Data Bank (HSDB)\n\nBased on a population pharmacokinetic analysis of data in 298 patients with non-Hodgkin's lymphoma receiving rituximab once weekly or once every 3 weeks, the estimated median terminal elimination half-life was 22 days (range: 6-52 days). \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1189\n\nHazardous Substances Data Bank (HSDB)\n\nIn 21 patients which chronic lymphocytic leukemia receiving rituximab 375 mg/sq m approximately every 28 days, the estimated median terminal half life was 32 days (range: 14-62 days). \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1189\n\nHazardous Substances Data Bank (HSDB)\n\nIn patients with non-Hodgkin's lymphoma (NHL) treated with rituximab once a week or once every three weeks (n=298), the median terminal elimination half-life was 22 days (range of 6.1-52 days). In patients with chronic lymphocytic leukemia (CLL) treated with rituximab (n=21), the estimated median terminal half-life was 32 days (range of 14-62 days). Based on a pharmacokinetic analysis that included 2005 patients with rheumatoid arthritis (RA), the mean terminal elimination half-life of rituximab is 18.0 days. In pediatric patients (6-17 years old) with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) given four doses of 375 mg/m<sup>2</sup> of rituximab intravenously once a week, the terminal half-life was 22 days (range from 11 to 42 days). In adult patients given the same dose, the terminal half-life was 25 days (range from 11 to 52 days). In patients with pemphigus vulgaris given an intravenous infusion of 1000 mg of rituximab, the terminal half-life was 21.1 days (range from 9.3 to 36.2 days) in the first infusion cycle (days 1 and 15), and 26.2 days (range from 16.4 to 42.8 days) in the second infusion cycle (days 168 and 182). \n\nDrugBank\n\n### 7.8 Mechanism of Action[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Mechanism-of-Action&fullscreen=true \"Open this section in a new browser window\")\n\nRituximab is an antineoplastic agent that binds specifically to antigen CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Antigen CD20 also is expressed on greater than 90% of B-cell non-Hodgkin's lymphomas but is not found on hematopoietic stem cells, early pre-B cells, normal plasma cells, or other normal tissues. Antigen CD20 is involved in the regulation of cell cycle initiation and differentiation and also may function as a calcium ion channel. \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1189\n\nHazardous Substances Data Bank (HSDB)\n\nFollowing binding of the Fab domain of rituximab to antigen CD20 on B lymphocytes, the Fc domain triggers a host immune response causing lysis of normal and malignant B cells; the exact mechanism of cell lysis has not been fully elucidated but is thought to involve complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Rapid and sustained depletion of circulating and tissue-based B cells occurs as a result of the lysis of B cells induced by rituximab. Depletion of circulating B cells lasted for up to 6-9 months in 83% of patients receiving rituximab in a clinical study. Antigen CD20 is not shed from the cell surface and does not internalize following antibody binding. Circulation of free CD20 antigen does not occur. Following completion of rituximab therapy, recovery of B cells begins at approximately 6 months, and median levels of B cells return to normal by 12 months. \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1189\n\nHazardous Substances Data Bank (HSDB)\n\nInhibition of cellular proliferation and induction of apoptosis by rituximab have been demonstrated in some non-Hodgkin's lymphoma cell lines. Rituximab also has been shown to increase the in vitro sensitivity of certain chemoresistant human lymphoma cell lines to some cytotoxic agents, including doxorubicin. \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1189\n\nHazardous Substances Data Bank (HSDB)\n\nThe anti-CD20 monoclonal antibody rituximab is the backbone of treatment for the B-cell malignancies non-Hodgkin lymphoma and chronic lymphocytic leukemia. However, there is a wide variability in response to rituximab treatment, and some patients are refractory to current standard therapies. Rituximab kills B cells by multiple mechanisms of action, including complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, which are immune-mediated mechanisms, as well as by direct effects on cell signaling pathways and cell membranes following CD20 binding. A large number of events that are affected by rituximab binding have been identified, including lipid raft modifications, kinase and caspase activation, and effects on transcription factors and apoptotic/antiapoptotic molecules. Studies on cell lines and isolated tumor cells have shown that by targeting these pathways, it may be possible to increase or decrease susceptibility to rituximab cell killing. An increased understanding of the direct effects of rituximab may therefore aid in the design of new, rational combinations to improve the outcome of CD20-based therapy for patients who currently have suboptimal outcome following standard treatments. \n\n[PMID:21921050](https://pubmed.ncbi.nlm.nih.gov/21921050)\n\nBezombes C et al; Mol Cancer Res 9 (11): 1435-42 (2011)\n\nHazardous Substances Data Bank (HSDB)\n\nFor more Mechanism of Action (Complete) data for RITUXIMAB (7 total), please visit the [HSDB record page](https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7455#section=Mechanism-of-Action-(Complete)).\n\nHazardous Substances Data Bank (HSDB)\n\nRituximab is a monoclonal antibody that targets CD20, an antigen expressed on the surface of pre-B and mature B-lymphocytes. About 85% of non-Hodgkin’s lymphoma (NHL) cases are B-cell lymphomas, characterized by the high expression of CD19, CD20 and CD22 cell surface antigens. CD20 is involved in cell cycle regulation, apoptosis and calcium signaling. By targeting CD20, rituximab promotes cell lysis while sparing hematopoietic and plasma cells without this surface antigen. It has been suggested that cell lysis mechanisms triggered by rituximab include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Rituximab is part of the immunoglobulin G1 (IgG1) subclass of antibodies, and is formed by a murine variable region (Fab region) and a human constant region (Fc region). The Fab region gives rituximab its specificity for CD20, while the Fc region interacts with cell surface receptors to activate the immune system, leading to the depletion of circulating B lymphocytes. In regards to the mechanism of action in rheumatoid arthritis (RA), B-cells are thought to play a role in the pathogenesis of RA and the associated condition of chronic synovitis. B-cells may act at various sites in the autoimmune/inflammatory process through the production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and the production of proinflammatory cytokines. The administration of rituximab in this condition has resulted in significant clinical and symptomatic improvements. Rituximab is also indicated for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two conditions characterized by the presence of circulating antineutrophil cytoplasmic antibodies and increased B-cell activity. It has been suggested that rituximab depletes CD20<sup>+</sup> B-cells at a higher rate in GPA and MPA patients with high levels of Fc receptor-like 5 (FCRL5). \n\nDrugBank\n\n8 Use and Manufacturing[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Use-and-Manufacturing&fullscreen=true \"Open this section in a new browser window\")\n------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 8.1 Uses[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Uses&fullscreen=true \"Open this section in a new browser window\")\n\nThe Rituxan (Rituximab) antibody is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. \n\nPhysicians Desk Reference 60th ed, Thomson PDR, Montvale, NJ 2006., p. 845\n\nHazardous Substances Data Bank (HSDB)\n\nAntineoplastic Agents; Antirheumatic Agents; Immunologic Factors \n\nNational Library of Medicine's Medical Subject Headings. Rituximab. Online file (MeSH, 2014). Available from, as of January 30, 2014: [https://www.nlm.nih.gov/mesh/2014/mesh_browser/MBrowser.html](https://www.nlm.nih.gov/mesh/2014/mesh_browser/MBrowser.html)\n\nHazardous Substances Data Bank (HSDB)\n\nTHERAPEUTIC CATEGORY: Antineoplastic; anti-inflammatory \n\nO'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 1533\n\nHazardous Substances Data Bank (HSDB)\n\nMEDICATION \n\nHazardous Substances Data Bank (HSDB)\n\n#### 8.1.1 Use Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Use-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nHuman drugs -> Antineoplastic agents -> Human pharmacotherapeutic group -> EMA Drug Category \n\nEuropean Medicines Agency (EMA)\n\nHuman Drugs -> EU pediatric investigation plans \n\nEuropean Medicines Agency (EMA)\n\nHuman drugs -> Rare disease (orphan) \n\nEuropean Medicines Agency (EMA)\n\n### 8.2 Methods of Manufacturing[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Methods-of-Manufacturing&fullscreen=true \"Open this section in a new browser window\")\n\nPreparation: D. R. Anderson et al., World Intellectual Property Organization patent 9411026; eidem, United States of America patent 5736137 (1994, 1998 both to IDEC). \n\nO'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 1533\n\nHazardous Substances Data Bank (HSDB)\n\n### 8.3 Formulations / Preparations[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Formulations-Preparations&fullscreen=true \"Open this section in a new browser window\")\n\nMabThera \n\nNational Library of Medicine, SIS; ChemIDplus Lite Record for Rituximab (174722-31-7). Available from, as of February 3, 2014: [https://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp](https://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp)\n\nHazardous Substances Data Bank (HSDB)\n\nParenteral for injection concentrate, for IV infusion 10 mg/mL (100 and 500 mg) Rituxan, Biogen Idac (also promoted by Genentech). \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1189\n\nHazardous Substances Data Bank (HSDB)\n\n### 8.4 U.S. Production[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=U-S-Production&fullscreen=true \"Open this section in a new browser window\")\n\nTypical production volumes for biopharmaceuticals made by mammalian cell technology ... Rituximab, 418 kg (USA). \n\nPollak P, Vouillamoz R; Fine Chemicals. Ullmann's Encyclopedia of Industrial Chemistry 7th ed. (1999-2014). NY, NY: John Wiley & Sons. Online Posting Date: January 15, 2013\n\nHazardous Substances Data Bank (HSDB)\n\n### 8.5 General Manufacturing Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=General-Manufacturing-Information&fullscreen=true \"Open this section in a new browser window\")\n\nAnti-(human CD20 (antigen)) immunoglobulin G1 (human-mouse monoclonal IDEC-C2B8 gamma1-chain) disulfide with human-mouse monoclonal IDEC-C2B8 kappa-chain, dimer \n\nO'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 1533\n\nHazardous Substances Data Bank (HSDB)\n\n9 Identification[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Identification&fullscreen=true \"Open this section in a new browser window\")\n----------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 9.1 Analytic Laboratory Methods[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Analytic-Laboratory-Methods&fullscreen=true \"Open this section in a new browser window\")\n\nHPLC determination of product purity. \n\nO'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Cambridge, UK: Royal Society of Chemistry, 2013., p. 1533\n\nHazardous Substances Data Bank (HSDB)\n\n10 Safety and Hazards[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Safety-and-Hazards&fullscreen=true \"Open this section in a new browser window\")\n-------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 10.1 Hazards Identification[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Hazards-Identification&fullscreen=true \"Open this section in a new browser window\")\n\n#### 10.1.1 GHS Classification[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=GHS-Classification&fullscreen=true \"Open this section in a new browser window\")\n\nPictogram(s)\n\n![Image 3: Health Hazard](https://pubchem.ncbi.nlm.nih.gov/images/ghs/GHS08.svg)\n\nSignal\n\nWarning\n\nGHS Hazard Statements\n\nH372 (100%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]\n\nPrecautionary Statement Codes\n\n[P260](https://pubchem.ncbi.nlm.nih.gov/ghs/#P260), [P264](https://pubchem.ncbi.nlm.nih.gov/ghs/#P264), [P270](https://pubchem.ncbi.nlm.nih.gov/ghs/#P270), [P319](https://pubchem.ncbi.nlm.nih.gov/ghs/#P319), and [P501](https://pubchem.ncbi.nlm.nih.gov/ghs/#P501)\n\nECHA C&L Notifications Summary\n\n_The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory._\n\nEuropean Chemicals Agency (ECHA)\n\n#### 10.1.2 Hazard Classes and Categories[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Hazard-Classes-and-Categories&fullscreen=true \"Open this section in a new browser window\")\n\nSTOT RE 1 (100%) \n\nEuropean Chemicals Agency (ECHA)\n\n### 10.2 Accidental Release Measures[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Accidental-Release-Measures&fullscreen=true \"Open this section in a new browser window\")\n\n#### 10.2.1 Disposal Methods[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Disposal-Methods&fullscreen=true \"Open this section in a new browser window\")\n\nSRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator. \n\nHazardous Substances Data Bank (HSDB)\n\n### 10.3 Handling and Storage[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Handling-and-Storage&fullscreen=true \"Open this section in a new browser window\")\n\n#### 10.3.1 Storage Conditions[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Storage-Conditions&fullscreen=true \"Open this section in a new browser window\")\n\nVials of rituximab should be stored at 2-8 °C and should not be frozen or shaken; when stored under recommended conditions, commercially available rituximab liquid concentrate for injection should be stable up to the date of expiration marked on the vial. Vials of rituximab should be protected from direct sunlight. \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1189\n\nHazardous Substances Data Bank (HSDB)\n\nFollowing dilution of rituximab as recommended, solutions of the drug may be stored for 24 hours at 2-8 °C. Rituximab solutions for infusion have been shown to be stable for an additional 24 hours at room temperature; however, since rituximab solutions do not contain a preservative, diluted solutions should be stored at 2-8 °C. \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1189\n\nHazardous Substances Data Bank (HSDB)\n\n### 10.4 Regulatory Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Regulatory-Information&fullscreen=true \"Open this section in a new browser window\")\n\n#### 10.4.1 FDA Requirements[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=FDA-Requirements&fullscreen=true \"Open this section in a new browser window\")\n\nDrug Name: Rituxan; FDA Application No.: (BLA) 103705; Active Ingredient: Rituximab; Company: Genentech; Original Approval or Tentative Approval Date: November 26, 1997. \n\nUSFDA; Drugs@FDA: FDA Approved Drug Products. Rituximab. Available from, as of March 5, 2014: [https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails](https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails)\n\nHazardous Substances Data Bank (HSDB)\n\n11 Toxicity[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Toxicity&fullscreen=true \"Open this section in a new browser window\")\n-----------------------------------------------------------------------------------------------------------------------------------------------\n\n### 11.1 Toxicological Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Toxicological-Information&fullscreen=true \"Open this section in a new browser window\")\n\n#### 11.1.1 Toxicity Summary[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Toxicity-Summary&fullscreen=true \"Open this section in a new browser window\")\n\nToxicity data for rituximab is not available. Patients who have had an overdose are at an increased risk of severe adverse effects, including fatal infusion-related/severe mucocutaneous reactions. Symptomatic and supportive measures are recommended. \n\nStatPearls\n\n#### 11.1.2 Hepatotoxicity[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Hepatotoxicity&fullscreen=true \"Open this section in a new browser window\")\n\nMild-to-moderate serum aminotransferase elevations are not uncommon (10% to 15%) during rituximab therapy, but are usually self-limited and resolve even with continuing cyclic therapy, and are no more common than with comparator chemotherapy arms without rituximab. In trials of rituximab in rheumatoid arthritis, serum ALT elevations were uncommon. Serum ALT elevations above 5 times the upper limit of normal (ULN) occur in 0.5% to 1.5% of patients, but clinically apparent liver injury during these episodes is rare. Few isolated case reports of clinically apparent, acute liver injury with symptoms or jaundice attributed to rituximab have been published. These have generally been marked by a rapid and abrupt onset of severe liver injury within days of starting rituximab. The association with administration of the monoclonal antibody is uncertain. The injury resembled acute hepatic necrosis as might occur with a direct toxin or with ischemia.\n\nRituximab is, however, a major cause of reactivation of hepatitis B which typically causes acute hepatocellular injury that can be severe and lead to acute liver failure and death or need for emergency liver transplantation. More than 100 cases of clinically apparent reactivation of hepatitis B attributed to rituximab have been reported in the literature, many of which have been severe or fatal. Reactivation can occur in patients who are HBsAg carriers and undergo chemotherapy with rituximab, but also in persons who have recovered from hepatitis B, who have no detectable HBsAg but have antibody to hepatitis B core antigen (anti-HBc) with or without antibody to HBsAg (anti-HBs) in serum. The onset of liver injury is delayed and may occur months after 3 to 6 courses of rituximab therapy. The usual sequence of events is appearance of rising levels of HBV DNA in serum shortly after rituximab is started, followed by rise in levels of HBsAg and HBeAg. When therapy is stopped and immune reconstitution has begun, serum ALT and AST levels start to rise followed by symptoms and jaundice. Reactivation of hepatitis B tends to be severe and the mortality rate in jaundiced cases exceeds 10%. Liver histology demonstrates an acute hepatitis-like pattern with focal or confluent necrosis and prominent lymphocytic infiltrates of activated T cells, which is compatible with an immune mediated hepatic injury. Restarting rituximab can result in recurrence of injury, although corticosteroid or antiviral treatment may block recurrence.\n\nReactivation of HBV in persons who have resolved hepatitis B (anti-HBc without HBsAg in serum) is usually referred to as “reverse seroconversion” and reactivation in persons with preexisting HBsAg in serum as “typical” HBV reactivation. The two forms of reactivation have somewhat different clinical, biochemical and virology courses. In general, patients with reverse seroconversion have received more rigorous immunosuppression, the latency until onset is longer, peak levels of HBV DNA are lower and the disease course is more severe in patients than in patients with typical reactivation. The time to appearance of clinically apparent reactivation tends to be 3 to 6 months in patients with typical reactivation, but 12 to 36 months in those with reverse seroconversion. Outcomes may also be different, reverse seroconversion tending to be more severe and more likely to resolve with disappearance of HBsAg than typical reactivation. Exceptions occur in both situations, however. Some patients with reverse seroconversion do not revert back to being HBsAg negative, particularly those who have had hematopoietic cell transplantation (HCT). In addition, some patients with classic reactivation of hepatitis B ultimately clear HBsAg as a result of the acute liver injury. Both forms of reactivation appear to be ameliorated by early intervention with oral antiviral therapy, but institution of therapy after appearance of clinical disease and jaundice may not be effective and many instances of fatal reactivation have occurred despite rapid institution of treatment with oral antiviral agents.\n\nFinally, rituximab can reactivate other viral infections, and severe instances of acute hepatitis due to adenovirus, parvovirus and other opportunistic viral infections after rituximab therapy have been described.\n\nLikelihood score: A (well known cause of reactivation of hepatitis B and rare cause of immune mediated, clinically apparent liver injury).\n\nLiverTox\n\n#### 11.1.3 Effects During Pregnancy and Lactation[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Effects-During-Pregnancy-and-Lactation&fullscreen=true \"Open this section in a new browser window\")\n\n◉ Summary of Use during Lactation\n\nRituximab is a genetically engineered chimeric murine/human monoclonal antibody that targets CD20, a B-cell-specific surface antigen. The amount in milk is very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Numerous breastfed infants apparently experienced no adverse effects during maternal use of rituximab, including no adverse effect on the CD19 +B cell count. The manufacturer recommends that breastfeeding be discontinued during rituximab therapy and for 6 months after the last dose. However, the American College of Rheumatology and others consider rituximab to be acceptable for use during breastfeeding. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant. Breastfeeding can resume after the injection. One group recommends waiting for 4 hours after the pre-injection antihistamine dose before resuming breastfeeding.\n\n◉ Effects in Breastfed Infants\n\nA woman received rituximab 375 mg/square meter once weekly for 4 weeks beginning at week 30 of gestation. Her infant was born at 40 weeks of gestation and was exclusively breastfed with no major health issues. At 4 months of age, the infant's B-cell population and immunoglobulin levels did not appear to be affected.\n\nA woman received an IV infusion of 1000 mg of rituximab at about 3 months postpartum. Her infant who was fully breastfed had no serious infections during the lactation period and developed normally during a 1.5 year follow-up period.\n\nA retrospective cohort study from the German Multiple Sclerosis and Pregnancy Registry database identified 5 mothers who received rituximab during breastfeeding. Three mothers receive one dose of rituximab while nursing, one received 500 mg and two received 1000 mg. The infants breastfed for 1.6, 1.8 and 0.3 months, respectively. Infant blood counts were normal at 1 to 1.5 months after the mothers’ doses. A blood count was not performed in the third infant. One infant developed omphalitis, but all had normal development. The fourth woman received rituximab 250 mg on day 55 postpartum and ocrelizumab 300 mg on day 333 postpartum. She breastfed for 22.9 months after the rituximab dose. Her infant had normal blood counts at 45 and 213 days after the rituximab dose, but had conjunctivitis and otitis media during this time.\n\nA woman was diagnosed with B-cell lymphoma at 27 weeks of pregnancy. Labor was induced at 34 4/7 weeks and treatment was begun with a standard regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in unspecified doses on a 21-day cycle, starting on day 2 postpartum. She pumped and discarded her milk and fed her infant donor milk for the first 10 days of each cycle and then breastfed her infant for the remaining 10 days before the next treatment cycle. The 10-day period of breastfeeding abstinence was determined by using about 3 half-lives of vincristine. After completion of 4 cycles of chemotherapy, her infant was reportedly healthy and developing without any complications.\n\nA woman with ANCA-associated vasculitis was treated with rituximab 500 mg intravenously at week 19 postpartum. She continued to breastfeed her infant (extent not stated) for another 4 months. The infant did not experience any serious infections or allergies, developed normally during the following 2 years and received all recommended vaccinations.\n\nSix nursing (extent not stated) mothers with relapsing-remitting multiple sclerosis received 500 or 1000 mg of rituximab postpartum. Infants were followed for at least 5 half-lives of the drug. No apparent abnormalities in the CD19 +B cell count, white blood cell count, lymphocytes or immunoglobulin levels were detected in the infants after rituximab infusion.\n\nA multicenter study of women who were receiving either ocrelizumab (n = 30) or rituximab (n = 15) for multiple sclerosis or neuromyelitis optica spectrum disorder followed their infants. Forty-three women breastfed their infants (n = 27 exclusively, n = 16 partially) for a median of 6.4 months (range 0.3–11.7). In the first 12 months of life, all infants grew and developed normally compared to WHO standards and a group of infants who were not breastfed. Beyond minor infections common to infancy, no unexpectedly severe or frequent infections arose. Four infants between the ages of 2.1 and 6.2 months who were breastfed after maternal ocrelizumab or rituximab had IgG and CD19 levels within the normal range.\n\nOne hundred eighty-three patients with multiple sclerosis or a related condition who received an anti-inflammatory monoclonal antibody were compared to 183 control patients. No differences were found in the annual rates of hospitalization, annual antibiotic use, or development of their breastfed (extent not stated) infants. Of the 183 patients, 11 received rituximab.\n\n◉ Effects on Lactation and Breastmilk\n\nRelevant published information was not found as of the revision date.\n\nDrugs and Lactation Database (LactMed)\n\n#### 11.1.4 Adverse Effects[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Adverse-Effects&fullscreen=true \"Open this section in a new browser window\")\n\n**Infusion reactions:** These are the drug's most common and most serious adverse effects. In randomized controlled trials, allergic or anaphylactic reactions were seen in 80% to 90% of patients receiving rituximab. These are usually seen within 30 to 120 minutes after the first infusion and range from mild to life-threatening. Infusion reactions can include fever, chills, skin rash, urticaria, angioedema, hypotension, ARDS, ventricular fibrillation, shock, anaphylaxis, and death.\n\n**Infections:** Serious bacterial, viral, and fungal infections can occur. New or reactivated viral infections can include JC virus, herpes simplex, CMV, varicella-zoster, West Nile Virus, and hepatitis B and C. Due to the risk of reactivation, live vaccines are contraindicated during treatment with rituximab. They should be given at least 4 weeks before starting rituximab.\n\nReactivation of hepatitis B with fulminant hepatitis, hepatic failure, and death can occur. Before starting rituximab, all patients should be screened with hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc). Patients should also be monitored for hepatitis B reactivation during and after treatment.\n\nReactivation of Hepatitis B and the development of PML (progressive multifocal leukoencephalopathy) due to the JC virus are indications to discontinue rituximab.\n\nPCP is an opportunistic fungal infection whose prophylaxis is recommended in patients receiving a fludarabine/cyclophosphamide/rituximab combination to treat CLL. This combination should be started during treatment and continued for a year following completion, and it is also recommended in patients with GPA and MPA during treatment and for at least 6 months after stopping rituximab.\n\n**Hematologic adverse effects:**Lymphopenia is the most commonly seen hematologic adverse effect. Others include leukopenia, neutropenia, thrombocytopenia, and anemia.\n\n**Dermatologic/mucocutaneous reactions:**\n\nThese include pruritis, alopecia, skin rash, and life-threatening reactions like toxic epidermal necrolysis, paraneoplastic pemphigus, and Stevens-Johnson syndrome.\n\n**Renal adverse effects:**Tumor lysis syndrome can present with hypocalcemia, hyperphosphatemia, hyperkalemia, hyperuricemia, and acute renal failure within 24 hours of the first infusion. Aggressive hydration and uric acid-lowering therapy should be given to high-risk patients. Renal toxicity has been seen in trials where rituximab was administered with cisplatin.\n\n**Respiratory adverse effects:** These include cough, upper respiratory tract infections, rhinitis, epistaxis, bronchospasm, dyspnea, pulmonary toxicity, and ILD. There have been reports of rare cases of hypersensitivity pneumonitis, status asthmaticus, diffuse alveolar hemorrhage, and bronchiolitis obliterans.\n\n**Cardiovascular adverse effects:** Tachycardia, supraventricular arrhythmias, non-ischemic cardiomyopathy, peripheral edema, chest pain, hypertension.\n\n**Gastrointestinal adverse effects:**Diarrhea, nausea, and vomiting can be seen. Symptoms of abdominal pain should be thoroughly investigated, as there have been reports of bowel obstruction and perforation.\n\n**Neuropsychiatric adverse effects:** Dizziness, headache, anxiety, depression, and insomnia can occur.\n\n**Pregnancy considerations:**A limited amount crosses the placental barrier during the first trimester, but crossing increases in the second and third trimesters. Administration of rituximab during the third trimester can lead to immunosuppression in the neonate. Levels of rituximab in fetal circulation are similar to maternal levels near term, and live vaccines are contraindicated in the neonate during the first 6 months of birth. Due to a poor understanding of long-term effects, it is recommended to use effective contraception during treatment with rituximab and for a year after the last dose.\n\n**Constitutional adverse effects:**These include asthenia, fever, chills, myalgia, arthralgia, muscle spasms, back pain, night sweats, and fatigue.\n\n**Drug-Drug Interactions**\n\nThe primary drugs contraindicated for concurrent use with rituximab are live vaccines. Cidofovir and talimogene laherparepvec are also absolutely contraindicated for concurrent use.\n\nStatPearls\n\n#### 11.1.5 Interactions[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Interactions&fullscreen=true \"Open this section in a new browser window\")\n\nRenal toxicity has been reported in patients receiving cisplatin in combination with rituximab for a non-Hodgkin's lymphoma (NHL) in clinical studies. If rituximab is administered concomitantly with cisplatin (e.g., in the clinical trial setting), extreme caution should be used, and patients should be monitored closely for signs of renal toxicity. \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1189\n\nHazardous Substances Data Bank (HSDB)\n\nRituximab is a chimeric anti-CD20 human/mouse monoclonal antibody. As its usage has increased, there have been growing concerns about rituximab-related infusion-related reactions (IRRs). Objective: The aim of this study is to verify the clinical features and risk factors of IRRs by rituximab, and to help establish clinical guidelines for their prevention. /The authors/ reviewed electronic medical records of all the adult patients who were prescribed rituximab from January 2005 to July 2010 for B cell malignancy at Seoul National University Hospital. A total of 389 cases of IRRs by rituximab (12.5% of a total of 3,104 infusions) were identified in 281 patients (49.4% of a total of 568 patients). IRRs most frequently occurred during the first infusion (40.5%) and abruptly decreased in subsequent infusions to rates of 3-8% (p < 0.001). The incidence of IRRs in patients premedicated with corticosteroid for their first infusion was significantly lower when compared to patients not pretreated with corticosteroid prior to rituximab infusion (8.3 vs. 41.2%, p = 0.017). Almost half of all patients in the study experienced IRRs at least once during their scheduled rituximab treatment. Premedication with corticosteroid can be recommended in patients with high risk of IRR in the first infusion. \n\n[PMID:24480856](https://pubmed.ncbi.nlm.nih.gov/24480856)\n\nJung JW et al; Oncology 86 (3): 127-134 (2014)\n\nHazardous Substances Data Bank (HSDB)\n\nThe safety of immunization with live viral vaccines following rituximab therapy has not been established. The manufacturer states that use of vaccines containing live virus is not recommended prior to or during rituximab therapy. \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1189\n\nHazardous Substances Data Bank (HSDB)\n\n#### 11.1.6 Antidote and Emergency Treatment[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Antidote-and-Emergency-Treatment&fullscreen=true \"Open this section in a new browser window\")\n\n/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/ \n\nCurrance, P.L. Clements, B., Bronstein, A.C. (Eds).; Emergency Care For Hazardous Materials Exposure. 3Rd edition, Elsevier Mosby, St. Louis, MO 2005, p. 160\n\nHazardous Substances Data Bank (HSDB)\n\n/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/ \n\nCurrance, P.L. Clements, B., Bronstein, A.C. (Eds).; Emergency Care For Hazardous Materials Exposure. 3Rd edition, Elsevier Mosby, St. Louis, MO 2005, p. 160\n\nHazardous Substances Data Bank (HSDB)\n\n/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: \"To keep open\", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/ \n\nCurrance, P.L. Clements, B., Bronstein, A.C. (Eds).; Emergency Care For Hazardous Materials Exposure. 3Rd edition, Elsevier Mosby, St. Louis, MO 2005, p. 160-1\n\nHazardous Substances Data Bank (HSDB)\n\nEmergency and supportive measures: Maintain an open airway and assist ventilation if necessary. Treat coma, seizures, hypotension, and arrhythmias if they occur. Treat nausea and vomiting with metoclopramide and fluid loss caused by gastroenteritis with intravenous crystalloid fluids. ... Immediately stop the infusion and withdraw as much fluid as possible by negative pressure on the syringe. Surgical intervention may be necessary. ... Specific drugs and antidotes: Very few specific treatments or antidotes are available. Decontamination: Administer activated charcoal orally if conditions are appropriate. Gastric lavage is not necessary after small to moderate ingestions if activated charcoal can be given promptly. Enhanced elimination: Because of the rapid intracellular incorporation of most of these agents, dialysis and other extracorporeal removal procedures are generally not effective. /Antineoplastic agents/ \n\nOLSON, K.R. (Ed). Poisoning and Drug Overdose, Sixth Edition. McGraw-Hill, New York, NY 2012, p. 117\n\nHazardous Substances Data Bank (HSDB)\n\n#### 11.1.7 Human Toxicity Excerpts[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Human-Toxicity-Excerpts&fullscreen=true \"Open this section in a new browser window\")\n\n/HUMAN EXPOSURE STUDIES/ Four patients from an estimated population of 129,000 exposed to rituximab therapy for rheumatoid arthritis (RA) are reported in whom progressive multifocal leukoencephalopathy (PML) developed after administration of this drug. All were women older than 50 years, commonly with Sjogren syndrome and a history of treatment for joint disease ranging from 3 to 14 years. One case had no prior biologic and minimal immunosuppressive therapy. Progressive multifocal leukoencephalopathy presented as a progressive neurological disorder, with diagnosis confirmed by detection of JC virus DNA in the cerebrospinal fluid or brain biopsy specimen. Two patients died in less than 1 year from PML diagnosis, while 2 remain alive after treatment withdrawal. Magnetic resonance scans and tissue evaluation confirmed the frequent development of inflammatory PML during the course of the disease. These cases suggest an increased risk, about 1 case per 25,000 individuals, of PML in patients with RA being treated with rituximab. Inflammatory PML may occur in this setting even while CD20 counts remain low. \n\n[PMID:21555606](https://pubmed.ncbi.nlm.nih.gov/21555606)\n\nFull text: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428054](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428054)\n\nClifford DB et al; Arch Neurol 68 (9): 1156-64 (2011)\n\nHazardous Substances Data Bank (HSDB)\n\n/SIGNS AND SYMPTOMS/ Rituxan administration can result in serious, including fatal infusion reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions. Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan. Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation. Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving Rituxan. \n\nUS Natl Inst Health; DailyMed. Current Medication Information for RITUXAN (rituximab) injection, solution (September 2013). Available from, as of January 31, 2014: [https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563)\n\nHazardous Substances Data Bank (HSDB)\n\n/SIGNS AND SYMPTOMS/ Severe mucocutaneous reactions, sometimes fatal, have been reported in patients receiving rituximab. Severe mucocutaneous reactions associated with rituximab therapy include paraneoplastic pemphigus (an uncommon disorder which is a manifestation of the underlying malignancy), Stevens-Johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis. The onset of severe mucocutaneous reactions has ranged from 1-13 weeks following rituximab administration. ... In the event of a severe mucocutaneous reaction, rituximab therapy should be discontinued, and the patient should undergo prompt medical evaluation. Skin biopsy may be useful to diagnose the mucocutaneous reaction and to guide treatment.... Adverse effects involving the skin or appendages were reported in 44% of patients receiving rituximab in clinical studies and were grade 3 or 4 in severity in 2% of patients. Rash, night sweats, pruritus, and urticaria were reported in 15, 15, 14, and 8% of patients, respectively. \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1186\n\nHazardous Substances Data Bank (HSDB)\n\n/SIGNS AND SYMPTOMS/ Myocardial infarction, ventricular fibrillation, cardiogenic shock, and/or hypotension have occurred as severe manifestations and sequelae of infusion-related reactions and sometimes led to death in patients receiving rituximab. Other severe adverse cardiac effects, including rare instances of fatal cardiac failure with onset of manifestations weeks after rituximab therapy, have been reported. Cardiac arrhythmias and angina also have been reported. \n\nAmerican Society of Health-System Pharmacists 2013; Drug Information 2013. Bethesda, MD. 2013, p. 1186\n\nHazardous Substances Data Bank (HSDB)\n\nFor more Human Toxicity Excerpts (Complete) data for RITUXIMAB (18 total), please visit the [HSDB record page](https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7455#section=Human-Toxicity-Excerpts-(Complete)).\n\nHazardous Substances Data Bank (HSDB)\n\n#### 11.1.8 Non-Human Toxicity Excerpts[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Non-Human-Toxicity-Excerpts&fullscreen=true \"Open this section in a new browser window\")\n\n/LABORATORY ANIMALS: Acute Exposure/ In a single high-dose experiment with doses of 10, 30 and 100 mg/kg (= 1345 mg/sq m), rituximab was systemically and locally well tolerated, with only a mild transient decrease of platelets observed after dosing in the 30 and 100 mg/kg dose groups. The only adverse event involved one male monkey, which vomited one day after dosing in the 100-mg/kg-dose group. Thus, serious dose limiting toxicity was not observed, even though the doses used in this study are far above a therapeutically effective dose in monkeys as well as the anticipated clinical dose. \n\nEuropean Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): MabThera (Rituximab), Scientific Discussion p.6 (2005). Available from, as of February 3, 2014: [https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000165/WC500025817.pdf](https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000165/WC500025817.pdf)\n\nHazardous Substances Data Bank (HSDB)\n\n/LABORATORY ANIMALS: Acute Exposure/ In Cynomolgus monkeys, B-cell depletion in the peripheral blood (along with gradual depletion in peripheral lymphatic tissues) could be induced with a single i.v. injection using a dose of 0.4 and 6.5 mg/kg, with only marginal recovery by day 35. No signs and symptoms of acute adverse reactions were observed. \n\nEuropean Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): MabThera (Rituximab), Scientific Discussion p.6 (2005). Available from, as of February 3, 2014: [https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000165/WC500025817.pdf](https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000165/WC500025817.pdf)\n\nHazardous Substances Data Bank (HSDB)\n\n/LABORATORY ANIMALS: Acute Exposure/ Twelve albino rabbits were included in the study. 1 mg/0.1 mL of rituximab was injected to the right (experimental) eye of each rabbit, and 0.1 mL of saline was injected into the left (control) eye. Electroretinogram was recorded before injection and 3 hours, 4 days, 1 week, 2 weeks and 4 weeks after injection (12 rabbits), and visual evoked potential was recorded before injection and 4 weeks after injection (10 rabbits). Histology and glial fibrillary acidic protein immunocytochemistry (12 rabbits) were performed at 4 weeks after injection. Clinical examination was conducted at all time points in all rabbits. The average dark-adapted electroretinogram b-wave Vmax ratios, and the average light-adapted b-wave amplitude ratios were approximately 1, and the average log s difference was around zero throughout the follow-up period. The average visual evoked potential amplitude ratio and the average visual evoked potential implicit time difference were approximately 1 and 0, respectively. No histologic damage was seen, but glial fibrillary acidic protein was mildly expressed in 6 of 12 experimental eyes. Results of clinical examination were normal in all the eyes. Intravitreal injection of 1 mg rituximab does not cause functional or histologic signs of retinal toxicity in albino rabbits. Mild glial fibrillary acidic protein expression in Muller cells probably indicates a mild degree of retinal stress. \n\n[PMID:22990324](https://pubmed.ncbi.nlm.nih.gov/22990324)\n\nHabot-Wilner Z et al; Retina 33 (3): 649-56 (2013)\n\nHazardous Substances Data Bank (HSDB)\n\n/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ A repeated pilot pharmacology/toxicology experiment in Cynomolgus monkeys (using 16.8 mg/kg doses) demonstrated the relationship between exposure of multiple injections of rituximab to the degree of B-cell depletion in the peripheral blood and bone marrow, as well as within the lymphatic tissues. This experiment formed the basis for the initial dose escalating study in humans. Weekly dose of rituximab up to 20 mg/kg (= 276 mg/m2) was generally well tolerated over up to 8 weeks of treatment in a further GLP toxicity study in Cynomolgus monkeys. Occasional emesis was also observed in these experiments. \n\nEuropean Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), European Public Assessment Report (EPAR): MabThera (Rituximab), Scientific Discussion p.6 (2005). Available from, as of February 3, 2014: [https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000165/WC500025817.pdf](https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000165/WC500025817.pdf)\n\nHazardous Substances Data Bank (HSDB)\n\nFor more Non-Human Toxicity Excerpts (Complete) data for RITUXIMAB (7 total), please visit the [HSDB record page](https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7455#section=Non-Human-Toxicity-Excerpts-(Complete)).\n\nHazardous Substances Data Bank (HSDB)\n\n#### 11.1.9 Protein Binding[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Protein-Binding&fullscreen=true \"Open this section in a new browser window\")\n\nNot available. \n\nDrugBank\n\n### 11.2 Ecological Information[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Ecological-Information&fullscreen=true \"Open this section in a new browser window\")\n\n#### 11.2.1 Milk Concentrations[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Milk-Concentrations&fullscreen=true \"Open this section in a new browser window\")\n\nEXPERIMENTAL MILK: It is not known whether rituximab is distributed into human breast milk. However, human IgG is distributed into human milk, although the potential for absorption and consequent immunosuppression in the infant is unknown. It is recommended that women treated with rituximab not breast feed until circulating drug levels are no longer detectable. \n\nThomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 2625\n\nHazardous Substances Data Bank (HSDB)\n\n12 Literature[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Literature&fullscreen=true \"Open this section in a new browser window\")\n---------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 12.1 Consolidated References[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Consolidated-References&fullscreen=true \"Open this section in a new browser window\")\n\nPubChem\n\n### 12.2 NLM Curated PubMed Citations[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=NLM-Curated-PubMed-Citations&fullscreen=true \"Open this section in a new browser window\")\n\nMedical Subject Headings (MeSH)\n\n13 Patents[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Patents&fullscreen=true \"Open this section in a new browser window\")\n---------------------------------------------------------------------------------------------------------------------------------------------\n\n*   CA2149329 \n*   CA1336826 \n*   [US5736137](https://pubchem.ncbi.nlm.nih.gov/patent/US5736137)\n\nDrugBank\n\n14 Interactions and Pathways[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Interactions-and-Pathways&fullscreen=true \"Open this section in a new browser window\")\n---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\n### 14.1 Drug-Drug Interactions[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Drug-Drug-Interactions&fullscreen=true \"Open this section in a new browser window\")\n\nDrugBank\n\n15 Information Sources[](https://pubchem.ncbi.nlm.nih.gov/compound/Rituximab#section=Information-Sources&fullscreen=true \"Open this section in a new browser window\")\n---------------------------------------------------------------------------------------------------------------------------------------------------------------------\n\nFilter by Source \n\n1.   PubChem[https://pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/) \n2.   [European Chemicals Agency (ECHA)](https://pubchem.ncbi.nlm.nih.gov/source/European%20Chemicals%20Agency%20(ECHA))LICENSE Use of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: \"Source: European Chemicals Agency, [http://echa.europa.eu/](http://echa.europa.eu/)\". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.  [https://echa.europa.eu/web/guest/legal-notice](https://echa.europa.eu/web/guest/legal-notice) Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal IDEC-C2B8 .gamma.1-chain), disulfide with human-mouse monoclonal IDEC-C2B8 .kappa.-chain, dimer (EC: 695-706-4) [https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/230463](https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/230463) Immunoglobulin G1, anti-(human CD20 (antigen)) (human-mouse monoclonal IDEC-C2B8 .gamma.1-chain), disulfide with human-mouse monoclonal IDEC-C2B8 .kappa.-chain, dimer [https://chem.echa.europa.eu/100.224.382](https://chem.echa.europa.eu/100.224.382) \n3.   [Hazardous Substances Data Bank (HSDB)](https://pubchem.ncbi.nlm.nih.gov/source/Hazardous%20Substances%20Data%20Bank%20(HSDB))LICENSE [https://www.nlm.nih.gov/web_policies.html](https://www.nlm.nih.gov/web_policies.html) RITUXIMAB [https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7455](https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7455) \n4.   [CAS Common Chemistry](https://pubchem.ncbi.nlm.nih.gov/source/CAS%20Common%20Chemistry)LICENSE The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. [https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/) Rituximab [https://commonchemistry.cas.org/detail?cas_rn=174722-31-7](https://commonchemistry.cas.org/detail?cas_rn=174722-31-7) \n5.   [ChemIDplus](https://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus)LICENSE [https://www.nlm.nih.gov/copyright.html](https://www.nlm.nih.gov/copyright.html) Rituximab [USAN:INN:BAN] [https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0174722317](https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0174722317) \n6.   [DrugBank](https://pubchem.ncbi.nlm.nih.gov/source/DrugBank)LICENSE Creative Common's Attribution-NonCommercial 4.0 International License ([http://creativecommons.org/licenses/by-nc/4.0/legalcode](http://creativecommons.org/licenses/by-nc/4.0/legalcode))  [https://www.drugbank.ca/legal/terms_of_use](https://www.drugbank.ca/legal/terms_of_use) Rituximab [https://www.drugbank.ca/drugs/DB00073](https://www.drugbank.ca/drugs/DB00073) \n7.   [DTP/NCI](https://pubchem.ncbi.nlm.nih.gov/source/DTP/NCI)LICENSE Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source. [https://www.cancer.gov/policies/copyright-reuse](https://www.cancer.gov/policies/copyright-reuse) NSC687451 [https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=687451](https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=687451) \n8.   [EPA DSSTox](https://pubchem.ncbi.nlm.nih.gov/source/EPA%20DSSTox)LICENSE [https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources](https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources) Rituximab [https://comptox.epa.gov/dashboard/DTXSID5040910](https://comptox.epa.gov/dashboard/DTXSID5040910) \n9.   [FDA Global Substance Registration System (GSRS)](https://pubchem.ncbi.nlm.nih.gov/source/FDA%20Global%20Substance%20Registration%20System%20(GSRS))LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) RITUXIMAB [https://gsrs.ncats.nih.gov/ginas/app/beta/substances/4F4X42SYQ6](https://gsrs.ncats.nih.gov/ginas/app/beta/substances/4F4X42SYQ6) \n10.   [DailyMed](https://pubchem.ncbi.nlm.nih.gov/source/DailyMed)LICENSE [https://www.nlm.nih.gov/copyright.html](https://www.nlm.nih.gov/copyright.html) RITUXIMAB [https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=RITUXIMAB](https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=RITUXIMAB) \n11.   [FDA Pharm Classes](https://pubchem.ncbi.nlm.nih.gov/source/FDA%20Pharm%20Classes)LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) RITUXIMAB [https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm](https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm) \n12.   [LiverTox](https://pubchem.ncbi.nlm.nih.gov/source/LiverTox)LICENSE [https://www.nlm.nih.gov/copyright.html](https://www.nlm.nih.gov/copyright.html) Rituximab [https://www.ncbi.nlm.nih.gov/books/n/livertox/Rituximab/](https://www.ncbi.nlm.nih.gov/books/n/livertox/Rituximab/) \n13.   [NCI Thesaurus (NCIt)](https://pubchem.ncbi.nlm.nih.gov/source/NCI%20Thesaurus%20(NCIt))LICENSE Unless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source. [https://www.cancer.gov/policies/copyright-reuse](https://www.cancer.gov/policies/copyright-reuse) [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1702](https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1702) \n14.   [European Medicines Agency (EMA)](https://pubchem.ncbi.nlm.nih.gov/source/European%20Medicines%20Agency%20(EMA))LICENSE Information on the European Medicines Agency's (EMA) website is subject to a disclaimer and copyright and limited reproduction notices. [https://www.ema.europa.eu/en/about-us/about-website/legal-notice](https://www.ema.europa.eu/en/about-us/about-website/legal-notice) Riximyo (EMEA/H/C/004729) [https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo](https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo) Blitzima (EMEA/H/C/004723) [https://www.ema.europa.eu/en/medicines/human/EPAR/blitzima](https://www.ema.europa.eu/en/medicines/human/EPAR/blitzima) Rixathon (EMEA/H/C/003903) [https://www.ema.europa.eu/en/medicines/human/EPAR/rixathon](https://www.ema.europa.eu/en/medicines/human/EPAR/rixathon) Truxima (EMEA/H/C/004112) [https://www.ema.europa.eu/en/medicines/human/EPAR/truxima](https://www.ema.europa.eu/en/medicines/human/EPAR/truxima) Ruxience (EMEA/H/C/004696) [https://www.ema.europa.eu/en/medicines/human/EPAR/ruxience](https://www.ema.europa.eu/en/medicines/human/EPAR/ruxience) MabThera (EMEA/H/C/000165) [https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera](https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera) Ritemvia (EMEA/H/C/004725) [https://www.ema.europa.eu/en/medicines/human/EPAR/ritemvia](https://www.ema.europa.eu/en/medicines/human/EPAR/ritemvia) Rituzena (previously Tuxella) (EMEA/H/C/004724) [https://www.ema.europa.eu/en/medicines/human/EPAR/rituzena-previously-tuxella](https://www.ema.europa.eu/en/medicines/human/EPAR/rituzena-previously-tuxella) rituximab (P/0060/2016) [https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000308-pip02-11-m01](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000308-pip02-11-m01) rituximab (P/0064/2019) [https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000308-pip01-08-m04](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000308-pip01-08-m04) rituximab (EU/3/17/1869) [https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171869](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171869) \n15.   [StatPearls](https://pubchem.ncbi.nlm.nih.gov/source/StatPearls)LICENSE This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ( [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.   Rituximab [https://www.ncbi.nlm.nih.gov/books/n/statpearls/article-98653/](https://www.ncbi.nlm.nih.gov/books/n/statpearls/article-98653/) \n16.   [Drugs and Lactation Database (LactMed)](https://pubchem.ncbi.nlm.nih.gov/source/Drugs%20and%20Lactation%20Database%20(LactMed))LICENSE [https://www.nlm.nih.gov/copyright.html](https://www.nlm.nih.gov/copyright.html) Rituximab [https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM888/](https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM888/) \n17.   [Drugs@FDA](https://pubchem.ncbi.nlm.nih.gov/source/Drugs@FDA)LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) RITUXIMAB [https://www.accessdata.fda.gov/scripts/cder/daf/](https://www.accessdata.fda.gov/scripts/cder/daf/) \n18.   [WHO Model Lists of Essential Medicines](https://pubchem.ncbi.nlm.nih.gov/source/WHO%20Model%20Lists%20of%20Essential%20Medicines)LICENSE Permission from WHO is not required for the use of WHO materials issued under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Intergovernmental Organization (CC BY-NC-SA 3.0 IGO) license. [https://www.who.int/about/policies/publishing/copyright](https://www.who.int/about/policies/publishing/copyright) Rituximab [https://list.essentialmeds.org/medicines/104](https://list.essentialmeds.org/medicines/104) \n19.   [WHO Anatomical Therapeutic Chemical (ATC) Classification](https://pubchem.ncbi.nlm.nih.gov/source/WHO%20Anatomical%20Therapeutic%20Chemical%20(ATC)%20Classification)LICENSE Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed. [https://www.whocc.no/copyright_disclaimer/](https://www.whocc.no/copyright_disclaimer/) Rituximab [https://atcddd.fhi.no/atc_ddd_index/?code=L01FA01](https://atcddd.fhi.no/atc_ddd_index/?code=L01FA01) \n20.   [WHO ATCvet - Classification of Veterinary Medicines](https://pubchem.ncbi.nlm.nih.gov/source/WHO%20ATCvet%20-%20Classification%20of%20Veterinary%20Medicines)LICENSE Use of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed. [https://atcddd.fhi.no/copyright_disclaimer/](https://atcddd.fhi.no/copyright_disclaimer/) Rituximab [https://atcddd.fhi.no/atcvet/atcvet_index/?code=QL01FA01](https://atcddd.fhi.no/atcvet/atcvet_index/?code=QL01FA01) \n21.   [FDA Medication Guides](https://pubchem.ncbi.nlm.nih.gov/source/FDA%20Medication%20Guides)LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) RITUXAN [https://dps.fda.gov/medguide](https://dps.fda.gov/medguide) \n22.   [National Drug Code (NDC) Directory](https://pubchem.ncbi.nlm.nih.gov/source/National%20Drug%20Code%20(NDC)%20Directory)LICENSE Unless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required. [https://www.fda.gov/about-fda/about-website/website-policies#linking](https://www.fda.gov/about-fda/about-website/website-policies#linking) RITUXIMAB [https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory](https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory) \n23.   [FDA Purple Book](https://pubchem.ncbi.nlm.nih.gov/source/FDA%20Purple%20Book)rituximab [https://purplebooksearch.fda.gov/productdetails?query=103705](https://purplebooksearch.fda.gov/productdetails?query=103705) rituximab [https://purplebooksearch.fda.gov/productdetails?query=103737](https://purplebooksearch.fda.gov/productdetails?query=103737) \n24.   [Japan Chemical Substance Dictionary (Nikkaji)](https://pubchem.ncbi.nlm.nih.gov/source/Japan%20Chemical%20Substance%20Dictionary%20(Nikkaji))[http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J1.653.613J](http://jglobal.jst.go.jp/en/redirect?Nikkaji_No=J1.653.613J) \n25.   [NCI Cancer Drugs](https://pubchem.ncbi.nlm.nih.gov/source/NCI%20Cancer%20Drugs)LICENSE [https://www.cancer.gov/policies/copyright-reuse](https://www.cancer.gov/policies/copyright-reuse) Riabni (Rituximab) [https://www.cancer.gov/about-cancer/treatment/drugs/rituximab](https://www.cancer.gov/about-cancer/treatment/drugs/rituximab) \n26.   [NLM RxNorm Terminology](https://pubchem.ncbi.nlm.nih.gov/source/NLM%20RxNorm%20Terminology)LICENSE The RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license. [https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html](https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html) rituximab [https://rxnav.nlm.nih.gov/id/rxnorm/121191](https://rxnav.nlm.nih.gov/id/rxnorm/121191) \n27.   [Medical Subject Headings (MeSH)](https://pubchem.ncbi.nlm.nih.gov/source/Medical%20Subject%20Headings%20(MeSH))LICENSE Works produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S. [https://www.nlm.nih.gov/copyright.html](https://www.nlm.nih.gov/copyright.html) Rituximab [https://id.nlm.nih.gov/mesh/M0244307.html](https://id.nlm.nih.gov/mesh/M0244307.html) Antineoplastic Agents, Immunological [https://id.nlm.nih.gov/mesh/M000626416.html](https://id.nlm.nih.gov/mesh/M000626416.html) Immunologic Factors [https://id.nlm.nih.gov/mesh/M0011157.html](https://id.nlm.nih.gov/mesh/M0011157.html) Antirheumatic Agents [https://id.nlm.nih.gov/mesh/M0027742.html](https://id.nlm.nih.gov/mesh/M0027742.html) [https://www.nlm.nih.gov/mesh/meshhome.html](https://www.nlm.nih.gov/mesh/meshhome.html) \n\nCite\n\nDownload\n\nCONTENTS\n\n*   Title and Summary \n*   1 Synonyms \n*   2 MeSH Entry Terms \n*   3 Names and Identifiers Expand this menu \n*   4 Chemical and Physical Properties Expand this menu \n*   5 Related Records Expand this menu \n*   6 Drug and Medication Information Expand this menu \n*   7 Pharmacology and Biochemistry Expand this menu \n*   8 Use and Manufacturing Expand this menu \n*   9 Identification Expand this menu \n*   10 Safety and Hazards Expand this menu \n*   11 Toxicity Expand this menu \n*   12 Literature Expand this menu \n*   13 Patents \n*   14 Interactions and Pathways Expand this menu \n*   15 Information Sources \n\nConnect with NLM\n\n*   [Twitter](https://twitter.com/NLM_NIH \"SM-Twitter\")\n*   [Facebook](https://www.facebook.com/nationallibraryofmedicine \"SM-Facebook\")\n*   [YouTube](https://www.youtube.com/user/NLMNIH \"SM-Youtube\")\n\n[National Library of Medicine 8600 Rockville Pike, Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323)\n\n[Web Policies](https://www.nlm.nih.gov/web_policies.html)\n\n[FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office)\n\n[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n[Help](https://support.nlm.nih.gov/)\n\n[Accessibility](https://www.nlm.nih.gov/accessibility.html)\n\n[Careers](https://www.nlm.nih.gov/careers/careers.html)\n\n*   [NLM](https://www.nlm.nih.gov/)\n*   [NIH](https://www.nih.gov/)\n*   [HHS](https://www.hhs.gov/)\n*   [USA.gov](https://www.usa.gov/)"
      },
      {
        "title": "Rituximab - StatPearls - NCBI Bookshelf",
        "url": "https://www.ncbi.nlm.nih.gov/books/NBK564374/",
        "content": "Go to:\n\nMechanism of Action\n\nRituximab is an anti-CD20 chimeric antibody with human IgG1 immunoglobulin constant regions and variable regions from an anti-CD20 murine antibody. CD20 is a surface transmembrane protein marker expressed on B cells during differentiation from the pre-B cell until the plasma cell stage. CD20 is believed to function as a calcium channel and play a role in the maturation and activation of B cells.(",
        "raw_content": "Rituximab - StatPearls - NCBI Bookshelf\n===============\n\n![Image 1: U.S. flag](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png)\nAn official website of the United States government\n\nHere's how you know\n\n![Image 2: Dot gov](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg)\n\n**The .gov means it's official.**\n\n Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.\n\n![Image 3: Https](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg)\n\n**The site is secure.**\n\n The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.\n\n[![Image 4: NIH NLM Logo](https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg)](https://www.ncbi.nlm.nih.gov/)\n\n[Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK564374%2F)Show account info\n\nClose\n#### Account\n\n Logged in as:\n\n**username**\n\n*   [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/)\n*   [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/)\n*   [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/)\n*   [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK564374%2F)\n\n[Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys)[NCBI Homepage](https://www.ncbi.nlm.nih.gov/)[MyNCBI Homepage](https://www.ncbi.nlm.nih.gov/myncbi/)[Main Content](https://www.ncbi.nlm.nih.gov/books/NBK564374/#maincontent)[Main Navigation](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\n[Bookshelf](https://www.ncbi.nlm.nih.gov/books/ \"Bookshelf home\")\n=================================================================\n\nSearch database \n\nSearch term \n\n[![Image 5: Clear input](https://www.ncbi.nlm.nih.gov/core/jig/1.15.2/img/clear.png)](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\nSearch\n\n*   [Browse Titles](https://www.ncbi.nlm.nih.gov/books/browse/)\n*   [Advanced](https://www.ncbi.nlm.nih.gov/books/advanced/)\n*   [Help](https://www.ncbi.nlm.nih.gov/books/NBK3833/)\n*   [Disclaimer](https://www.ncbi.nlm.nih.gov/books/about/disclaimer/)\n\nNCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.\n\nStatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.\n\n[![Image 6: Cover of StatPearls](https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-statpearls-lrg.png)](https://www.ncbi.nlm.nih.gov/books/n/statpearls/ \"Table of Contents Page\")\n\nStatPearls [Internet].\n----------------------\n\n[Show details](https://www.ncbi.nlm.nih.gov/books/NBK564374/#__NBK564374_dtls__)\n\nTreasure Island (FL): [StatPearls Publishing](https://www.statpearls.com/); 2025 Jan-.\n\nSearch term \n\n[![Image 7: Clear input](https://www.ncbi.nlm.nih.gov/core/jig/1.15.2/img/clear.png)](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\nRituximab\n=========\n\nNazma Hanif; Faiz Anwer.\n\n[Author Information and Affiliations](https://www.ncbi.nlm.nih.gov/books/NBK564374/#__NBK564374_ai__)\n\n#### Authors\n\nNazma Hanif; Faiz Anwer 1.\n#### Affiliations\n\n1 Cleveland Clinic\n\nLast Update: February 28, 2024.\n\n[Go to:](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Go to other sections in this page\")\n\nContinuing Education Activity\n-----------------------------\n\nThis activity centers on rituximab, an anti-CD20 monoclonal antibody pivotal in treating various lymphoproliferative and autoimmune disorders. The program provides an in-depth exploration of rituximab's indications, mechanisms of action, and crucial aspects of its therapeutic application. From lymphomas to autoimmune conditions, the activity elucidates the clinical efficacy of rituximab, shedding light on the intricate mechanisms that underlie its targeting of CD20-positive cells, thereby modulating immune responses and delivering therapeutic effects. Emphasis is placed on essential pharmacological considerations and monitoring parameters vital to ensuring patient safety.\n\nThis activity systematically addresses the validated indications and potential off-label applications of rituximab across diverse medical contexts, equipping healthcare team members with a comprehensive understanding of its adverse effects and contraindications. This knowledge is vital for informed decision-making in treatment planning. The activity aims to enhance healthcare professionals' ability to manage rituximab therapy effectively by outlining monitoring strategies. This optimization of therapeutic outcomes and vigilance for potential complications contribute to fostering competent and safer patient care.\n\n**Objectives:**\n\n*   Identify the appropriate indications and patient profiles suitable for rituximab therapy in the setting of lymphoproliferative and autoimmune disorders. \n*   Screen patients thoroughly for contraindications, previous allergic reactions, and underlying health conditions prior to initiating rituximab therapy. \n*   Assess the clinical response and monitor for potential adverse reactions during and after rituximab therapy, adjusting treatment plans as necessary. \n*   Develop effective communication with patients, caregivers, and the healthcare team, discussing the benefits, risks, and expectations related to rituximab treatment. \n\n[Access free multiple choice questions on this topic.](https://www.statpearls.com/account/trialuserreg/?articleid=98653&utm_source=pubmed&utm_campaign=reviews&utm_content=98653)\n\n[Go to:](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Go to other sections in this page\")\n\nIndications\n-----------\n\nRituximab is an anti-CD20 monoclonal antibody that was first approved by the FDA in 1997. Currently,the drug has received FDA approval for use in several conditions.\n\n**FDA-Approved Indications**\n\n*   \nCD20-positive B-cell non-Hodgkin’s lymphoma (NHL) \n    *   Approved for use as a single agent in relapsed/refractory, low-grade, or follicular B cell NHL \n    *   Single-agent maintenance therapy for patients with previously untreated follicular B cell NHL who are achieving a complete or some degree of response to combination chemotherapy with rituximab \n    *   As a single agent in low-grade non-progressive/stable B cell NHL after Cyclophosphamide, Vincristine, and Prednisolone (CVP) chemotherapy. \n    *   In combination with anthracycline-based chemotherapy in previously untreated diffuse large B cell NHL \n\n*   Chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia(SLL): Approved for use in combination with fludarabine and cyclophosphamide to treat newly diagnosed or previously treated CLL. \n\n*   Rheumatoid arthritis (RA): Rituximab is considered a biologic disease-modifying antirheumatic drug (DMARD) for the treatment of RA.Rituximab is approved for use with methotrexate in adult patients who have an inadequate response to anti-TNF therapy. \n\n*   Microscopic olyangiitis (MP) and granulomatosis with polyangiitis (GPA): Approved for use in combination with glucocorticoids. \n\n*   Pemphigus ulgaris (PV): Approved in 2018 for glucocorticoid use for adult patients with moderate to severe disease.[[1]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#) \n\nIn addition, rituximab has orphan designations for immune thrombocytopenic purpura (ITP) and Rasmussen encephalitis.\n\n**Off-Label Uses**\n\n**Myasthenia gravis**\n\nThe FDA has recently approved 2 biosimilars of rituximab for adult patients. Biosimilars are drugs that have no clinically significant difference from the reference drug. These have a similar structure, safety profile, and function. Developing biosimilars aims to make medicines more accessible by lowering the cost.[[2]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)Rituximab-abbs is approved for use in NHL alone or as part of a combination chemotherapy regimen and CLL in combination with fludarabine and cyclophosphamide. Rituximab-pvvr has approval for use in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA).\n\nThere are numerous off-label uses of rituximab. According to a retrospective cross-sectional study performed in the US, the use of rituximab for off-label indications increased from 1.2% in 2009 to 55.6% in 2017.[[1]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)Off-label uses include refractory autoimmune hemolytic anemia, refractory myasthenia gravis, multiple sclerosis, chronic steroid-refractory GVHD, Hodgkin lymphoma, systemic lupus erythematosus, thrombotic thrombocytopenic purpura, Waldenstrom macroglobulinemia, and membranous nephropathy.\n\nIn combination with hyaluronidase (rituximab-hyaluronidase human), rituximab was approved by the FDA in 2017. This formulation is available for use in the subcutaneous form, giving the advantage of a faster administration over 5 to 7 minutes instead of prolonged infusion times with IV formulations.This combination is approved for use in chronic lymphocytic leukemia, follicular lymphoma, and diffuse large B-cell lymphoma. One limitation of use is that it can only be given after receiving a full dose of a rituximab product by IV infusion.[[3]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\n[Go to:](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Go to other sections in this page\")\n\nMechanism of Action\n-------------------\n\nRituximab is an anti-CD20 chimeric antibody with human IgG1 immunoglobulin constant regions and variable regions from an anti-CD20 murine antibody. CD20 is a surface transmembrane protein marker expressed on B cells during differentiation from the pre-B cell until the plasma cell stage. CD20 is believed to function as a calcium channel and play a role in the maturation and activation of B cells.[[4]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)[[5]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\nOnce rituximab is bound to CD20-positive cells, cell death is induced by various mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-mediated-cytotoxicity (CDC), antibody-dependent phagocytosis (ADP), and direct effects of binding of rituximab to CD20.[[4]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)The mechanism of action of rituximab in autoimmune disease is thought to be due to a disruption in B cells' function in the immune system or a decrease in plasma cell production, as CD20-positive B cells are intermediates in the process of maturation.[[6]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\nThe combination of rituximab and hyaluronidase (rituximab-hyaluronidase human) is used in the subcutaneous form. Hyaluronidase causes a reversible increase in permeability of subcutaneous tissue by causing depolymerization of hyaluronan, which leads to an increase in the absorption rate of rituximab.\n\n**Pharmacokinetics**\n\n**Absorption:**Rituximab follows a linear pharmacokinetic model.[[7]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)Intravenously administered rituximab has close to 100% bioavailability.\n\n**Distribution:**Per the packaging insert available at the FDA, rituximab has a volume of distribution of 3.1 L.\n\n**Metabolism:**Rituximab is metabolized by various proteases throughout the body and the hepatic CYP450 system of enzymes.\n\n**Elimination:**The endogenous elimination of rituximab occurs following its formation of antidrug-monoclonal antibody immune complexes and is mediated by the reticuloendothelial system, most likely via the action of fragment crystallizable-gamma (Fcγ)-mediated endocytosis.[[7]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)The drug's half-life is 18 to 32 days.\n\n[Go to:](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Go to other sections in this page\")\n\nAdministration\n--------------\n\n**Dosage Forms**\n\nRituximab and its biosimilars are approved for use by intravenous infusion. They should not be administered as an IV bolus or push. Patients should be given acetaminophen and antihistamines before each infusion. Rituximab should be diluted in an infusion bag of 0.9% sodium chloride, 5% dextrose in water, or USP. No other drugs should be mixed with it, and patients should be closely monitored for infusion reactions.[[8]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\nRituximab-hyaluronidase human is approved for subcutaneous use.The drug should be administered in the subcutaneous abdominal tissue over 5 to 7 minutes. Patients should be observed for 15 minutes after administration.[[3]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\n**Adult Dosing**\n\nThe following are adult dosing regimens for approved indications. Clinicians should refer to institutional protocols and the packaging insert for indications, premedications, and dosing.\n\nRelapsed or refractory CD20-positive B-cell NHL:\n\n*   Monotherapy: 375 mg/m 2/dose IV weekly for 4 or 8 weeks. \n*   Ibritumomab tiuxetan combination therapy:250 mg/m 2/dose IV x 1 on the first day, then on days 7, 8, or 9 of the regimen. \n\nPreviously untreated CD20-positive B-cell NHL:\n\n*   Follicular type - combination chemotherapy:375 mg/m 2/dose IV x 1 on day 1 of each cycle for up to 8 cycles. \n*   Follicular type - ibritumomab tiuxetan combination therapy:250 mg/m 2/dose IV x 1 on the first day, then on days 7, 8, or 9 of the regimen. \n*   Diffuse large B-cell type - combination chemotherapy:375 mg/m 2/dose IV x 1 on day 1 of each cycle for up to 8 cycles. \n\nNon-progressing CD20-positive B-cell NHL:\n\n*   375 mg/m 2/dose IV x 1 on days 1, 8, 15, 22, or a 6-month cycle. \n\nCD-20-positive CLL/SLL:\n\n*   Start 375 mg/m 2/dose IV x 1 on the day before cycle 1; then 500 mg/m 2/dose IV x 1 on day 1 of cycle 2 of a 28-day cycle, for 6 cycles. \n\nModerate to severe rheumatoid arthritis:\n\n*   1000 mg IV every 2 weeks for 2 doses. \n\nGranulomatosis with polyangiitis (GPA):\n\n*   Induction:375 mg/m 2/dose IV weekly for 4 weeks. \n*   Subsequent:500 mg/m 2/dose IV every 2 weeks for 2 doses, then 500 mg/m 2/dose IV every 6 months. \n\nMicroscopic polyangiitis (MPA)\n\n*   Induction:375 mg/m 2/dose IV weekly for 4 weeks; use with glucocorticoids. \n*   Subsequent:500 mg/m 2/dose IV every 2 weeks for 2 doses, then 500 mg/m 2/dose IV every 6 months; start 16 to 24 weeks after the induction dose. \n\nModerate to severe pemphigous vulgaris:\n\n*   Start with 1000 mg IV every 2 weeks for 2 doses, then 500 mg IV every 6 months. \n\n**Special Patient Populations**\n\n**Hepatic impairment:**Hepatic dosing for rituximab is undefined.\n\n**Renal impairment:**Renal impairment requires no dose adjustments.\n\n**Pregnancy considerations:**Rituximab has no known risk of teratogenicity, although there is a risk of transient B-cell depletion based on limited human data.Females of reproductive potential should obtain a pregnancy test before initiation of treatment and avoid pregnancy by using effective contraception during treatment and for 12 months following the end of treatment.\n\n**Breastfeeding considerations:**Women should avoid breastfeeding during treatment and for 6 months following cessation.\n\n**Pediatric patients:**\n\n*   Approved pediatric indications include CD20-positive B-cell NHL, GPA, and MPA. \n*   Rituximab is used off-label in pediatric patients for relapsed or refractory B-cell precursor ALL, moderate to severe pemphigus vulgaris, refractory autoimmune hemolytic anemia, chronic immune thrombocytopenia (ITP), post-transplant lymphoproliferative disorder (11 months and older), and refractory systemic lupus erythematosus (8 years and older). Consult package inserts or institutional guidelines for dosing and premedication regimens. \n\n**Older patients:**Rituximab is a viable treatment in older patients, albeit with diligent monitoring and vigilance.[[9]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\n[Go to:](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Go to other sections in this page\")\n\nAdverse Effects\n---------------\n\n**Infusion reactions:**These are the drug's most common and most serious adverse effects. In randomized controlled trials, allergic or anaphylactic reactions were seen in 80% to 90% of patients receiving rituximab.[[10]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)These are usually seen within 30 to 120 minutes after the first infusion and range from mild to life-threatening. Infusion reactions can include fever, chills, skin rash, urticaria, angioedema, hypotension, ARDS, ventricular fibrillation, shock, anaphylaxis, and death.\n\n**Infections:**Serious bacterial, viral, and fungal infections can occur. New or reactivated viral infections can include JC virus, herpes simplex, CMV, varicella-zoster, West Nile Virus, and hepatitis B and C. Due to the risk of reactivation, live vaccines are contraindicated during treatment with rituximab. They should be given at least 4 weeks before starting rituximab.\n\nReactivation of hepatitis B with fulminant hepatitis, hepatic failure, and death can occur. Before starting rituximab, all patients should be screened with hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc). Patients should also be monitored for hepatitis B reactivation during and after treatment.[[11]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)[[12]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\nReactivation of Hepatitis B and the development of PML (progressive multifocal leukoencephalopathy) due to the JC virus are indications to discontinue rituximab.\n\nPCP is an opportunistic fungal infection whose prophylaxis is recommended in patients receiving a fludarabine/cyclophosphamide/rituximab combination to treat CLL.This combination should be started during treatment and continued for a year following completion, and it is also recommended in patients with GPA and MPA during treatment and for at least 6 months after stopping rituximab.[[13]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\n**Hematologic adverse effects:**Lymphopenia is the most commonly seen hematologic adverse effect. Others include leukopenia, neutropenia, thrombocytopenia, and anemia.\n\n**Dermatologic/mucocutaneous reactions:**\n\nThese include pruritis, alopecia, skin rash, and life-threatening reactions like toxic epidermal necrolysis, paraneoplastic pemphigus, and Stevens-Johnson syndrome.\n\n**Renal adverse effects:**Tumor lysis syndrome can present with hypocalcemia, hyperphosphatemia, hyperkalemia, hyperuricemia, and acute renal failure within 24 hours of the first infusion. Aggressive hydration and uric acid-lowering therapy should be given to high-risk patients.Renal toxicity has been seen in trials where rituximab was administered with cisplatin.\n\n**Respiratory adverse effects:**These include cough, upper respiratory tract infections, rhinitis, epistaxis, bronchospasm, dyspnea, pulmonary toxicity, and ILD.There have been reports of rare cases of hypersensitivity pneumonitis, status asthmaticus, diffuse alveolar hemorrhage, and bronchiolitis obliterans.[[10]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\n**Cardiovascular adverse effects:**Tachycardia, supraventricular arrhythmias, non-ischemic cardiomyopathy, peripheral edema, chest pain, hypertension.[[14]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\n**Gastrointestinal adverse effects:**Diarrhea, nausea, and vomiting can be seen. Symptoms of abdominal pain should be thoroughly investigated, as there have been reports of bowel obstruction and perforation.\n\n**Neuropsychiatric adverse effects:**Dizziness, headache, anxiety, depression, and insomnia can occur.\n\n**Pregnancy considerations:**A limited amount crosses the placental barrier during the first trimester, but crossing increases in the second and third trimesters.Administration of rituximab during the third trimester can lead to immunosuppression in the neonate.Levels of rituximab in fetal circulation are similar to maternal levels near term, and live vaccines are contraindicated in the neonate during the first 6 months of birth.[[15]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)Due to a poor understanding of long-term effects, it is recommended to use effective contraception during treatment with rituximab and for a year after the last dose.[[16]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)[[17]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\n**Constitutional adverse effects:**These include asthenia, fever, chills, myalgia, arthralgia, muscle spasms, back pain, night sweats, and fatigue.\n\n**Drug-Drug Interactions**\n\nThe primary drugs contraindicated for concurrent use with rituximab are live vaccines. Cidofovir and talimogene laherparepvec are also absolutely contraindicated for concurrent use.\n\n[Go to:](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Go to other sections in this page\")\n\nContraindications\n-----------------\n\nAbsolute and relative contraindications of the drug exist[[6]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)[[12]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)and include the following:\n\n*   Severe, active infection \n*   Hypersensitivity to any of the components of the formulation \n*   Severe heart failure \n*   Uncontrolled cardiac disease \n*   Hypersensitivity to murine protein \n\n[Go to:](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Go to other sections in this page\")\n\nMonitoring\n----------\n\nRituximab has an excellent safety profile, and overdosage has not been experienced in clinical trials. Patients should be regularly monitored for the development of adverse effects.\n\nBefore initiating treatment with rituximab, a CBC, routine chemistries, serum immunoglobulin levels, a chest x-ray, and serologic testing for hepatitis B, C, and HIV should be obtained. If HBsAg or anti-HBc is positive, HBV DNA PCR should be obtained. If HBV DNA is positive, entecavir should be given for prophylaxis. Lamivudine prophylaxis is indicated if HBV DNA is negative.[[11]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\nThe following should be regularly monitored during treatment:\n\n*   Development of infusion reactions. Acetaminophen and an antihistamine should be administered before starting the infusion to reduce the incidence of infusion reactions \n*   CBC to look for the development of any cytopenias \n*   Electrolytes and renal function in patients at high risk of tumor lysis syndrome \n*   Cardiac monitoring for patients with a history of cardiac disease \n*   Serum immunoglobulin levels \n*   Liver function tests and HBV DNA in patients with risk of reactivation of hepatitis B \n*   Patients should be monitored for signs and symptoms of opportunistic infections. The neurological function should be assessed to look for the onset of any new deficits. \n\n[Go to:](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Go to other sections in this page\")\n\nToxicity\n--------\n\nToxicity data for rituximab is not available.Patients who have had an overdose are at an increased risk of severe adverse effects,including fatal infusion-related/severe mucocutaneous reactions.Symptomatic and supportive measures are recommended.\n\n[Go to:](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Go to other sections in this page\")\n\nEnhancing Healthcare Team Outcomes\n----------------------------------\n\nRituximab is a relatively safe and well-tolerated drug, and its off-label use has increased over the years. Patients should be educated regarding the benefits and risks of rituximab therapy.\n\nRituximab therapy requires the efforts and collaboration of a coordinated interprofessional healthcare team. Hypersensitivity reactions (HSR) are commonly seen with rituximab infusions. These can be reduced through premedication and titrated infusions. Priming the IV line with rituximab can have a positive impact. Reducing the HSR rate can reduce the cost for cancer centers, improve patient safety and satisfaction, and prevent delays in treatment. Nurses have a crucial role as members of the multidisciplinary team involved in the care of these patients. Care should be coordinated between the oncologist, other physicians/advanced practice practitioners, nurses, and pharmacists.[[18]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\nRecent evidence has shown a comparable clinical efficacy of subcutaneous and IV rituximab. SC rituximab allows faster delivery of the drug and reduces dosage errors and drug wastage. Faster delivery time allows more patients to be scheduled. Cancer centers should consider the subcutaneous route for most patients with chronic lymphocytic leukemia, follicular lymphoma, and diffuse large B cell lymphoma. The subcutaneous route could also be an alternative for patients with poor IV access.[[19]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)[[20]](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\n[Go to:](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Go to other sections in this page\")\n\nReview Questions\n----------------\n\n*   [Access free multiple choice questions on this topic.](https://www.statpearls.com/account/trialuserreg/?articleid=98653&utm_source=pubmed&utm_campaign=reviews&utm_content=98653) \n*   [Comment on this article.](https://www.statpearls.com/articlelibrary/commentarticle/98653/?utm_source=pubmed&utm_campaign=comments&utm_content=98653) \n\n[Go to:](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Go to other sections in this page\")\n\nReferences\n----------\n\n1.\n\nDelate T, Hansen ML, Gutierrez AC, Le KN. Indications for Rituximab Use in an Integrated Health Care Delivery System. J Manag Care Spec Pharm. 2020 Jul;26(7):832-838. [[PMC free article: PMC10391100](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391100/)] [[PubMed: 32584674](https://pubmed.ncbi.nlm.nih.gov/32584674)]\n\n2.\n\nGreenwald M, Tesser J, Sewell KL. Biosimilars Have Arrived: Rituximab. Arthritis. 2018;2018:3762864. [[PMC free article: PMC5885398](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885398/)] [[PubMed: 29765782](https://pubmed.ncbi.nlm.nih.gov/29765782)]\n\n3.\n\nYelvington BJ. Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma. J Adv Pract Oncol. 2018 Jul-Aug;9(5):530-534. [[PMC free article: PMC6505540](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505540/)] [[PubMed: 31086689](https://pubmed.ncbi.nlm.nih.gov/31086689)]\n\n4.\n\nMaloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002 Feb;29(1 Suppl 2):2-9. [[PubMed: 11842383](https://pubmed.ncbi.nlm.nih.gov/11842383)]\n\n5.\n\nPierpont TM, Limper CB, Richards KL. Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. Front Oncol. 2018;8:163. [[PMC free article: PMC5994406](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994406/)] [[PubMed: 29915719](https://pubmed.ncbi.nlm.nih.gov/29915719)]\n\n6.\n\nRandall KL. Rituximab in autoimmune diseases. Aust Prescr. 2016 Aug;39(4):131-134. [[PMC free article: PMC4993704](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993704/)] [[PubMed: 27756976](https://pubmed.ncbi.nlm.nih.gov/27756976)]\n\n7.\n\nRyman JT, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):576-588. [[PMC free article: PMC5613179](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613179/)] [[PubMed: 28653357](https://pubmed.ncbi.nlm.nih.gov/28653357)]\n\n8.\n\nKosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord. 2010 Mar;3(2):93-105. [[PMC free article: PMC3002645](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002645/)] [[PubMed: 21179602](https://pubmed.ncbi.nlm.nih.gov/21179602)]\n\n9.\n\nMielnik P, Sexton J, Lie E, Bakland G, Loli LP, Kristianslund EK, Rødevand E, Lexberg ÅS, Kvien TK. Does Older Age have an Impact on Rituximab Efficacy and Safety? Results from the NOR-DMARD Register. Drugs Aging. 2020 Aug;37(8):617-626. [[PubMed: 32648248](https://pubmed.ncbi.nlm.nih.gov/32648248)]\n\n10.\n\nKasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care. 2012 Aug 31;16(4):231. [[PMC free article: PMC3580676](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580676/)] [[PubMed: 22967460](https://pubmed.ncbi.nlm.nih.gov/22967460)]\n\n11.\n\nNixon A, Ogden L, Woywodt A, Dhaygude A. Infectious complications of rituximab therapy in renal disease. Clin Kidney J. 2017 Aug;10(4):455-460. [[PMC free article: PMC5570071](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570071/)] [[PubMed: 28852481](https://pubmed.ncbi.nlm.nih.gov/28852481)]\n\n12.\n\nBuch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P., Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011 Jun;70(6):909-20. [[PMC free article: PMC3086093](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086093/)] [[PubMed: 21378402](https://pubmed.ncbi.nlm.nih.gov/21378402)]\n\n13.\n\nMaertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen J, Matos O, Bretagne S, Cordonnier C., 5th European Conference on Infections in Leukaemia (ECIL-5), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organisation for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (ICHS) and the European LeukemiaNet (ELN). ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016 Sep;71(9):2397-404. [[PubMed: 27550992](https://pubmed.ncbi.nlm.nih.gov/27550992)]\n\n14.\n\nCheungpasitporn W, Kopecky SL, Specks U, Bharucha K, Fervenza FC. Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. J Renal Inj Prev. 2017;6(1):18-25. [[PMC free article: PMC5414514](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414514/)] [[PubMed: 28487867](https://pubmed.ncbi.nlm.nih.gov/28487867)]\n\n15.\n\nChakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011 Feb 03;117(5):1499-506. [[PubMed: 21098742](https://pubmed.ncbi.nlm.nih.gov/21098742)]\n\n16.\n\nTraila A, Dima D, Achimas-Cadariu P, Micu R. Fertility preservation in Hodgkin's lymphoma patients that undergo targeted molecular therapies: an important step forward from the chemotherapy era. Cancer Manag Res. 2018;10:1517-1526. [[PMC free article: PMC6005299](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005299/)] [[PubMed: 29942153](https://pubmed.ncbi.nlm.nih.gov/29942153)]\n\n17.\n\nLeroy C, Rigot JM, Leroy M, Decanter C, Le Mapihan K, Parent AS, Le Guillou AC, Yakoub-Agha I, Dharancy S, Noel C, Vantyghem MC. Immunosuppressive drugs and fertility. Orphanet J Rare Dis. 2015 Oct 21;10:136. [[PMC free article: PMC4618138](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618138/)] [[PubMed: 26490561](https://pubmed.ncbi.nlm.nih.gov/26490561)]\n\n18.\n\nLaudati C, Clark C, Knezevic A, Zhang Z, Barton-Burke M. Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment. Clin J Oncol Nurs. 2018 Aug 01;22(4):407-414. [[PMC free article: PMC6192040](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192040/)] [[PubMed: 30035788](https://pubmed.ncbi.nlm.nih.gov/30035788)]\n\n19.\n\nStewart D, Aucoin JS, Crosbie T, Forman M, Lye E, Christofides A, Mitha A. Update on the subcutaneous administration of rituximab in Canadian cancer centres. Curr Oncol. 2020 Apr;27(2):113-116. [[PMC free article: PMC7253745](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253745/)] [[PubMed: 32489254](https://pubmed.ncbi.nlm.nih.gov/32489254)]\n\n20.\n\nDavies A, Berge C, Boehnke A, Dadabhoy A, Lugtenburg P, Rule S, Rummel M, McIntyre C, Smith R, Badoux X. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Adv Ther. 2017 Oct;34(10):2210-2231. [[PMC free article: PMC5656720](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656720/)] [[PubMed: 28983819](https://pubmed.ncbi.nlm.nih.gov/28983819)]\n\n**Disclosure:**Nazma Hanif declares no relevant financial relationships with ineligible companies.\n\n**Disclosure:**Faiz Anwer declares no relevant financial relationships with ineligible companies.\n\n*   [Continuing Education Activity](https://www.ncbi.nlm.nih.gov/books/NBK564374/#_article-98653_s1_)\n*   [Indications](https://www.ncbi.nlm.nih.gov/books/NBK564374/#_article-98653_s2_)\n*   [Mechanism of Action](https://www.ncbi.nlm.nih.gov/books/NBK564374/#_article-98653_s3_)\n*   [Administration](https://www.ncbi.nlm.nih.gov/books/NBK564374/#_article-98653_s4_)\n*   [Adverse Effects](https://www.ncbi.nlm.nih.gov/books/NBK564374/#_article-98653_s5_)\n*   [Contraindications](https://www.ncbi.nlm.nih.gov/books/NBK564374/#_article-98653_s6_)\n*   [Monitoring](https://www.ncbi.nlm.nih.gov/books/NBK564374/#_article-98653_s7_)\n*   [Toxicity](https://www.ncbi.nlm.nih.gov/books/NBK564374/#_article-98653_s8_)\n*   [Enhancing Healthcare Team Outcomes](https://www.ncbi.nlm.nih.gov/books/NBK564374/#_article-98653_s9_)\n*   [Review Questions](https://www.ncbi.nlm.nih.gov/books/NBK564374/#_article-98653_s10_)\n*   [References](https://www.ncbi.nlm.nih.gov/books/NBK564374/#_article-98653_s11_)\n\n[Copyright](https://www.ncbi.nlm.nih.gov/books/about/copyright/) © 2025, StatPearls Publishing LLC.\nThis book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) ([http://creativecommons.org/licenses/by-nc-nd/4.0/](https://creativecommons.org/licenses/by-nc-nd/4.0/)), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.\n\nBookshelf ID: NBK564374 PMID: [33232044](https://pubmed.ncbi.nlm.nih.gov/33232044 \"PubMed record of this page\")\n\n*   Share on Facebook\n*   Share on Twitter\n\n### Views\n\n[](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Show/hide content\")\n\n*   [PubReader](https://www.ncbi.nlm.nih.gov/books/NBK564374/?report=reader)\n*   [Print View](https://www.ncbi.nlm.nih.gov/books/NBK564374/?report=printable)\n*   [Cite this Page](https://www.ncbi.nlm.nih.gov/books/NBK564374/#_ncbi_dlg_citbx_NBK564374)\n\n### In this Page\n\n[](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Show/hide content\")\n\n*   [Continuing Education Activity](https://www.ncbi.nlm.nih.gov/books/NBK564374/#article-98653.s1)\n*   [Indications](https://www.ncbi.nlm.nih.gov/books/NBK564374/#article-98653.s2)\n*   [Mechanism of Action](https://www.ncbi.nlm.nih.gov/books/NBK564374/#article-98653.s3)\n*   [Administration](https://www.ncbi.nlm.nih.gov/books/NBK564374/#article-98653.s4)\n*   [Adverse Effects](https://www.ncbi.nlm.nih.gov/books/NBK564374/#article-98653.s5)\n*   [Contraindications](https://www.ncbi.nlm.nih.gov/books/NBK564374/#article-98653.s6)\n*   [Monitoring](https://www.ncbi.nlm.nih.gov/books/NBK564374/#article-98653.s7)\n*   [Toxicity](https://www.ncbi.nlm.nih.gov/books/NBK564374/#article-98653.s8)\n*   [Enhancing Healthcare Team Outcomes](https://www.ncbi.nlm.nih.gov/books/NBK564374/#article-98653.s9)\n*   [Review Questions](https://www.ncbi.nlm.nih.gov/books/NBK564374/#article-98653.s10)\n*   [References](https://www.ncbi.nlm.nih.gov/books/NBK564374/#article-98653.s11)\n\n### Related information\n\n[](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Show/hide content\")\n\n*   [PMC](https://www.ncbi.nlm.nih.gov/books/?Db=pmc&DbFrom=books&Cmd=Link&LinkName=books_pmc_refs&IdsFromResult=5110982)PubMed Central citations \n*   [PubMed](https://www.ncbi.nlm.nih.gov/books/?Db=pubmed&DbFrom=books&Cmd=Link&LinkName=books_pubmed_refs&IdsFromResult=5110982)Links to PubMed \n\n### Recent Activity\n\n[](https://www.ncbi.nlm.nih.gov/books/NBK564374/# \"Show/hide content\")\n\n[Clear](javascript:historyDisplayState('ClearHT'))[Turn Off](javascript:historyDisplayState('HTOff'))[Turn On](javascript:historyDisplayState('HTOn'))\n\n*   [Rituximab - StatPearls](https://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=696a2faa103a2747fe11dcce)Rituximab - StatPearls   \n\nYour browsing activity is empty.\n\nActivity recording is turned off.\n\n[Turn recording back on](javascript:historyDisplayState('HTOn'))\n\n[See more...](https://www.ncbi.nlm.nih.gov/sites/myncbi/recentactivity)\n\nFollow NCBI\n\n[](https://twitter.com/ncbi)[](https://www.facebook.com/ncbi.nlm)[](https://www.linkedin.com/company/ncbinlm)[](https://github.com/ncbi)[](https://ncbiinsights.ncbi.nlm.nih.gov/)\n\n[Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html)\n\n*   [](https://twitter.com/NLM_NIH)\n*   [](https://www.facebook.com/nationallibraryofmedicine)\n*   [](https://www.youtube.com/user/NLMNIH)\n\nNational Library of Medicine\n\n[8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323)\n\n[Web Policies](https://www.nlm.nih.gov/web_policies.html)\n\n[FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office)\n\n[HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html)\n\n[Help](https://support.nlm.nih.gov/?pagename=bookshelf%3Abooks%3Abook-part%3A%2FNBK564374%2F)\n\n[Accessibility](https://www.nlm.nih.gov/accessibility.html)\n\n[Careers](https://www.nlm.nih.gov/careers/careers.html)\n\n*   [NLM](https://www.nlm.nih.gov/)\n*   [NIH](https://www.nih.gov/)\n*   [HHS](https://www.hhs.gov/)\n*   [USA.gov](https://www.usa.gov/)\n\n[Preferences](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)[Turn off](https://www.ncbi.nlm.nih.gov/books/NBK564374/#)\n\nExternal link. Please review our [privacy policy](https://www.nlm.nih.gov/privacy.html).\n\nCite this Page Close\n\nHanif N, Anwer F. Rituximab. [Updated 2024 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.  Available from: https://www.ncbi.nlm.nih.gov/books/NBK564374/\n\nMaking content easier to read in Bookshelf Close\n\nWe are experimenting with display styles that make it easier to read books and documents in Bookshelf. Our first effort uses ebook readers, which have several \"ease of reading\" features already built in.\n\nThe content is best viewed in the _iBooks reader_. You may notice problems with the display of some features of books or documents in other eReaders.\n\nCancel Download\n\nShare \n*   Share on Facebook\n*   Share on Twitter\n\nURL"
      }
    ]
  },
  "firm_searches": {
    "[\"merck\"]": {
      "fetched_at": "2026-01-16T12:31:35.206975+00:00",
      "firms": [
        "Merck"
      ],
      "results": [
        {
          "title": "A Clinical Study of Zilovertamab Vedotin Plus Rituximab Plus ...",
          "url": "https://www.merckclinicaltrials.com/trial/nct06890884/",
          "content": "## What can you do next?\n\nIf you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.\n\n### Discuss with your doctor or care team\n\nPrint this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.\n\nGet help talking with your doctor or care team\n\n### Contact our Trial Information Center\n\nTo learn more, call 1-888-577-8839.\n\nNATIONAL TRIAL REFERENCE NUMBER\n\nNCT06890884\n\nWhen speaking to your doctor or clinical trial representative, please have the trial reference number available.\n\nMerck Clinical Trials Logo\n\nCopyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. [...] Merck Clinical Trials Primary\n\nMK 2140-011\n\nMK-2140-011\n\n# A Clinical Study of Zilovertamab Vedotin Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma\n\n## Trial Purpose\n\nResearchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing.\n\nThe goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.\n\nNATIONAL TRIAL REFERENCE NUMBER\n\nNCT06890884 [...] Merck Clinical Trials Logo\n\n# INTERNATIONAL VERSIONS OF THE SITE\n\nMerck & Co, Inc, Rahway, NJ, USA, known as MSD outside of the United States and Canada, provides international versions of this site for both healthcare professionals and the general public.\n\nSelect a language below to be redirected to the MSD version of the site in your chosen language.\n\nLATIN AMERICA\n\nARGENTINA\n\nBRAZIL\n\nCENTRAL AMERICA\n\nChile\n\nColombia\n\nMEXICO\n\nPeru\n\nEurope\n\nAustria\n\nDenmark\n\nFrance\n\nGermany\n\nGreece\n\nItaly\n\nPoland\n\nSpain\n\nAsia Pacific\n\nAustralia\n\nAfrica\n\nSouth Africa\n\nMerck Clinical Trials Primary\n\nMK 2140-011\n\nMK-2140-011",
          "raw_content": "![Merck Clinical Trials Logo](https://www.merckclinicaltrials.com/app/uploads/2021/09/merck-full-color.svg)\n\n# INTERNATIONAL VERSIONS OF THE SITE\n\nMerck & Co, Inc, Rahway, NJ, USA, known as MSD outside of the United States and Canada, provides international versions of this site for both healthcare professionals and the general public.\n\nSelect a language below to be redirected to the MSD version of the site in your chosen language.\n\nLATIN AMERICA\n\nARGENTINA\n\nBRAZIL\n\nCENTRAL AMERICA\n\nChile\n\nColombia\n\nMEXICO\n\nPeru\n\nEurope\n\nAustria\n\nDenmark\n\nFrance\n\nGermany\n\nGreece\n\nItaly\n\nPoland\n\nSpain\n\nAsia Pacific\n\nAustralia\n\nAfrica\n\nSouth Africa\n\nMerck Clinical Trials Primary\n\nMK 2140-011\n\nMK-2140-011\n\n# A Clinical Study of Zilovertamab Vedotin Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma\n\n## Trial Purpose\n\nResearchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing.\n\nThe goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.\n\nNATIONAL TRIAL REFERENCE NUMBER\n\nNCT06890884\n\nWhen speaking to your doctor or clinical trial representative, please have the trial reference number available.\n\n### Resources\n\n## Eligibility\n\nOnly a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.\n\n![](https://www.merckclinicaltrials.com/app/themes/merck-theme/dist/images/icon-conditions.svg)\n\nConditions\n\nLymphoma, Large B-Cell, Diffuse\n\n![](https://www.merckclinicaltrials.com/app/themes/merck-theme/dist/images/icon-age.svg)\n\nAge Range\n\n18+\n\n![](https://www.merckclinicaltrials.com/app/themes/merck-theme/dist/images/icon-sex.svg)\n\nSex\n\nAll\n\n## About The Study\n\n![](https://www.merckclinicaltrials.com/app/themes/merck-theme/dist/images/icon-phase.svg)\n\n### Trial Phase 2\n\nIn Phase 2 trials, researchers try to find out if a treatment works in about 100 to 500 participantsResearch participantIn clinical research, a person who qualifies and agrees to participate in a study. Also called volunteer, trial participant. – usually people who have the health condition the treatment is intended to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.\n\n![](https://www.merckclinicaltrials.com/app/themes/merck-theme/dist/images/icon-calendar.svg)\n\n## Trial Locations\n\nLocations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.\n\n## What can you do next?\n\nIf you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.\n\n### Discuss with your doctor or care team\n\nPrint this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.\n\n[Get help talking with your doctor or care team](https://www.merckclinicaltrials.com/important-conversations/)\n\n### Contact our Trial Information Center\n\nTo learn more, call 1-888-577-8839.\n\nNATIONAL TRIAL REFERENCE NUMBER\n\nNCT06890884\n\nWhen speaking to your doctor or clinical trial representative, please have the trial reference number available.\n\n![Merck Clinical Trials Logo](https://www.merckclinicaltrials.com/app/uploads/2021/09/merck-white-color.svg)\n\nCopyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.\n\nTHIS WEBSITE IS INTENDED FOR A UNITED STATES AUDIENCE ONLY\n\n![](https://www.merckclinicaltrials.com/app/themes/merck-theme/dist/images/icons/accessibility-icon.svg)"
        },
        {
          "title": "Long-term safety of rituximab in rheumatoid arthritis",
          "url": "https://ard.bmj.com/content/72/9/1496",
          "content": "Competing interests RFvV has received grants, consultancy fees and payments for lectures from Abbott, GSK, MSD, Pfizer, Roche and UCB. PE has received grants from Roche and consultancy fees/honoraria from Pfizer, Merck, Abbot, UCB, Roche and Novartis. COB has received grants and consulting fees/honoraria from Genentech, Roche, Abbott, Amgen, Bristol Myers Squibb, Centocor, Johnson & Johnson, Janssen, Pfizer and UCB, grants from Biogen Idec, consulting fees from Celgene and Millennium, and royalties from Up-to-Date. EK is a board member of and has received consultancy fees from Abbott, AstraZeneca, Biotest, Bristol Myers Squibb, Centocor, Roche, Genentech, Merck, Nycomed, Pfizer and UCB, has received grants and lecture fees from Abbott, Amgen, Bristol Myers Squibb, Roche, Merck, Pfizer [...] Abbott, Amgen, Bristol Myers Squibb, Roche, Merck, Pfizer and UCB, grants from AstraZeneca, Centocor, Genzyme and Novartis, and lecture fees from Janssen. RF has received a grant from Metroplex Clinical Research Center, and grants and consultancy from Abbott, Amgen, Jansen, UCB, Pfizer, Bristol Myers Squibb, Roche, Lilly, Sanofi and Merck. DEF has received grants and consulting fees or honoraria from Roche, Genentech and Abbott, grants from Bristol Myers Squibb, consultancy fees and support for travel to meetings from Amgen, UCB and Bristol Myers Squibb, and is a Board member of Arthritis Foundation. NT is an employee of and owns stock in Roche. NC and PBL are both employees of Roche. [...] This was a pooled observed case analysis of safety data of patients with moderate-to-severe, active RA treated with rituximab in combination with MTX in a global clinical trial programme (eight randomised trials and two long-term, open-label extensions). Trials included in the ‘All Exposure’ analysis are shown in online supplementary figure S1. Eligibility criteria and study designs have been published previously.8–16 Each rituximab course consisted of intravenous infusions of either 2×1000 mg or 2×500 mg given 2 weeks apart. Prior to each infusion, all patients received intravenous methylprednisolone 100 mg; most patients also received acetaminophen and an antihistamine. Repeat treatment was based on the physician's decision of clinical need and included evidence of active disease",
          "raw_content": "Intended for healthcare professionals\n\n* [Log In](/)  [More](# )\n\n  [Log in via Institution](/login/shibboleth?subcode=bmjjournals&env=prod&uri=https%3A//ard.bmj.com/accallback/content%25252F72%25252F9%25252F1496)\n\n  [Log in via OpenAthens](https://openathens-sp.highwire.org/session/init?entityID=https%3A//idp.eduserv.org.uk/openathens&hw-shib-return-uri=https%3A//ard.bmj.com/accallback/content%25252F72%25252F9%25252F1496&subcode=bmjjournals)\n\n  ### Log in using your username and password\n* [Basket](/cart)\n* [Search](/search)  [More](# )\n\n  [Advanced search](/search)\n\n[Advanced search](/search)\n\n* [Close](/) [More](# )\n\n  ## Main menu\n\n  + [Archive](/content/by/year)\n* [Log in](/)  [More](# )\n\n  [Log in via Institution](/login/shibboleth?subcode=bmjjournals&env=prod&uri=https%3A//ard.bmj.com/accallback/content%25252F72%25252F9%25252F1496)\n\n  [Log in via OpenAthens](https://openathens-sp.highwire.org/session/init?entityID=https%3A//idp.eduserv.org.uk/openathens&hw-shib-return-uri=https%3A//ard.bmj.com/accallback/content%25252F72%25252F9%25252F1496&subcode=bmjjournals)\n\n  ### Log in using your username and password\n* [BMJ Journals](http://journals.bmj.com/)\n\n## You are here\n\n* [Home](/)\n* [Archive](/content/by/year)\n* [Volume 72, Issue 9](/content/72/9)\n* Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients\n\n[Email alerts](https://myaccount.bmj.com/myaccount/signup.html?regService=etoc-alerts&corpusCode=annrheumdis&fwdUrl=https://ard.bmj.com/)\n\nArticle Text\n\n[Article menu](#block-system-main)\n\n* [Article   \n  Text](/content/72/9/1496)\n* [Article   \n  info](/content/72/9/1496.info)\n* [Citation   \n  Tools](/content/72/9/1496.citation-tools)\n* [Share](/content/72/9/1496.share)\n* [Rapid Responses](/content/72/9/1496.responses)\n* [Article   \n  metrics](/content/72/9/1496.altmetrics)\n* [Alerts](/content/72/9/1496.alerts)\n\n[**PDF**](/content/annrheumdis/72/9/1496.full.pdf)\n\n[**PDF +  \n Supplementary  \n Material**](/content/annrheumdis/72/9/1496.full.pdf?with-ds=yes)\n\nClinical and epidemiological research\n\nExtended report\n\nLong-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients\n\n1. Ronald F van Vollenhoven[1](#aff-1),\n2. Paul Emery[2](#aff-2),\n3. Clifton O Bingham III[3](#aff-3),\n4. Edward C Keystone[4](#aff-4),\n5. Roy M Fleischmann[5](#aff-5),\n6. Daniel E Furst[6](#aff-6),\n7. Nicola Tyson[7](#aff-7),\n8. Neil Collinson[7](#aff-7),\n9. Patricia B Lehane[7](#aff-7)\n\n1. 1Unit for Clinical Therapy Research, The Karolinska Institute, Stockholm, Sweden\n2. 2Section of Musculoskeletal Disease, Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, University of Leeds, Leeds, UK\n3. 3Department of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA\n4. 4Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada\n5. 5Department of Rheumatology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA\n6. 6Department of Rheumatology, UCLA, Los Angeles, California, USA\n7. 7Roche Products Ltd, Welwyn Garden City, UK\n\n1. Correspondence to Dr Ronald F van Vollenhoven, Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska University Hospital, D1:00, 17176, Stockholm, Sweden; ronald.van.vollenhoven{at}ki.se\n\n## Abstract\n\n**Objectives** Evaluation of long-term safety of rituximab in rheumatoid arthritis (RA).\n\n**Methods** Pooled observed case analysis of data from patients with moderate-to-severe, active RA treated with rituximab in a global clinical trial programme.\n\n**Results** As of September 2010, 3194 patients had received up to 17 rituximab courses over 9.5 years (11 962 patient-years). Of these, 627 had >5 years’ follow-up (4418 patient-years). A pooled placebo population (n=818) (placebo+methotrexate (MTX)) was also analysed. Serious adverse event and infection rates generally remained stable over time and multiple courses. The overall serious infection event (SIE) rate was 3.94/100 patient-years (3.26/100 patient-years in patients observed for >5 years) and was comparable with placebo+MTX (3.79/100 patient-years). Serious opportunistic infections were rare. Overall, 22.4% (n=717) of rituximab-treated patients developed low immunoglobulin (Ig)M and 3.5% (n=112) low IgG levels for ≥4 months after ≥1 course. SIE rates were similar before and during/after development of low Ig levels; however, in patients with low IgG, rates were higher than in patients who never developed low IgG. Rates of myocardial infarction and stroke were consistent with rates in the general RA population. No increased risk of malignancy over time was observed.\n\n**Conclusions** This analysis demonstrates that rituximab remains generally well tolerated over time and multiple courses, with a safety profile consistent with published data and clinical trial experience. Overall, the findings indicate that there was no evidence of an increased safety risk or increased reporting rates of any types of adverse events with prolonged exposure to rituximab during the 9.5 years of observation.\n\n* Rheumatoid Arthritis\n* Treatment\n* B cells\n\nThis is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>\n\n<https://doi.org/10.1136/annrheumdis-2012-201956>\n\n## Statistics from Altmetric.com\n\n* [Rheumatoid Arthritis](/keyword/rheumatoid-arthritis)\n* [Treatment](/keyword/treatment)\n* [B cells](/keyword/b-cells)\n\n## Introduction\n\nRheumatoid arthritis (RA) is associated with an increased risk of serious infection events (SIE),[1](#ref-1) lymphomas[2](#ref-2) and with increased death rates due to cardiovascular disease.[3](#ref-3) Biological disease-modifying antirheumatic drugs (DMARDs), including tumour necrosis factor (TNF) inhibitors, may further increase the risk of SIE and malignancies.[1](#ref-1) ,[4–7](#ref-4) Continual monitoring of long-term safety of patients receiving biological therapies is therefore of paramount importance.\n\nB cell-targeted therapy using the anti-CD20 monoclonal antibody rituximab is an effective treatment for RA. In combination with methotrexate (MTX), rituximab improves the signs and symptoms of RA and slows joint damage progression.[8–15](#ref-8) Data from eight randomised, placebo-controlled trials in patients with moderately to severely active RA demonstrated that the overall rates of adverse events (AEs) and serious AEs (SAEs), including SIE, were similar to those observed with placebo+ MTX.[8–11](#ref-8) [13–16](#ref-13) Long-term follow-up of patients in these trials indicated that rituximab remained well tolerated over time and multiple courses.[17](#ref-17) These data are encouraging; however, the safety of repeated peripheral B cell depletion, in particular regarding the potential cumulative risk of SIE and malignancies, remains to be fully established.\n\nThis analysis further evaluated the long-term safety of rituximab to determine the consequences of repeat treatment with a peripheral B cell depleting therapy over many years. We focused on specific AEs that could potentially be attributed to the immunological effects of peripheral B cell depletion as well as on AEs of special interest in RA patients. The current analysis involves a larger number of patients than previously reported (>3000 patients with nearly 12 000 patient-years of observation), including a substantial number of patients treated for >5 years.\n\n## Materials and methods\n\n### Studies and analysis\n\nThis was a pooled observed case analysis of safety data of patients with moderate-to-severe, active RA treated with rituximab in combination with MTX in a global clinical trial programme (eight randomised trials and two long-term, open-label extensions). Trials included in the ‘All Exposure’ analysis are shown in online supplementary figure S1. Eligibility criteria and study designs have been published previously.[8–16](#ref-8) Each rituximab course consisted of intravenous infusions of either 2×1000 mg or 2×500 mg given 2 weeks apart. Prior to each infusion, all patients received intravenous methylprednisolone 100 mg; most patients also received acetaminophen and an antihistamine. Repeat treatment was based on the physician's decision of clinical need and included evidence of active disease (either swollen joint count and tender joint count ≥8 or disease activity score in 28 joints–erythrocyte sedimentation rate ≥2.6). Patients received concomitant MTX 10–25 mg/week at a stable dose. Background oral corticosteroids and non-steroidal anti-inflammatory drugs were also permitted.\n\n### Safety assessments\n\nSafety assessments were conducted as previously reported.[17](#ref-17) Patients were followed for the study period and for 1 year after completion or withdrawal. Patients who remained B cell depleted after this time were followed until peripheral B cells returned to lower limit of normal or baseline, whichever occurred earlier. All AEs were captured for the first month in safety follow-up periods, after which time only SAEs and all infection events were collected. Original reported terms were assigned preferred terms using the Medical Dictionary for Regulatory Activities (MedDRA), V.13.1. All potential malignant events (identified by the wide, malignant or unspecified tumours standard MedDRA query (SMQ)), were medically reviewed by the Sponsor to confirm actual malignancies (evidenced by reported histology and information from investigational sites). AEs classified as infections included all preferred terms of the ‘Infections and Infestations’ System Organ Class (SOC) and an additional nine terms from other MedDRA SOCs that could be considered to be due to underlying infection. SIE were defined as infections reported as an SAE or which required treatment with intravenous anti-infectives.\n\n### Data analysis\n\nThe analysis populations consisted of the All Exposure population (all patients exposed to at least one or part of one rituximab infusion, regardless of dose), the 5-year population (a subset of the All Exposure population with >5 years’ follow-up) and the pooled placebo population (all patients who received placebo during placebo-controlled study periods and patients who initially received placebo but were subsequently treated with rituximab (placebo-switch patients)) (placebo+MTX). For placebo-switch patients, safety data were included in the placebo+MTX population up to the time of first rituximab exposure; thereafter, the data were included in the rituximab-treated population. The All Exposure population included patients who had never received prior MTX treatment, DMARD-inadequate responders and inadequate responders to prior TNF inhibitors and/or other biologicals (primarily anakinra). TNF inhibitor/biological-inadequate responders comprised 40% of the All Exposure population.\n\n## Results\n\n### Duration of exposure\n\nAs of September 2010, 3194 patients had been treated with up to 17 courses of rituximab for up to 9.5 years, providing 11 962 patient-years of observation in the All Exposure population. Of patients exposed to rituximab, 1935 had been followed for >3 years and 627 for >5 years. All patients received at least one treatment course; 2428, 1739, 1451, 1154 and 849 patients received ≥2, ≥3, ≥4, ≥5 and ≥6 courses, respectively (see online supplementary figure S2). The greatest number of withdrawals occurred following the first two courses (962 patients (30%)), principally for non-safety reasons and because two studies limited patients to receive one or two courses per protocol. Across the trials, there was a normal expected drop-out rate (1%–13%) for subsequent courses. Overall, withdrawals due to AEs were infrequent (190 patients). Most withdrawals were attributed to ‘other’ reasons which included insufficient therapeutic response, failure to return, violation of selection criteria at entry, other protocol violation, refused treatment/did not cooperate, withdrew consent, administrative/other (including patient entry to extension protocols), lost to follow-up, physician's decision to withdraw and pregnancy. Of those patients who remained in the study, there were very little data that were not recorded and of the data that were missing, they were missing at random.\n\nThe placebo+MTX population included 818 patients (1107 patient-years) with a substantially shorter mean duration of follow-up (>50% withdrew from placebo follow-up by 1 year and 93% by 3 years). Differences in patient numbers and duration of follow-up should be considered during interpretation of data.\n\n### Baseline demographics and disease characteristics\n\nMost patients were female subjects with a mean age of approximately 51 years. Patients had received an average of two previous DMARDs (excluding MTX). Baseline demographics and disease characteristics were comparable across the analysis populations ([table 1](#T1)) except for a longer mean RA disease duration and a greater number of previous DMARDs in the 5-year population ([table 1](#T1)).\n\nView this table:\n\n* View inline\n* [View popup](/highwire/markup/188717/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed)\n\nTable 1\n\nPatient characteristics at baseline\\*\n\n### AEs and SAEs\n\nOverall rates of AEs and SAEs were comparable in the All Exposure (including the 5-year population) and placebo+MTX populations ([table 2](#T2)). AE rates were the highest during the 6 months after first rituximab exposure (owing in part to infusion-related reactions (IRRs)) and generally remained stable thereafter, irrespective of number of courses received (data not shown). The most common AE was IRR; most were common terminology criteria (CTC) grade 1 or 2 and were rarely serious, with the majority occurring at first infusion of the first course (734/3194 patients; 23.0%). The frequency, type and intensity of IRRs and other AEs were consistent with that previously reported.[17](#ref-17) Serious IRRs were rare and included anaphylactic or anaphylactoid reactions, drug hypersensitivity and angioedema. Overall, 19 events were reported in 17 (0.5%) patients, of which 10 occurred during the first infusion of Course 1. No serious IRRs occurred beyond Course 6. SAEs most commonly observed in the All Exposure population were RA exacerbation (n=76; 2%), pneumonia (n=59; 2%), fall (n=55; 2%) and osteoarthritis (n=49; 2%). Withdrawals due to AEs were infrequent (n=190; 6%), the most common causes being RA disease activity (n=44; 1.4%), neoplasms (n=41; 1.3%), IRRs (n=40; 1.3%), infections and infestations (n=29; 0.9%), respiratory disorders (n=16; 0.5%) and cardiac disorders (n=9; 0.3%).\n\nView this table:\n\n* View inline\n* [View popup](/highwire/markup/189054/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed)\n\nTable 2\n\nSummary of adverse events/100 pt-years\n\n### Deaths\n\nThere were 61 deaths in the All Exposure (0.51/100 patient-years (95% CI 0.40 to 0.66)) and seven in the placebo+MTX population (0.63/100 patient-years (95% CI 0.30 to 1.33)). Causes of death varied and were typical for a patient population with active RA. In rituximab-treated patients, primary causes of death included infection (n=14), cardiovascular events (n=13), malignancies (n=11) and respiratory disorders (n=5). In placebo patients, deaths were attributed to cardiovascular events (n=3), infection (n=2) and gastrointestinal disorders (n=2). Incidence of death did not appear to increase with cumulative exposure to rituximab and there were no infusion-related deaths. Death rates were consistent with the previous analysis[17](#ref-17) and with the rate expected in an age- and sex-matched general US population.[18](#ref-18)\n\n### Infections\n\nSIE rates in both the All Exposure and 5-year populations were comparable with that observed in the placebo+MTX population ([table 2](#T2)). Infection rates generally remained stable over time ([figure 1](#F1)A,B) and multiple treatment courses. The most commonly reported infections (>5% patients) in rituximab patients were upper respiratory tract infections, nasopharyngitis, urinary tract infections, bronchitis, sinusitis, diarrhoea, influenza and gastroenteritis, while the most frequent SIE was lower respiratory tract infection, predominantly pneumonia (2%). There was no increase in SIE rates among patients who received subsequent biological therapy (including TNF inhibitors) following rituximab treatment ([table 3](#T3)). SIE rates were also similar (4.25 (95% CI 1.91 to 9.4) vs 4.21 (95% CI 2.33 to 7.60) patient-years) in patients who received their biologic <6 months (n=90) and ≥6 months (n=224) after last rituximab dose. A proportion of these patients (194/314, 62%) had CD19+cell counts <20 cells/μl prior to their subsequent biologic; the SIE rate post-biologic in these patients was 5.35/100 patient-years (95% CI 3.28 to 8.74).\n\nView this table:\n\n* View inline\n* [View popup](/highwire/markup/188753/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed)\n\nTable 3\n\nSIE rate before and after treatment with subsequent biologics, including TNF inhibitors\n\n* [Download figure](https://ard.bmj.com/content/annrheumdis/72/9/1496/F1.large.jpg?download=true \"Download Figure 1\")\n* [Open in new tab](https://ard.bmj.com/content/annrheumdis/72/9/1496/F1.large.jpg)\n* [Download powerpoint](/highwire/powerpoint/188707)\n\nFigure 1\n\n(A) Infection rates and (B) serious infection rates over time—All Exposure population (including subgroup with follow-up of >5 years). Bars indicate (A) infections or (B) serious infection events/100 patient-years. Error bars indicate 95% CIs. pt-yrs, patient years.\n\n### Infections of special interest\n\nSerious opportunistic infections were rare, with seven events reported in the All Exposure population (two cases of atypical pneumonia (no organisms isolated) and one case each of *Candida* septicaemia, pharyngeal abscess (organism unspecified), Scedosporium lung infection, *Pneumocystis jirovecii* pneumonia and progressive multifocal leucoencephalopathy (PML) with fatal outcome[19](#ref-19)), and one event in the placebo+MTX population (*P jirovecii* pneumonia), corresponding to rates of 0.06/100 patient-years and 0.09/100 patient-years, respectively. Two cases of pulmonary tuberculosis (TB), both treated with anti-TB medication, occurred in the All Exposure population; no cases of extra-pulmonary TB, atypical mycobacterial infection or multidrug-resistant TB were observed. No cases of hepatitis B reactivation occurred in the All Exposure population. A single case of *de novo* hepatitis B infection occurred in a 59-year-old female patient following a dental procedure, as reported previously.[11](#ref-11) In the All Exposure population, 108 AEs of herpes zoster were reported in 100 patients, including two cases of ophthalmic herpes zoster and five SAEs. In the placebo+MTX population, 13 events of herpes zoster were reported. Among patients with herpes zoster, 73% were receiving concomitant oral corticosteroids that were ongoing prior to or that had started on the same day as the AE. Rates of herpes zoster (9.0/1000 patient-years) were comparable with the placebo+MTX (11.7/1000 patient-years) and general RA populations (11.5/1000 patient-years).[20](#ref-20)\n\n### Infection risk in patients with low Ig levels\n\nImmunoglobulins (Igs) were generally measured every 8–16 weeks. Analysis was performed to assess the rates of all infections and SIE in patients before and after a low (table 4). For IgG, SIE rates were similar before and during/after low IgG, but both rates were significantly higher than in patients who never developed low IgG. At baseline these patients were on average older, had longer disease duration, lower mean CD19+count, lower mean IgG levels (8.4 vs 13.2 mg/ml) and had received more non-biological DMARDs. Baseline oral steroid use was similar across subgroups. For IgM, SIE rates were not significantly higher during/after low IgM versus before low IgM, and were similar to rates in patients who never developed low IgM. In patients with low IgM/IgG, the SIE profile was consistent with the All Exposure population. Analysis of SIE onset relative to the timing of low Ig was limited due to discrete protocol-defined time points for Ig assessments; in addition, low patient numbers in some subgroups and the lack of a placebo comparator further restricted Ig analysis.\n\nView this table:\n\n* View inline\n* [View popup](/highwire/markup/189332/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed)\n\nTable 4\n\nSummary of infections in patients with IgG/IgM\n\n### Cardiac events\n\nMyocardial infarction (MI) was the most common serious cardiac event in the All Exposure population (49 events in 42 patients; 1.3%). The event rate was 0.41/100 patient-years (95% CI 0.31 to 0.54) versus 0.27/100 patient-years (95% CI 0.09 to 0.84) in the placebo+MTX population. As previously reported,[17](#ref-17) most patients experiencing MI had at least one conventional risk factor. The rate of stroke in the All Exposure population was 0.19/100 patient-years (95% CI 0.13 to 0.29) versus 0.18/100 patient-years (95% CI 0.05 to 0.72) in the placebo+MTX population.\n\n### Malignancies\n\nThe rate of all malignant and unspecified tumours and non-melanoma skin cancers (NMSC) in the All Exposure population was 1.32/100 patient-years (95% CI 1.13 to 1.54) versus 1.17/100 patient-years (95% CI 0.68 to 2.02) in the placebo+ MTX population. The rate of serious malignancies (SAEs as reported by the investigator) was 0.74/100 and 0.81/100 patient-years in the All Exposure and placebo+MTX populations, respectively. NMSC represented approximately a third of reported events; however, as NMSC is not generally reported to cancer surveillance databases these events were excluded in the evaluation of overall malignancy rate. There were 83 confirmed malignancies identified by the Sponsor medical review (from a total of 158 events captured by the MedDRA SMQ) in the All Exposure population, excluding duplications, NMSC and non-malignant (benign) events, providing a malignancy incidence rate (any site) of 0.69/100 patient-years (95% CI 0.56 to 0.86). For solid tumours, the most frequently reported malignancy was breast cancer ([table 5](#T5)). Rituximab-treated patients did not have an increased rate of any malignancy compared with other patients with RA in observational studies.[21](#ref-21) ,[22](#ref-22) There was no evidence of an increased risk of malignancy with cumulative exposure to rituximab as malignancy rates did not increase with number of courses or over time. Furthermore, no increased risk of malignancy for rituximab-treated patients was indicated when comparing the age- and sex-matched standardised incidence ratios for all confirmed malignancies and breast cancer with the general US population Surveillance Epidemiology and End Results (SEER) database,[23](#ref-23) and with published data in adults with RA[24](#ref-24) ([table 5](#T5)).\n\nView this table:\n\n* View inline\n* [View popup](/highwire/markup/188637/expansion?width=1000&height=500&iframe=true&postprocessors=highwire_tables%2Chighwire_reclass%2Chighwire_figures%2Chighwire_math%2Chighwire_inline_linked_media%2Chighwire_embed)\n\nTable 5\n\nRate of malignancy and standardised incidence ratio for malignancy in the rituximab All Exposure population and published data in adults with RA\n\n## Discussion\n\nThis report presents safety data from the global rituximab RA clinical trial programme in 3194 patients with 11 962 patient-years of follow-up. Compared with a previous analysis,[17](#ref-17) this represents almost 7000 additional patient-years of follow-up with 20% more patients, and includes a placebo+MTX population for comparison. The inclusion of 627 patients with >5 years of observation, with some patients having received up to 17 rituximab courses over 9.5 years of observation, affords a high level of confidence in the data and increases the probability of detecting common and infrequent safety risks compared with previous studies.[12](#ref-12) ,[17](#ref-17)\n\nAE and SAE rates generally remained stable over time and over multiple courses, and the most common SAEs in the All Exposure population were typical of biological-treated RA patients.[25](#ref-25) ,[26](#ref-26) The overall SIE rate (3.94/100 patient-years) was within the range reported (3.0 to 5.2/100 patient-years) for long-term follow-up with other RA biologics.[6](#ref-6) ,[25–27](#ref-25) These observations are consistent with controlled rituximab trials[10](#ref-10) ,[11](#ref-11) and a meta-analysis of randomised controlled trials that did not identify a significant increase in SIE risk during rituximab treatment.[28](#ref-28) Opportunistic infections were rare. No further cases of PML in the RA clinical trial programme have been reported other than the single case previously described.[19](#ref-19) The occurrence of confirmed PML from spontaneous reporting and clinical trial sources remains very rare (six confirmed cases in estimated 188 228 RA patients treated with rituximab, as of November 2011 (Roche data on file)). Herpes zoster rates were consistent with placebo+MTX and general RA populations.[20](#ref-20)\n\nDecreases in Ig levels were observed in some patients following rituximab treatment although the clinical consequences of this are unclear. Analysis of registry data has previously shown that a low IgG level (<6 g/l) *before* rituximab treatment was associated with an increased risk of SIE.[29](#ref-29) Low baseline IgG was an exclusion criterion in the RA clinical trials and therefore this observation could not be confirmed or refuted. Following rituximab treatment, low Ig concentrations (particularly IgM) were observed in some patients. Patients with low IgM had no increased risk of infections or SIE. It is well established that reduced IgG levels are inherently associated with an increased risk of infections.[30](#ref-30) Nevertheless, for the small subgroup of patients with low IgG, a higher SIE rate was seen both before and after the development of low IgG compared with patients who never developed low IgG, suggesting that these patients had a higher inherent risk of developing SIE, possibly associated with demographical and/or clinical characteristics rather than with low IgG itself. Thus, for both Ig classes, SIE rates were similar before and after development of low levels. Limitations of the Ig analysis included low patient numbers in the IgG subgroup, lack of a placebo comparator and lack of correlation (due to protocol-defined Ig measurements) between SIE onset and recording of low Ig levels.\n\nRA patients are known to be at an increased risk of cardiovascular disease.[31](#ref-31) Consistent with this, MI was the most frequent cardiac AE reported in rituximab-treated patients. Most patients experiencing MI had at least one conventional risk factor, although it has been reported that cardiovascular morbidity in RA patients cannot be fully explained by such risk factors and that RA-associated inflammation and underlying disease may also be a contributing factor.[32](#ref-32) The MI rate reported for rituximab-treated patients is consistent with epidemiological data from a general RA population receiving TNF inhibitors or DMARDs (0.48 to 0.59/100 patient-years)[31](#ref-31) ,[33](#ref-33) and there was no evidence to suggest an increased risk of MI associated with rituximab treatment. The rate of stroke was also consistent with published data in RA patients.[31](#ref-31) ,[34](#ref-34)\n\nAs might be expected in a predominantly female study population with a mean age of 51 years, the most common solid tumour was breast cancer. Age- and sex-matched standardised incidence ratios for all confirmed malignancies and breast cancer did not indicate an increased risk of malignancy for rituximab-treated RA patients compared with the general US population (SEER database)[23](#ref-23) and with published data in adults with RA.[21](#ref-21) ,[22](#ref-22) ,[24](#ref-24) ,[35](#ref-35)\n\nThe rate of fatal AEs remained consistent through the observation period and there was no evidence of an increased rate of any type of fatal event with prolonged rituximab exposure. The overall death rate observed in the rituximab RA clinical development programme was within the expected range for patients receiving a biological therapy[36](#ref-36) and leading causes of death were also consistent with those expected in such a population.\n\nThe analysis has potential limitations. Data were pooled from diverse studies in which rituximab doses, retreatment regimens and prior or active disease status could differ. Notably, two of the studies limited patients to receive one or two rituximab courses, thus reducing the overall number of patients receiving higher numbers of courses. In addition, clinical trial data are heavily influenced by the fact that patients are selected at baseline to exclude significant comorbidities, and only those who did well clinically remained in the study. Finally, the mean observation period of patients in the placebo+MTX population was considerably shorter than that of patients in the All Exposure population, and this should be borne in mind when making comparisons. Notwithstanding these limitations, the key strength of this analysis is the long observation and follow-up period in a population of patients with active RA, which included frequent assessments, including those performed after study withdrawal or completion (minimum 1 year) and during extended periods of peripheral B cell depletion. In addition, the overall number of patients withdrawing due to AEs was low (6% in total).\n\nIn summary, evidence from the RA clinical trial data of up to 9.5 years of follow-up of 3194 patients treated with rituximab, including a substantial number of patients with >5 years’ observation, revealed no new safety signals. Rituximab has remained generally well tolerated over time and over multiple courses, with a safety profile consistent with published data of patients with moderate-to-severe RA. These findings also indicate that repeated peripheral B cell depletion with rituximab did not give rise to any increased safety risk over time or increased reporting rates of any types of AEs (including infections, cardiovascular events, malignancies or fatal AEs) in the global RA clinical trial programme. Overall, these results are encouraging and should provide clinicians with reassurance regarding the long-term safety of rituximab in RA.\n\n## Acknowledgments\n\nSupport for third-party writing assistance for this manuscript was provided by F Hoffmann-La Roche.\n\n## References\n\n1. [↵](#xref-ref-1-1 \"View reference 1 in text\")\n\n   1. Bongartz T,\n   2. Sutton AJ,\n   3. Sweeting MJ,\n   4. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275–85.\n\n   [OpenUrl]({openurl}?query=rft.jtitle%253DJAMA%26rft.stitle%253DJAMA%26rft.issn%253D0002-9955%26rft.aulast%253DBongartz%26rft.auinit1%253DT.%26rft.volume%253D295%26rft.issue%253D19%26rft.spage%253D2275%26rft.epage%253D2285%26rft.atitle%253DAnti-TNF%2Bantibody%2Btherapy%2Bin%2Brheumatoid%2Barthritis%2Band%2Bthe%2Brisk%2Bof%2Bserious%2Binfections%2Band%2Bmalignancies%253A%2Bsystematic%2Breview%2Band%2Bmeta-analysis%2Bof%2Brare%2Bharmful%2Beffects%2Bin%2Brandomized%2Bcontrolled%2Btrials.%26rft_id%253Dinfo%253Adoi%252F10.1001%252Fjama.295.19.2275%26rft_id%253Dinfo%253Apmid%252F16705109%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1001/jama.295.19.2275&link_type=DOI)[PubMed](/lookup/external-ref?access_num=16705109&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000237556600026&link_type=ISI)\n2. [↵](#xref-ref-2-1 \"View reference 2 in text\")\n\n   1. Baecklund E,\n   2. Iliadou A,\n   3. Askling J,\n   4. et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692–701.\n\n   [OpenUrl]({openurl}?query=rft.jtitle%253DArthritis%2Band%2Brheumatism%26rft.stitle%253DArthritis%2BRheum%26rft.aulast%253DBaecklund%26rft.auinit1%253DE.%26rft.volume%253D54%26rft.issue%253D3%26rft.spage%253D692%26rft.epage%253D701%26rft.atitle%253DAssociation%2Bof%2Bchronic%2Binflammation%252C%2Bnot%2Bits%2Btreatment%252C%2Bwith%2Bincreased%2Blymphoma%2Brisk%2Bin%2Brheumatoid%2Barthritis.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fart.21675%26rft_id%253Dinfo%253Apmid%252F16508929%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1002/art.21675&link_type=DOI)[PubMed](/lookup/external-ref?access_num=16508929&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000236019700002&link_type=ISI)\n3. [↵](#xref-ref-3-1 \"View reference 3 in text\")\n\n   1. Wolfe F,\n   2. Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305–11.\n\n   [OpenUrl]({openurl}?query=rft.jtitle%253DThe%2BAmerican%2Bjournal%2Bof%2Bmedicine%26rft.stitle%253DAm%2BJ%2BMed%26rft.aulast%253DWolfe%26rft.auinit1%253DF.%26rft.volume%253D116%26rft.issue%253D5%26rft.spage%253D305%26rft.epage%253D311%26rft.atitle%253DHeart%2Bfailure%2Bin%2Brheumatoid%2Barthritis%253A%2Brates%252C%2Bpredictors%252C%2Band%2Bthe%2Beffect%2Bof%2Banti-tumor%2Bnecrosis%2Bfactor%2Btherapy.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.amjmed.2003.09.039%26rft_id%253Dinfo%253Apmid%252F14984815%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1016/j.amjmed.2003.09.039&link_type=DOI)[PubMed](/lookup/external-ref?access_num=14984815&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000189191300003&link_type=ISI)\n4. [↵](#xref-ref-4-1 \"View reference 4 in text\")\n\n   1. Maini RN,\n   2. Breedveld FC,\n   3. Kalden JR,\n   4. et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051–65.\n\n   [OpenUrl]({openurl}?query=rft.jtitle%253DArthritis%2Band%2Brheumatism%26rft.stitle%253DArthritis%2BRheum%26rft.aulast%253DMaini%26rft.auinit1%253DR.%2BN.%26rft.volume%253D50%26rft.issue%253D4%26rft.spage%253D1051%26rft.epage%253D1065%26rft.atitle%253DSustained%2Bimprovement%2Bover%2Btwo%2Byears%2Bin%2Bphysical%2Bfunction%252C%2Bstructural%2Bdamage%252C%2Band%2Bsigns%2Band%2Bsymptoms%2Bamong%2Bpatients%2Bwith%2Brheumatoid%2Barthritis%2Btreated%2Bwith%2Binfliximab%2Band%2Bmethotrexate.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fart.20159%26rft_id%253Dinfo%253Apmid%252F15077287%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1002/art.20159&link_type=DOI)[PubMed](/lookup/external-ref?access_num=15077287&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000220763600006&link_type=ISI)\n5. [↵](#xref-ref-4-1 \"View reference 5 in text\")\n\n   1. Genovese MC,\n   2. Bathon JM,\n   3. Fleischmann RM,\n   4. et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 2005;32:1232–42.\n\n   [OpenUrl]({openurl}?query=rft.jtitle%253DThe%2BJournal%2Bof%2BRheumatology%26rft.stitle%253DThe%2BJournal%2Bof%2BRheumatology%26rft.issn%253D0315-162X%26rft.aulast%253DGenovese%26rft.auinit1%253DM.%2BC%26rft.volume%253D32%26rft.issue%253D7%26rft.spage%253D1232%26rft.epage%253D1242%26rft.atitle%253DLongterm%2Bsafety%252C%2Befficacy%252C%2Band%2Bradiographic%2Boutcome%2Bwith%2Betanercept%2Btreatment%2Bin%2Bpatients%2Bwith%2Bearly%2Brheumatoid%2Barthritis.%26rft_id%253Dinfo%253Apmid%252F15996057%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[Abstract/FREE Full Text](/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoianJoZXVtIjtzOjU6InJlc2lkIjtzOjk6IjMyLzcvMTIzMiI7czo0OiJhdG9tIjtzOjI3OiIvYW5ucmhldW1kaXMvNzIvOS8xNDk2LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==)\n6. [↵](#xref-ref-4-1 \"View reference 6 in text\")\n\n   1. Schiff MH,\n   2. Burmester GR,\n   3. Kent JM,\n   4. et al. Safety analyses of adalimumab (HUMIRA®) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889–94.\n\n   [OpenUrl]({openurl}?query=rft.jtitle%253DAnn%2BRheum%2BDis%26rft_id%253Dinfo%253Adoi%252F10.1136%252Fard.2005.043166%26rft_id%253Dinfo%253Apmid%252F16439435%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[Abstract/FREE Full Text](/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6ImFubnJoZXVtZGlzIjtzOjU6InJlc2lkIjtzOjg6IjY1LzcvODg5IjtzOjQ6ImF0b20iO3M6Mjc6Ii9hbm5yaGV1bWRpcy83Mi85LzE0OTYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)\n7. [↵](#xref-ref-4-1 \"View reference 7 in text\")\n\n   1. Askling J,\n   2. Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008;20:138–44.\n\n   [OpenUrl]({openurl}?query=rft.jtitle%253DCurrent%2Bopinion%2Bin%2Brheumatology%26rft.stitle%253DCurr%2BOpin%2BRheumatol%26rft.aulast%253DAskling%26rft.auinit1%253DJ.%26rft.volume%253D20%26rft.issue%253D2%26rft.spage%253D138%26rft.epage%253D144%26rft.atitle%253DThe%2Bsafety%2Bof%2Banti-tumour%2Bnecrosis%2Bfactor%2Btherapy%2Bin%2Brheumatoid%2Barthritis.%26rft_id%253Dinfo%253Adoi%252F10.1097%252FBOR.0b013e3282f4b392%26rft_id%253Dinfo%253Apmid%252F18349742%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1097/BOR.0b013e3282f4b392&link_type=DOI)[PubMed](/lookup/external-ref?access_num=18349742&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000253475200004&link_type=ISI)\n8. [↵](#xref-ref-8-1 \"View reference 8 in text\")\n\n   1. Emery P,\n   2. Deodhar A,\n   3. Rigby WF,\n   4. et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629–35.\n\n   [OpenUrl]({openurl}?query=rft.jtitle%253DAnn%2BRheum%2BDis%26rft_id%253Dinfo%253Adoi%252F10.1136%252Fard.2009.119933%26rft_id%253Dinfo%253Apmid%252F20488885%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[Abstract/FREE Full Text](/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6ImFubnJoZXVtZGlzIjtzOjU6InJlc2lkIjtzOjk6IjY5LzkvMTYyOSI7czo0OiJhdG9tIjtzOjI3OiIvYW5ucmhldW1kaXMvNzIvOS8xNDk2LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==)\n9. [↵](#xref-ref-8-1 \"View reference 9 in text\")\n\n   1. Edwards JC,\n   2. Szczepañski L,\n   3. Szechiñski J,\n   4. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350: 2572–81.\n\n   [OpenUrl]({openurl}?query=rft.jtitle%253DNew%2BEngland%2BJournal%2Bof%2BMedicine%26rft.stitle%253DNEJM%26rft.issn%253D0028-4793%26rft.aulast%253DEdwards%26rft.auinit1%253DJ.%2BC.W.%26rft.volume%253D350%26rft.issue%253D25%26rft.spage%253D2572%26rft.epage%253D2581%26rft.atitle%253DEfficacy%2Bof%2BB-Cell-Targeted%2BTherapy%2Bwith%2BRituximab%2Bin%2BPatients%2Bwith%2BRheumatoid%2BArthritis%26rft_id%253Dinfo%253Adoi%252F10.1056%252FNEJMoa032534%26rft_id%253Dinfo%253Apmid%252F15201414%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1056/NEJMoa032534&link_type=DOI)[PubMed](/lookup/external-ref?access_num=15201414&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000222054700008&link_type=ISI)\n10. [↵](#xref-ref-8-1 \"View reference 10 in text\")\n\n    1. Emery P,\n    2. Fleischmann R,\n    3. Filipowicz-Sosnowska A,\n    4. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390–400.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DArthritis%2Band%2Brheumatism%26rft.stitle%253DArthritis%2BRheum%26rft.aulast%253DEmery%26rft.auinit1%253DP.%26rft.volume%253D54%26rft.issue%253D5%26rft.spage%253D1390%26rft.epage%253D1400%26rft.atitle%253DThe%2Befficacy%2Band%2Bsafety%2Bof%2Brituximab%2Bin%2Bpatients%2Bwith%2Bactive%2Brheumatoid%2Barthritis%2Bdespite%2Bmethotrexate%2Btreatment%253A%2Bresults%2Bof%2Ba%2Bphase%2BIIB%2Brandomized%252C%2Bdouble-blind%252C%2Bplacebo-controlled%252C%2Bdose-ranging%2Btrial.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fart.21778%26rft_id%253Dinfo%253Apmid%252F16649186%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1002/art.21778&link_type=DOI)[PubMed](/lookup/external-ref?access_num=16649186&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000237533100005&link_type=ISI)\n11. [↵](#xref-ref-8-1 \"View reference 11 in text\")\n\n    1. Cohen SB,\n    2. Emery P,\n    3. Greenwald MW,\n    4. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793–806.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DArthritis%2Band%2Brheumatism%26rft.stitle%253DArthritis%2BRheum%26rft.aulast%253DCohen%26rft.auinit1%253DS.%2BB.%26rft.volume%253D54%26rft.issue%253D9%26rft.spage%253D2793%26rft.epage%253D2806%26rft.atitle%253DRituximab%2Bfor%2Brheumatoid%2Barthritis%2Brefractory%2Bto%2Banti-tumor%2Bnecrosis%2Bfactor%2Btherapy%253A%2BResults%2Bof%2Ba%2Bmulticenter%252C%2Brandomized%252C%2Bdouble-blind%252C%2Bplacebo-controlled%252C%2Bphase%2BIII%2Btrial%2Bevaluating%2Bprimary%2Befficacy%2Band%2Bsafety%2Bat%2Btwenty-four%2Bweeks.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fart.22025%26rft_id%253Dinfo%253Apmid%252F16947627%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1002/art.22025&link_type=DOI)[PubMed](/lookup/external-ref?access_num=16947627&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000240872900010&link_type=ISI)\n12. [↵](#xref-ref-8-1 \"View reference 12 in text\")\n\n    1. Keystone E,\n    2. Fleischmann R,\n    3. Emery P,\n    4. et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896–908.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DArthritis%2Band%2Brheumatism%26rft.stitle%253DArthritis%2BRheum%26rft.aulast%253DKeystone%26rft.auinit1%253DE.%26rft.volume%253D56%26rft.issue%253D12%26rft.spage%253D3896%26rft.epage%253D3908%26rft.atitle%253DSafety%2Band%2Befficacy%2Bof%2Badditional%2Bcourses%2Bof%2Brituximab%2Bin%2Bpatients%2Bwith%2Bactive%2Brheumatoid%2Barthritis%253A%2Ban%2Bopen-label%2Bextension%2Banalysis.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fart.23059%26rft_id%253Dinfo%253Apmid%252F18050221%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1002/art.23059&link_type=DOI)[PubMed](/lookup/external-ref?access_num=18050221&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000251781200004&link_type=ISI)\n13. [↵](#xref-ref-8-1 \"View reference 13 in text\")\n\n    1. Mease PJ,\n    2. Cohen S,\n    3. Gaylis NB,\n    4. et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE Trial. J Rheumatol 2010;37:917–27.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DJ%2BRheumatol%26rft_id%253Dinfo%253Adoi%252F10.3899%252Fjrheum.090442%26rft_id%253Dinfo%253Apmid%252F20194448%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[Abstract/FREE Full Text](/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoianJoZXVtIjtzOjU6InJlc2lkIjtzOjg6IjM3LzUvOTE3IjtzOjQ6ImF0b20iO3M6Mjc6Ii9hbm5yaGV1bWRpcy83Mi85LzE0OTYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)\n14. [↵](#xref-ref-8-1 \"View reference 14 in text\")\n\n    1. Rubbert-Roth A,\n    2. Tak PP,\n    3. Zerbini C,\n    4. et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 2010;49:1683–93.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DRheumatology%2B%2528Oxford%2529%26rft_id%253Dinfo%253Adoi%252F10.1093%252Frheumatology%252Fkeq116%26rft_id%253Dinfo%253Apmid%252F20463186%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[Abstract/FREE Full Text](/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTI6InJoZXVtYXRvbG9neSI7czo1OiJyZXNpZCI7czo5OiI0OS85LzE2ODMiO3M6NDoiYXRvbSI7czoyNzoiL2FubnJoZXVtZGlzLzcyLzkvMTQ5Ni5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=)\n15. [↵](#xref-ref-8-1 \"View reference 15 in text\")\n\n    1. Tak PP,\n    2. Rigby WF,\n    3. Rubbert-Roth A,\n    4. et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39–46.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DAnn%2BRheum%2BDis%26rft_id%253Dinfo%253Adoi%252F10.1136%252Fard.2010.137703%26rft_id%253Dinfo%253Apmid%252F20937671%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[Abstract/FREE Full Text](/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6ImFubnJoZXVtZGlzIjtzOjU6InJlc2lkIjtzOjc6IjcwLzEvMzkiO3M6NDoiYXRvbSI7czoyNzoiL2FubnJoZXVtZGlzLzcyLzkvMTQ5Ni5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=)\n16. [↵](#xref-ref-13-1 \"View reference 16 in text\")\n\n    1. Bingham CO III.,\n    2. Looney RJ,\n    3. Deodhar A,\n    4. et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010;62:64–74.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DArthritis%2Band%2Brheumatism%26rft.stitle%253DArthritis%2BRheum%26rft.aulast%253DBingham%26rft.auinit1%253DC.%2BO.%26rft.volume%253D62%26rft.issue%253D1%26rft.spage%253D64%26rft.epage%253D74%26rft.atitle%253DImmunization%2Bresponses%2Bin%2Brheumatoid%2Barthritis%2Bpatients%2Btreated%2Bwith%2Brituximab%253A%2Bresults%2Bfrom%2Ba%2Bcontrolled%2Bclinical%2Btrial.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fart.25034%26rft_id%253Dinfo%253Apmid%252F20039397%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1002/art.25034&link_type=DOI)[PubMed](/lookup/external-ref?access_num=20039397&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000279275700008&link_type=ISI)\n17. [↵](#xref-ref-17-1 \"View reference 17 in text\")\n\n    1. van Vollenhoven RF,\n    2. Emery P,\n    3. Bingham CO III.,\n    4. et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010;37:558–67.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DJ%2BRheumatol%26rft_id%253Dinfo%253Adoi%252F10.3899%252Fjrheum.090856%26rft_id%253Dinfo%253Apmid%252F20110520%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[Abstract/FREE Full Text](/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoianJoZXVtIjtzOjU6InJlc2lkIjtzOjg6IjM3LzMvNTU4IjtzOjQ6ImF0b20iO3M6Mjc6Ii9hbm5yaGV1bWRpcy83Mi85LzE0OTYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)\n18. [↵](#xref-ref-18-1 \"View reference 18 in text\")\n\n    Centers for Disease Control and Prevention (CDC). Deaths: final data for 2009. 2010;1–90.\n19. [↵](#xref-ref-19-1 \"View reference 19 in text\")\n\n    1. Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009;60:3225–8.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DArthritis%2Band%2Brheumatism%26rft.stitle%253DArthritis%2BRheum%26rft.aulast%253DFleischmann%26rft.auinit1%253DR.%2BM.%26rft.volume%253D60%26rft.issue%253D11%26rft.spage%253D3225%26rft.epage%253D3228%26rft.atitle%253DProgressive%2Bmultifocal%2Bleukoencephalopathy%2Bfollowing%2Brituximab%2Btreatment%2Bin%2Ba%2Bpatient%2Bwith%2Brheumatoid%2Barthritis.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fart.24906%26rft_id%253Dinfo%253Apmid%252F19877057%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1002/art.24906&link_type=DOI)[PubMed](/lookup/external-ref?access_num=19877057&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000271781400010&link_type=ISI)\n20. [↵](#xref-ref-20-1 \"View reference 20 in text\")\n\n    1. Bongartz T,\n    2. Orenstein R. Therapy: the risk of herpes zoster: another cost of anti-TNF therapy? Nat Rev Rheumatol 2009;5:361–3.\n\n    [OpenUrl]({openurl}?query=rft.stitle%253DNat%2BRev%2BRheumatol%26rft.aulast%253DBongartz%26rft.auinit1%253DT.%26rft.volume%253D5%26rft.issue%253D7%26rft.spage%253D361%26rft.epage%253D363%26rft.atitle%253DTherapy%253A%2BThe%2Brisk%2Bof%2Bherpes%2Bzoster%253A%2Banother%2Bcost%2Bof%2Banti-TNF%2Btherapy%253F%26rft_id%253Dinfo%253Adoi%252F10.1038%252Fnrrheum.2009.120%26rft_id%253Dinfo%253Apmid%252F19568250%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1038/nrrheum.2009.120&link_type=DOI)[PubMed](/lookup/external-ref?access_num=19568250&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)\n21. [↵](#xref-ref-21-1 \"View reference 21 in text\")\n\n    1. Mellemkjaer L,\n    2. Linet MS,\n    3. Gridley G,\n    4. et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753–7.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DEur%2BJ%2BCancer%26rft.volume%253D32%26rft.spage%253D1753%26rft_id%253Dinfo%253Adoi%252F10.1016%252F0959-8049%252896%252900210-9%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1016/0959-8049(96)00210-9&link_type=DOI)\n22. [↵](#xref-ref-22-1 \"View reference 22 in text\")\n\n    1. Wolfe F,\n    2. Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886–95.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DArthritis%2Band%2Brheumatism%26rft.stitle%253DArthritis%2BRheum%26rft.aulast%253DWolfe%26rft.auinit1%253DF.%26rft.volume%253D56%26rft.issue%253D9%26rft.spage%253D2886%26rft.epage%253D2895%26rft.atitle%253DBiologic%2Btreatment%2Bof%2Brheumatoid%2Barthritis%2Band%2Bthe%2Brisk%2Bof%2Bmalignancy%253A%2Banalyses%2Bfrom%2Ba%2Blarge%2BUS%2Bobservational%2Bstudy.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fart.22864%26rft_id%253Dinfo%253Apmid%252F17729297%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1002/art.22864&link_type=DOI)[PubMed](/lookup/external-ref?access_num=17729297&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000249832600009&link_type=ISI)\n23. [↵](#xref-ref-23-1 \"View reference 23 in text\")\n\n    National Cancer Institute. Surveillance Epidemiology and End Results database. 2011.\n24. [↵](#xref-ref-24-1 \"View reference 24 in text\")\n\n    1. Smitten AL,\n    2. Simon TA,\n    3. Hochberg MC,\n    4. et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DArthritis%2Bresearch%2B%2526%2Btherapy%26rft.stitle%253DArthritis%2BRes%2BTher%26rft.aulast%253DSmitten%26rft.auinit1%253DA.%2BL.%26rft.volume%253D10%26rft.issue%253D2%26rft.spage%253DR45%26rft.epage%253DR45%26rft.atitle%253DA%2Bmeta-analysis%2Bof%2Bthe%2Bincidence%2Bof%2Bmalignancy%2Bin%2Badult%2Bpatients%2Bwith%2Brheumatoid%2Barthritis.%26rft_id%253Dinfo%253Adoi%252F10.1186%252Far2404%26rft_id%253Dinfo%253Apmid%252F18433475%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1186/ar2404&link_type=DOI)[PubMed](/lookup/external-ref?access_num=18433475&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)\n25. [↵](#xref-ref-25-1 \"View reference 25 in text\")\n\n    1. Westhovens R,\n    2. Kremer JM,\n    3. Moreland LW,\n    4. et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended Phase IIB study. J Rheumatol 2009;36:736–42.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DJ%2BRheumatol%26rft_id%253Dinfo%253Adoi%252F10.3899%252Fjrheum.080813%26rft_id%253Dinfo%253Apmid%252F19273451%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[Abstract/FREE Full Text](/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoianJoZXVtIjtzOjU6InJlc2lkIjtzOjg6IjM2LzQvNzM2IjtzOjQ6ImF0b20iO3M6Mjc6Ii9hbm5yaGV1bWRpcy83Mi85LzE0OTYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)\n26. [↵](#xref-ref-26-1 \"View reference 26 in text\")\n\n    1. Moreland LW,\n    2. Weinblatt ME,\n    3. Keystone EC,\n    4. et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854–61.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DThe%2BJournal%2Bof%2BRheumatology%26rft.stitle%253DThe%2BJournal%2Bof%2BRheumatology%26rft.issn%253D0315-162X%26rft.aulast%253DMoreland%26rft.auinit1%253DL.%2BW%26rft.volume%253D33%26rft.issue%253D5%26rft.spage%253D854%26rft.epage%253D861%26rft.atitle%253DEtanercept%2Btreatment%2Bin%2Badults%2Bwith%2Bestablished%2Brheumatoid%2Barthritis%253A%2B7%2Byears%2Bof%2Bclinical%2Bexperience.%26rft_id%253Dinfo%253Apmid%252F16541481%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[Abstract/FREE Full Text](/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoianJoZXVtIjtzOjU6InJlc2lkIjtzOjg6IjMzLzUvODU0IjtzOjQ6ImF0b20iO3M6Mjc6Ii9hbm5yaGV1bWRpcy83Mi85LzE0OTYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)\n27. [↵](#xref-ref-25-2 \"View reference 27 in text\")\n\n    1. Galloway JB,\n    2. Hyrich KL,\n    3. Mercer LK,\n    4. et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50:124–31.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DRheumatology%2B%2528Oxford%2529%26rft_id%253Dinfo%253Adoi%252F10.1093%252Frheumatology%252Fkeq242%26rft_id%253Dinfo%253Apmid%252F20675706%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[Abstract/FREE Full Text](/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTI6InJoZXVtYXRvbG9neSI7czo1OiJyZXNpZCI7czo4OiI1MC8xLzEyNCI7czo0OiJhdG9tIjtzOjI3OiIvYW5ucmhldW1kaXMvNzIvOS8xNDk2LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==)\n28. [↵](#xref-ref-28-1 \"View reference 28 in text\")\n\n    1. Salliot C,\n    2. Dougados M,\n    3. Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009;68:25–32.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DAnn%2BRheum%2BDis%26rft_id%253Dinfo%253Adoi%252F10.1136%252Fard.2007.083188%26rft_id%253Dinfo%253Apmid%252F18203761%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[Abstract/FREE Full Text](/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6ImFubnJoZXVtZGlzIjtzOjU6InJlc2lkIjtzOjc6IjY4LzEvMjUiO3M6NDoiYXRvbSI7czoyNzoiL2FubnJoZXVtZGlzLzcyLzkvMTQ5Ni5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=)\n29. [↵](#xref-ref-29-1 \"View reference 29 in text\")\n\n    1. Gottenberg JE,\n    2. Ravaud P,\n    3. Bardin T,\n    4. et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2625–32.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DArthritis%2Band%2Brheumatism%26rft.stitle%253DArthritis%2BRheum%26rft.aulast%253DGottenberg%26rft.auinit1%253DJ.%26rft.volume%253D62%26rft.issue%253D9%26rft.spage%253D2625%26rft.epage%253D2632%26rft.atitle%253DRisk%2Bfactors%2Bfor%2Bsevere%2Binfections%2Bin%2Bpatients%2Bwith%2Brheumatoid%2Barthritis%2Btreated%2Bwith%2Brituximab%2Bin%2Bthe%2Bautoimmunity%2Band%2Brituximab%2Bregistry.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fart.27555%26rft_id%253Dinfo%253Apmid%252F20506353%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1002/art.27555&link_type=DOI)[PubMed](/lookup/external-ref?access_num=20506353&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000283059100010&link_type=ISI)\n30. [↵](#xref-ref-30-1 \"View reference 30 in text\")\n\n    1. Lee ML,\n    2. Gale RP,\n    3. Yap PL. Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency. Annu Rev Med 1997;48:93–102.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DAnnual%2Breview%2Bof%2Bmedicine%26rft.stitle%253DAnnu%2BRev%2BMed%26rft.issn%253D0066-4219%26rft.aulast%253DLee%252C%2BPhD%252C%2BCStat%26rft.auinit1%253DM.%2BL.%26rft.volume%253D48%26rft.issue%253D1%26rft.spage%253D93%26rft.epage%253D102%26rft.atitle%253DUSE%2BOF%2BINTRAVENOUS%2BIMMUNOGLOBULIN%2BTO%2BPREVENT%2BOR%2BTREAT%2BINFECTIONS%2BIN%2BPERSONS%2BWITH%2BIMMUNE%2BDEFICIENCY%26rft_id%253Dinfo%253Adoi%252F10.1146%252Fannurev.med.48.1.93%26rft_id%253Dinfo%253Apmid%252F9046948%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1146/annurev.med.48.1.93&link_type=DOI)[PubMed](/lookup/external-ref?access_num=9046948&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=A1997WH48600009&link_type=ISI)\n31. [↵](#xref-ref-31-1 \"View reference 31 in text\")\n\n    1. Solomon DH,\n    2. Goodson NJ,\n    3. Katz JN,\n    4. et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608–12.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DAnn%2BRheum%2BDis%26rft_id%253Dinfo%253Adoi%252F10.1136%252Fard.2005.050377%26rft_id%253Dinfo%253Apmid%252F16793844%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[Abstract/FREE Full Text](/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6ImFubnJoZXVtZGlzIjtzOjU6InJlc2lkIjtzOjEwOiI2NS8xMi8xNjA4IjtzOjQ6ImF0b20iO3M6Mjc6Ii9hbm5yaGV1bWRpcy83Mi85LzE0OTYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)\n32. [↵](#xref-ref-32-1 \"View reference 32 in text\")\n\n    1. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 2008;121:S9–14.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DThe%2BAmerican%2Bjournal%2Bof%2Bmedicine%26rft.stitle%253DAm%2BJ%2BMed%26rft.aulast%253DRolla%26rft.auinit1%253DA.%26rft.volume%253D121%26rft.issue%253D10%2BSuppl%2B1%26rft.spage%253DS9%26rft.epage%253D14%26rft.atitle%253DCardiovascular%2Bmorbidity%2Band%2Bmortality%2Bin%2Brheumatoid%2Barthritis.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.amjmed.2008.01.005%26rft_id%253Dinfo%253Apmid%252F18926169%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1016/j.amjmed.2008.01.005&link_type=DOI)[PubMed](/lookup/external-ref?access_num=18926169&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)\n33. [↵](#xref-ref-33-1 \"View reference 33 in text\")\n\n    1. Dixon WG,\n    2. Watson KD,\n    3. Lunt M,\n    4. et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905–12.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DArthritis%2Band%2Brheumatism%26rft.stitle%253DArthritis%2BRheum%26rft.aulast%253DDixon%26rft.auinit1%253DW.%2BG.%26rft.volume%253D56%26rft.issue%253D9%26rft.spage%253D2905%26rft.epage%253D2912%26rft.atitle%253DReduction%2Bin%2Bthe%2Bincidence%2Bof%2Bmyocardial%2Binfarction%2Bin%2Bpatients%2Bwith%2Brheumatoid%2Barthritis%2Bwho%2Brespond%2Bto%2Banti-tumor%2Bnecrosis%2Bfactor%2Balpha%2Btherapy%253A%2Bresults%2Bfrom%2Bthe%2BBritish%2BSociety%2Bfor%2BRheumatology%2BBiologics%2BRegister.%26rft_id%253Dinfo%253Adoi%252F10.1002%252Fart.22809%26rft_id%253Dinfo%253Apmid%252F17763428%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1002/art.22809&link_type=DOI)[PubMed](/lookup/external-ref?access_num=17763428&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000249832600011&link_type=ISI)\n34. [↵](#xref-ref-34-1 \"View reference 34 in text\")\n\n    1. Watson DJ,\n    2. Rhodes T,\n    3. Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003;30:1196–202.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DThe%2BJournal%2Bof%2BRheumatology%26rft.stitle%253DThe%2BJournal%2Bof%2BRheumatology%26rft.issn%253D0315-162X%26rft.aulast%253DWatson%26rft.auinit1%253DD.%2BJ%26rft.volume%253D30%26rft.issue%253D6%26rft.spage%253D1196%26rft.epage%253D1202%26rft.atitle%253DAll-cause%2Bmortality%2Band%2Bvascular%2Bevents%2Bamong%2Bpatients%2Bwith%2Brheumatoid%2Barthritis%252C%2Bosteoarthritis%252C%2Bor%2Bno%2Barthritis%2Bin%2Bthe%2BUK%2BGeneral%2BPractice%2BResearch%2BDatabase.%26rft_id%253Dinfo%253Apmid%252F12784389%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[Abstract/FREE Full Text](/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NjoianJoZXVtIjtzOjU6InJlc2lkIjtzOjk6IjMwLzYvMTE5NiI7czo0OiJhdG9tIjtzOjI3OiIvYW5ucmhldW1kaXMvNzIvOS8xNDk2LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==)\n35. [↵](#xref-ref-35-1 \"View reference 35 in text\")\n\n    1. Slimani S,\n    2. Lukas C,\n    3. Combe B,\n    4. et al. Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine 2011;78:484–7.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DJoint%252C%2Bbone%252C%2Bspine%2B%253A%2B%2Brevue%2Bdu%2Brhumatisme%26rft.stitle%253DJoint%2BBone%2BSpine%26rft.aulast%253DSlimani%26rft.auinit1%253DS.%26rft.volume%253D78%26rft.issue%253D5%26rft.spage%253D484%26rft.epage%253D487%26rft.atitle%253DRituximab%2Bin%2Brheumatoid%2Barthritis%2Band%2Bthe%2Brisk%2Bof%2Bmalignancies%253A%2Breport%2Bfrom%2Ba%2BFrench%2Bcohort.%26rft_id%253Dinfo%253Adoi%252F10.1016%252Fj.jbspin.2010.11.012%26rft_id%253Dinfo%253Apmid%252F21196130%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[CrossRef](/lookup/external-ref?access_num=10.1016/j.jbspin.2010.11.012&link_type=DOI)[PubMed](/lookup/external-ref?access_num=21196130&link_type=MED&atom=%2Fannrheumdis%2F72%2F9%2F1496.atom)[Web of Science](/lookup/external-ref?access_num=000296383600011&link_type=ISI)\n36. [↵](#xref-ref-36-1 \"View reference 36 in text\")\n\n    1. Jacobsson LT,\n    2. Turesson C,\n    3. Nilsson JA,\n    4. et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670–5.\n\n    [OpenUrl]({openurl}?query=rft.jtitle%253DAnn%2BRheum%2BDis%26rft_id%253Dinfo%253Adoi%252F10.1136%252Fard.2006.062497%26rft_id%253Dinfo%253Apmid%252F17158824%26rft.genre%253Darticle%26rft_val_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Ajournal%26ctx_ver%253DZ39.88-2004%26url_ver%253DZ39.88-2004%26url_ctx_fmt%253Dinfo%253Aofi%252Ffmt%253Akev%253Amtx%253Actx)[Abstract/FREE Full Text](/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTE6ImFubnJoZXVtZGlzIjtzOjU6InJlc2lkIjtzOjg6IjY2LzUvNjcwIjtzOjQ6ImF0b20iO3M6Mjc6Ii9hbm5yaGV1bWRpcy83Mi85LzE0OTYuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9)\n\n[View Abstract](https://ard.bmj.com/content/72/9/1496.abstract)\n\n## Supplementary materials\n\n* ## Supplementary Data\n\n  This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.\n\n  **Files in this Data Supplement:**\n\n  + [Data supplement 1](/highwire/filestream/202927/field_highwire_adjunct_files/0/annrheumdis-2012-201956supp.pdf) - Online supplement\n\n## Footnotes\n\n* **Handling editor** Tore K Kvien\n* Contributors All authors contributed to the interpretation of the data, drafting and/or revising the manuscript for intellectual content and approved the final version of the manuscript.\n* Funding This study and the manuscript preparation were funded by F Hoffmann-La Roche.\n* Ethics approval The study was conducted in full accordance with the ethical principles of the Declaration of Helsinki or with the laws and regulations of the country in which the research was conducted, whichever afforded greater protection to the individual. The study adhered to the principles outlined in the ICH Guideline for Good Clinical Practice. All participating sites received approval from their institutional review board/Ethics Committee (or equivalent), and all patients provided written informed consent prior to participation in the study.\n* Competing interests RFvV has received grants, consultancy fees and payments for lectures from Abbott, GSK, MSD, Pfizer, Roche and UCB. PE has received grants from Roche and consultancy fees/honoraria from Pfizer, Merck, Abbot, UCB, Roche and Novartis. COB has received grants and consulting fees/honoraria from Genentech, Roche, Abbott, Amgen, Bristol Myers Squibb, Centocor, Johnson & Johnson, Janssen, Pfizer and UCB, grants from Biogen Idec, consulting fees from Celgene and Millennium, and royalties from Up-to-Date. EK is a board member of and has received consultancy fees from Abbott, AstraZeneca, Biotest, Bristol Myers Squibb, Centocor, Roche, Genentech, Merck, Nycomed, Pfizer and UCB, has received grants and lecture fees from Abbott, Amgen, Bristol Myers Squibb, Roche, Merck, Pfizer and UCB, grants from AstraZeneca, Centocor, Genzyme and Novartis, and lecture fees from Janssen. RF has received a grant from Metroplex Clinical Research Center, and grants and consultancy from Abbott, Amgen, Jansen, UCB, Pfizer, Bristol Myers Squibb, Roche, Lilly, Sanofi and Merck. DEF has received grants and consulting fees or honoraria from Roche, Genentech and Abbott, grants from Bristol Myers Squibb, consultancy fees and support for travel to meetings from Amgen, UCB and Bristol Myers Squibb, and is a Board member of Arthritis Foundation. NT is an employee of and owns stock in Roche. NC and PBL are both employees of Roche.\n* Provenance and peer review Not commissioned; externally peer reviewed.\n* Data sharing statement No additional data are available.\n\n## Read the full text or download the PDF:\n\n[Log in via Institution](/login/shibboleth?subcode=bmjjournals&env=prod&uri=https%3A//ard.bmj.com/accallback/content%25252F72%25252F9%25252F1496)\n\n[Log in via OpenAthens](https://openathens-sp.highwire.org/session/init?entityID=https%3A//idp.eduserv.org.uk/openathens&hw-shib-return-uri=https%3A//ard.bmj.com/accallback/content%25252F72%25252F9%25252F1496&subcode=bmjjournals)\n\n### Log in using your username and password\n\n "
        },
        {
          "title": "A Study to Evaluate Zilovertamab Vedotin (MK-2140) ...",
          "url": "https://clinicaltrials.gov/study/NCT06717347",
          "content": "IV infusion  Other Names:  MK-2140  VLS-101 Biological: Rituximab  IV infusion  Other Names:  RITUXAN® Drug: Cyclophosphamide  IV infusion  Other Names:  CYTOXAN®  NEOSAR® Drug: Doxorubicin  IV infusion  Other Names:  ADRIAMYCIN® Biological: Rituximab Biosimilar  IV infusion  Other Names:  TRUXIMA®  RUXIENCE®  RIABNI® Drug: Prednisone  Per Approved Product Label Drug: Prednisolone  Oral administration Drug: Rescue medication  Participants receive rescue medication at the investigator's discretion, per approved product label. The recommended rescue medication is granulocyte colony-stimulating factor (G-CSF). | [...] Cyclophosphamide  IV infusion  Other Names:  CYTOXAN®  NEOSAR® Drug: Doxorubicin  IV infusion  Other Names:  ADRIAMYCIN® Biological: Rituximab Biosimilar  IV infusion  Other Names:  TRUXIMA®  RUXIENCE®  RIABNI® Drug: Prednisone  Per Approved Product Label Drug: Prednisolone  Oral administration Drug: Vincristine  IV infusion | [...] | Participant Group/Arm | Active Comparator: Rituximab + Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) Participants receive 750 mg/m^2 cyclophosphamide, 50 mg/m^2 doxorubicin, and 375 mg/m^2 rituximab or rituximab biosimilar, 1.4 mg/m^2 vincristine administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months) plus 2 cycles of rituximab or biosimilar for participants with high risk DLBCL. Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). | Intervention/Treatment | Biological: Rituximab  IV infusion  Other Names:  RITUXAN® Drug: Cyclophosphamide  IV infusion  Other Names:  CYTOXAN®",
          "raw_content": "Study Details | NCT06717347 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) | ClinicalTrials.gov\n===============\n\nHide glossary\n#### Glossary\n\nStudy record managers: refer to the [Data Element Definitions](https://clinicaltrials.gov/policy#data-element-definitions) if submitting registration or results information.\n\nSearch for terms\n\n*   Accepts healthy volunteers A type of eligibility criteria that indicates whether people who do not have the condition/disease being studied can participate in that clinical study. \n*   Active comparator arm An arm type in which a group of participants receives an intervention/treatment considered to be effective (or active) by health care providers. \n*   Adverse event An unfavorable change in the health of a participant, including abnormal laboratory findings, that happens during a clinical study or within a certain amount of time after the study has ended. This change may or may not be caused by the intervention/treatment being studied. \n*   Age or age group\n\nA type of eligibility criteria that indicates the age a person must be to participate in a clinical study. This may be indicated by a specific age or the following age groups:\nThe age groups are:\n\n    *   Child (birth-17)\n    *   Adult (18-64)\n    *   Older Adult (65+)\n\n*   All-cause mortality A measure of all deaths, due to any cause, that occur during a clinical study. \n*   Allocation A method used to assign participants to an arm of a clinical study. The types of allocation are randomized allocation and nonrandomized. \n*   Arm A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol. \n*   Arm type A general description of the clinical trial arm. It identifies the role of the intervention that participants receive. Types of arms include experimental arm, active comparator arm, placebo comparator arm, sham comparator arm, and no intervention arm. \n*   Baseline characteristics Data collected at the beginning of a clinical study for all participants and for each arm or comparison group. These data include demographics, such as age, sex/gender, race and ethnicity, and study-specific measures (for example, systolic blood pressure, prior antidepressant treatment). \n*   Canceled submission Indicates that the study sponsor or investigator recalled a submission of study results before quality control (QC) review took place. If the submission was canceled on or after May 8, 2018, the date is shown. After submission of study results, a study record cannot be modified until QC review is completed, unless the submission is canceled. \n*   Certain agreements Information required by the Food and Drug Administration Amendments Act of 2007. In general, this is a description of any agreement between the sponsor of a clinical study and the principal investigator (PI) that does not allow the PI to discuss the results of the study or publish the study results in a scientific or academic journal after the study is completed. \n*   Certification A sponsor or investigator may submit a certification to delay submission of results information if they are applying for FDA approval of a new drug or device, or new use of an already approved drug or device. A sponsor or investigator who submits a certification can delay results submission up to 2 years after the certification/extension first submitted date, unless certain events occur sooner. See [Delay Results Type](https://clinicaltrials.gov/policy/results-definitions#DelayResultsType) in the Results Data Element definitions for more information about this certification. \n*   Certification/extension first posted The date on which information about a certification to delay submission of results or an extension request was first available on ClinicalTrials.gov. ClinicalTrials.gov does not indicate whether the submission was a certification or extension request. There is typically a delay between the date the study sponsor or investigator submitted the certification or extension request and the first posted date. \n*   Certification/extension first submitted The date on which the study sponsor or investigator first submitted a certification or an extension request to delay submission of results. A sponsor or investigator who submits a certification can delay results submission up to 2 years after this date, unless certain events occur sooner. There is typically a delay between the date the certification or extension request was submitted and the date the information is first available on ClinicalTrials.gov (certification/extension first posted). \n*   Certification/extension first submitted that met QC criteria The date on which the study sponsor or investigator first submitted a certification or an extension request that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a certification or extension request one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria. Meeting QC criteria for an extension request does not mean that the National Institutes of Health (NIH) has determined that the request demonstrates good cause. The process for review and granting of extension requests by the NIH is being developed. \n*   Clinical study A research study involving human volunteers (also called participants) that is intended to add to medical knowledge. There are two types of clinical studies: interventional studies (also called clinical trials) and observational studies. \n*   Clinical trial Another name for an interventional study. \n*   ClinicalTrials.gov identifier (NCT number)The unique identification code given to each clinical study upon registration at ClinicalTrials.gov. The format is \"NCT\" followed by an 8-digit number (for example, NCT00000419). \n*   Collaborator An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting. \n*   Condition/disease The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks. \n*   Contact The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions. \n*   Cross-over assignment A type of intervention model describing a clinical trial in which groups of participants receive two or more interventions in a specific order. For example, two-by-two cross-over assignment involves two groups of participants. One group receives drug A during the initial phase of the trial, followed by drug B during a later phase. The other group receives drug B during the initial phase, followed by drug A. So during the trial, participants \"cross over\" to the other drug. All participants receive drug A and drug B at some point during the trial but in a different order, depending on the group to which they are assigned. \n*   Data Monitoring Committee (DMC)A group of independent scientists who monitor the safety and scientific integrity of a clinical trial. The DMC can recommend to the sponsor that the trial be stopped if it is not effective, is harming participants, or is unlikely to serve its scientific purpose. Members are chosen based on the scientific skills and knowledge needed to monitor the particular trial. Also called a data safety and monitoring board, or DSMB. \n*   Early Phase 1 (formerly listed as Phase 0)A phase of research used to describe exploratory trials conducted before traditional phase 1 trials to investigate how or whether a drug affects the body. They involve very limited human exposure to the drug and have no therapeutic or diagnostic goals (for example, screening studies, microdose studies). \n*   Eligibility criteria The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study  accepts healthy volunteers, has age or age group requirements, or is limited by sex. \n*   Enrollment The number of participants in a clinical study. The \"estimated\" enrollment is the target number of participants that the researchers need for the study. \n*   Exclusion criteria A type of eligibility criteria. These are reasons that a person is not allowed to participate in a clinical study. \n*   Expanded access A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved by the U.S. Food and Drug Administration (FDA). Also called compassionate use. There are different expanded access types. \nFor more information, see FDA [Expanded Access: Information for Patients](https://www.fda.gov/news-events/public-health-focus/expanded-access \"Expanded Access: Information for Patients (opens in a new tab)\"). \n*   Expanded access status\n\n    *   **Available:**Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.\n    *   **No longer available:**Expanded access was available for this intervention previously but is not currently available and will not be available in the future.\n    *   **Temporarily not available:**Expanded access is not currently available for this intervention but is expected to be available in the future.\n    *   **Approved for marketing:** The intervention has been approved by the  U.S. Food and Drug Administration for use by the public.\n\n*   Expanded access type\n\nDescribes the category of expanded access under U.S. Food and Drug Administration (FDA) regulations. There are three types of expanded access: \n    *   **Individual Patients**: Allows a single patient, with a serious disease or condition who cannot participate in a clinical trial, access to a drug or biological product that has not been approved by the FDA. This category also includes access in an emergency situation.\n    *   **Intermediate-size Population**: Allows more than one patient (but generally fewer patients than through a Treatment IND/Protocol) access to a drug or biological product that has not been approved by the FDA. This type of expanded access is used when multiple patients with the same disease or condition seek access to a specific drug or biological product that has not been approved by the FDA.\n    *   **[](https://clinicaltrials.gov/)Treatment IND/Protocol**: Allows a large, widespread population access to a drug or biological product that has not been approved by the FDA. This type of expanded access can only be provided if the product is already being developed for marketing for the same use as the expanded access use.\n\n*   Experimental arm An arm type in which a group of participants receives the intervention/treatment that is the focus of the clinical trial. \n*   Extension request In certain circumstances, a sponsor or investigator may request an extension to delay the standard results submission deadline (generally one year after the primary completion date). The request for an extension must demonstrate good cause (for example, the need to preserve the scientific integrity of an ongoing masked trial). All requests must be reviewed and granted by the National Institutes of Health. This process for review and granting of extension requests is being developed. See [Delay Results Type](https://clinicaltrials.gov/policy/results-definitions#DelayResultsType) in the Results Data Element definitions for more information. \n*   Facility name The name of the hospital or institution where a clinical study takes place. Note that not all study records include this information. To use this filter, you can enter some or all of a facility name, or type a few letters and select from the list that appears. \n*   Factorial assignment A type of intervention model describing a clinical trial in which groups of participants receive one of several combinations of interventions. For example, two-by-two factorial assignment involves four groups of participants. Each group receives one of the following pairs of interventions: (1) drug A and drug B, (2) drug A and a placebo, (3) a placebo and drug B, or (4) a placebo and a placebo. So during the trial, all possible combinations of the two drugs (A and B) and the placebos are given to different groups of participants. \n*   FDAAA 801 Violations\n\nA FDAAA 801 Violation is shown on a study record when the U.S. Food and Drug Administration (FDA) has issued a Notice of Noncompliance to the responsible party of an applicable clinical trial. A Notice of Noncompliance indicates that the FDA has determined the responsible party was not in compliance with the registration or results reporting requirements for the clinical trial under the Food and Drug Administration Amendments Act of 2007, Section 801 (FDAAA 801).\nThe National Library of Medicine (NLM) is required by FDAAA 801 to add information to a study record about any FDAAA 801 Violation. This information is provided by the FDA. There are three categories of information that may be included:\n\n    *   Violation: Shown when the FDA issues a Notice of Noncompliance and posts the Notice of Noncompliance on its designated webpage. There are three types of violations:\n        *   Failure to submit required clinical trial information\n        *   Submission of false or misleading clinical trial information\n        *   Failure to submit primary and secondary outcomes\n\n    *   Correction: Shown when the FDA confirms that the responsible party has updated the study record to correct the violation and posts the correction notice on its designated webpage. Because of the time for FDA review and processing, there may be a delay between the date when the study record was updated and the addition of correction information to the FDAAA 801 Violation information. \n    *   Penalty: Shown when the FDA imposes a penalty for the violation and posts the penalty notice on its designated webpage.\n\n*   First posted The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) [quality control (QC) review](https://clinicaltrials.gov/submit-studies/prs-help/protocol-registration-quality-control-review-criteria) has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date. \n*   First submitted The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date). \n*   First submitted that met QC criteria The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria. \n*   Food and Drug Administration Amendments Act of 2007, Section 801 (FDAAA 801)U.S. Public Law 110-85, which was enacted on September 27, 2007. Section 801 of FDAAA amends Section 402 of the U.S. Public Health Service Act to expand ClinicalTrials.gov and create a clinical study results database. For more information on FDAAA 801, see the [Clinical Trial Reporting Requirements](https://clinicaltrials.gov/policy/reporting-requirements#final-rule) page on this site. \n*   Funder type\n\nDescribes the organization that provides funding or support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting. Organizations listed as sponsors and collaborators for a study are considered the funders of the study. ClinicalTrials.gov refers to four types of funders: \n    *   U.S. National Institutes of Health\n    *   Other U.S. Federal agencies (for example, Food and Drug Administration, Centers for Disease Control and Prevention, or U.S. Department of Veterans Affairs)\n    *   Industry (for example: pharmaceutical and device companies)\n    *   All others (including individuals, universities, and community-based organizations)\n\n*   Gender-based eligibility A type of eligibility criteria that indicates whether eligibility to participate in a clinical study is based on a person's self-representation of gender identity. Gender identity refers to a person's own sense of gender, which may or may not be the same as their biological sex. \n*   Group/cohort A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes. \n*   Human subjects protection review board A group of people who review, approve, and monitor the clinical study's protocol. Their role is to protect the rights and welfare of people participating in a study (referred to as human research subjects), such as reviewing the informed consent form. The group typically includes people with varying backgrounds, including a community member, to make sure that research activities conducted by an organization are completely and adequately reviewed. Also called an institutional review board, or IRB, or an ethics committee.\nFor more information, see [Who can join clinical research?](https://clinicaltrials.gov/study-basics/learn-about-studies#q3) on this site. \n*   Inclusion criteria A type of eligibility criteria. These are the reasons that a person is allowed to participate in a clinical study. \n*   Informed consent A process used by researchers to communicate to potential and enrolled participants the risks and potential benefits of participating in a clinical study. \nFor more information, see [Who can join clinical research?](https://clinicaltrials.gov/study-basics/learn-about-studies#q3) on this site. \n*   Informed consent form (ICF)The document used in the informed consent or process. \n*   Intervention model The general design of the strategy for assigning interventions to participants in a clinical study. Types of intervention models include: single group assignment, parallel assignment, cross-over assignment, and factorial assignment. \n*   Intervention/treatment A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise. \n*   Interventional study (clinical trial)A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. The assignments are determined by the study's protocol. Participants may receive diagnostic, therapeutic, or other types of interventions. \n*   Investigator A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator. \n*   Last update posted The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date. \n*   Last update submitted The most recent date on which the study sponsor or investigator submitted changes to a study record to ClinicalTrials.gov. There is typically a delay of a few days between the last update submitted date and when the date changes are posted on ClinicalTrials.gov (the last update posted date). \n*   Last update submitted that met QC criteria The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria. \n*   Last verified The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown. \n*   Location A place where a research site for a clinical study can be found. Location information can be searched using a facility name, a city, state, zip code, or country. A location where a study is being conducted may also include contact information.  \n*   Location countries Countries in which research facilities for a study are located. A country is listed only once, even if there is more than one facility in the country. The list includes all countries as of the last update submitted date; any country for which all facilities were removed from the study record are listed under removed location countries. \n*   Masking A clinical trial design strategy in which one or more parties involved in the trial, such as the investigator or participants, do not know which participants have been assigned which interventions. Types of masking include: open label, single blind masking, and double-blind masking. \n*   NCT number A unique identification code given to each clinical study record registered on ClinicalTrials.gov. The format is \"NCT\" followed by an 8-digit number (for example, NCT00000419). Also called the ClinicalTrials.gov identifier. \n*   No intervention arm An arm type in which a group of participants does not receive any intervention/treatment during the clinical trial. \n*   Observational study A type of clinical study in which participants are identified as belonging to study groups and are assessed for biomedical or health outcomes. Participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to a specific interventions/treatment.\nA patient registry is a type of observational study. \n*   Observational study model The general design of the strategy for identifying and following up with participants during an observational study. Types of observational study models include cohort, case-control, case-only, case-cross-over, ecologic or community studies, family-based, and other. \n*   Other adverse event An adverse event that is not a serious adverse event, meaning that it does not result in death, is not life-threatening, does not require inpatient hospitalization or extend a current hospital stay, does not result in an ongoing or significant incapacity or interfere substantially with normal life functions, and does not cause a congenital anomaly or birth defect; it also does not put the participant in danger and does not require medical or surgical intervention to prevent one of the results listed above. \n*   Other study IDs Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers. \n*   Other terms In the search feature, the Other terms field is used to narrow a search. For example, you may enter the name of a drug or the NCT number of a clinical study to limit the search to study records that contain these words. \n*   Outcome measure For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure. \n*   Parallel assignment A type of intervention model describing a clinical trial in which two or more groups of participants receive different interventions. For example, a two-arm parallel assignment involves two groups of participants. One group receives drug A, and the other group receives drug B. So during the trial, participants in one group receive drug A \"in parallel\" to participants in the other group, who receive drug B. \n*   Participant flow A summary of the progress of participants through each stage of a clinical study, by study arm or group/cohort. This includes the number of participants who started, completed, and dropped out of the study. \n*   Patient registry A type of observational study that collects information about patients' medical conditions and/or treatments to better understand how a condition or treatment affects patients in the real world. \n*   Phase The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions. \n*   Phase 1 A phase of research to describe clinical trials that focus on the safety of a drug. They are usually conducted with healthy volunteers, and the goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These trials usually involve a small number of participants. \n*   Phase 2 A phase of research to describe clinical trials that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied. \n*   Phase 3 A phase of research to describe clinical trials that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants. \n*   Phase 4 A phase of research to describe clinical trials occurring after FDA has approved a drug for marketing. They include postmarket requirement and commitment studies that are required of or agreed to by the study sponsor. These trials gather additional information about a drug's safety, efficacy, or optimal use. \n*   Phase Not Applicable Describes trials without FDA-defined phases, including trials of devices or behavioral interventions. \n*   Placebo An inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied. \n*   Placebo comparator arm An arm type in which a group of participants receives a placebo during a clinical trial. \n*   Primary completion date The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The \"estimated\" primary completion date is the date that the researchers think will be the primary completion date for the study.  \n*   Primary outcome measure In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one. \n*   Primary purpose The main reason for the clinical trial. The types of primary purpose are: treatment, prevention, diagnostic, supportive care, screening, health services research, basic science, and other. \n*   Principal investigator (PI)The person who is responsible for the scientific and technical direction of the entire clinical study. \n*   Protocol The written description of a clinical study. It includes the study's objectives, design, and methods. It may also include relevant scientific background and statistical information. \n*   Quality control (QC) review National Library of Medicine (NLM) staff perform a limited review of submitted study records for apparent errors, deficiencies, or inconsistencies. NLM staff identify potential major and advisory issues and provide comments directly to the study sponsor or investigator. Major issues identified in QC review must be addressed or corrected (see First submitted that met QC criteria and Results first submitted that met QC criteria). Advisory issues are suggestions to help improve the clarity of the record. NLM staff do not verify the scientific validity or relevance of the submitted information. The study sponsor or investigator is responsible for ensuring that the studies follow all applicable laws and regulations. \n*   Randomized allocation A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance. \n*   Recruitment status\n\n    *   **Not yet recruiting:** The study has not started recruiting participants.\n    *   **Recruiting:** The study is currently recruiting participants.\n    *   **Enrolling by invitation:** The study is selecting its participants from a population, or group of people, decided on by the researchers in advance. These studies are not open to everyone who meets the eligibility criteria but only to people in that particular population, who are specifically invited to participate.\n    *   **Active, not recruiting:** The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.\n    *   **Suspended:** The study has stopped early but may start again.\n    *   **Terminated:** The study has stopped early and will not start again. Participants are no longer being examined or treated.\n    *   **Completed:** The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).\n    *   **Withdrawn:** The study stopped early, before enrolling its first participant.\n    *   **Unknown:** A study on ClinicalTrials.gov whose last known status was recruiting; not yet recruiting; or active, not recruiting but that has passed its completion date, and the status has not been last verified within the past 2 years.\n\n*   Registration The process of submitting and updating summary information about a clinical study and its protocol, from its beginning to end, to a structured, public Web-based study registry that is accessible to the public, such as ClinicalTrials.gov. \n*   Removed location countries Countries that appeared under location countries but were removed from the study record by the sponsor or investigator. \n*   Reporting group A grouping of participants in a clinical study that is used for summarizing the data collected during the study. This grouping may be the same as or different from a study arm or group. \n*   Responsible party The person responsible for submitting information about a clinical study to ClinicalTrials.gov and updating that information. Usually the study sponsor or investigator. \n*   Results database A structured online system, such as the ClinicalTrials.gov results database, that provides the public with access to registration and summary results information for completed or terminated clinical studies. A study with results available on ClinicalTrials.gov is described as having the results \"posted.\" \n**Note:** The ClinicalTrials.gov results database became available in September 2008. Older studies are unlikely to have results available in the database. \n*   Results delayed Indicates that the sponsor or investigator submitted a certification or extension request. \n*   Results first posted The date on which summary results information was first available on ClinicalTrials.gov after National Library of Medicine (NLM) [quality control (QC) review](https://clinicaltrials.gov/submit-studies/prs-help/results-quality-control-review-criteria) has concluded. There is typically a delay between the date the study sponsor or investigator first submits summary results information (the results first submitted date) and the results first posted date. Some results information may be available at an earlier date if Results First Posted with QC Comments. \n*   Results first posted with QC comments The date on which summary results information was first available on ClinicalTrials.gov with quality control review comments from the National Library of Medicine (NLM) identifying major issues that must be addressed by the sponsor or investigator. As of January 1, 2020, initial results submissions for applicable clinical trials (ACTs) that do not meet [quality control review criteria](https://clinicaltrials.gov/submit-studies/prs-help/results-quality-control-review-criteria) will be publicly posted on ClinicalTrials.gov with brief standardized major comments. Accordingly, the Results First Posted with QC Comments date may be earlier than the Results First Posted date for an ACT with summary results information that is not consistent with NLM quality control review criteria. \n*   Results first submitted The date on which the study sponsor or investigator first submits a study record with summary results information. There is typically a delay between the results first submitted date and when summary results information becomes available on ClinicalTrials.gov (the results first posted date). \n*   Results first submitted that met QC criteria The date on which the study sponsor or investigator first submits a study record with summary results information that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit results information one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria. \n*   Results returned after quality control review The date on which the National Library of Medicine provided quality control (QC) review comments to the study sponsor or investigator. The sponsor or investigator must address major issues identified in the review comments. If there is a date listed for results returned after quality control review, but there is not a subsequent date listed for results submitted to ClinicalTrials.gov, this means that the submission is pending changes by the sponsor or investigator. \n*   Results submitted to ClinicalTrials.gov Indicates that the study sponsor or investigator has submitted summary results information for a clinical study to ClinicalTrials.gov but the quality control (QC) review process has not concluded.\nThe results submitted date indicates when the study sponsor or investigator first submitted summary results information or submitted changes to summary results information. Submissions with changes are typically in response to QC review comments from the National Library of Medicine (NLM). If there is a date listed for results submitted to ClinicalTrials.gov, but there is not a subsequent date listed for results returned after quality control review, this means that the submission is pending review by NLM. \n*   Secondary outcome measure In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure. \n*   Serious adverse event An adverse event that results in death, is life-threatening, requires inpatient hospitalization or extends a current hospital stay, results in an ongoing or significant incapacity or interferes substantially with normal life functions, or causes a congenital anomaly or birth defect. Medical events that do not result in death, are not life-threatening, or do not require hospitalization may be considered serious adverse events if they put the participant in danger or require medical or surgical intervention to prevent one of the results listed above. \n*   Sex A type of eligibility criteria that indicates the sex of people who may participate in a clinical study (all, female, male). Sex is a person's classification as female or male based on biological distinctions. Sex is distinct from gender-based eligibility. \n*   Sham comparator arm An arm type in which a group of participants receives a procedure or device that appears to be the same as the actual procedure or device being studied but does not contain active processes or components. \n*   Single group assignment A type of intervention model describing a clinical trial in which all participants receive the same intervention/treatment. \n*   Sort studies by\n\nThe Sort studies by option is used to change the order of studies listed on the Search Results page. You can sort by Relevance or Newest First: \n    *   Relevance: Studies that best match your search terms appear higher in the search results list. This is the default display for all searches.\n    *   Newest First: Studies with the most recent First posted dates appear higher in the search results list.\n\n*   Sponsor The organization or person who initiates the study and who has authority and control over the study. \n*   Statistical analysis plan (SAP)The written description of the statistical considerations and methods for analyzing the data collected in the clinical study. \n*   Status Indicates the current recruitment status or the expanded access status. \n*   Study completion date The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The \"estimated\" study completion date is the date that the researchers think will be the study completion date. \n*   Study design The investigative methods and strategies used in the clinical study. \n*   Study documents Refers to the type of documents that the study sponsor or principal investigator may add to their study record. These include a study protocol, statistical analysis plan, and informed consent form. \n*   Study IDs Identifiers that are assigned to a clinical study by the study's sponsor, funders, or others. They include unique identifiers from other trial study registries and National Institutes of Health grant numbers. Note: ClinicalTrials.gov assigns a unique identification code to each clinical study registered on ClinicalTrials.gov. Also called the NCT number, the format is \"NCT\" followed by an 8-digit number (for example, NCT00000419). \n*   Study record An entry on ClinicalTrials.gov that contains a summary of a clinical study's protocol information, including the recruitment status; eligibility criteria; contact information; and, in some cases, summary results. Each study record is assigned a ClinicalTrials.gov identifier, or NCT number. \n*   Study registry A structured online system, such as ClinicalTrials.gov, that provides the public with access to summary information about ongoing and completed clinical studies. \n*   Study results A study record that includes the summary results posted in the ClinicalTrials.gov results database. Summary results information includes participant flow, baseline characteristics, outcome measures, and adverse events (including serious adverse events). \n*   Study start date The actual date on which the first participant was enrolled in a clinical study. The \"estimated\" study start date is the date that the researchers think will be the study start date. \n*   Study type Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access. \n*   Submitted date The date on which the study sponsor or investigator submitted a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. \n*   Title The official title of a protocol used to identify a clinical study or a short title written in language intended for the lay public. \n*   Title acronym The acronym or initials used to identify a clinical study (not all studies have one). For example, the title acronym for the Women's Health Initiative is \"WHI.\" \n*   Type of intervention A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise. \n*   U.S. Agency for Healthcare Research and Quality (AHRQ)An agency within the U.S. Department of Health and Human Services. AHRQ's mission is to produce evidence to make health care safer, higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. \n*   U.S. Food and Drug Administration (FDA)An agency within the U.S. Department of Health and Human Services. The FDA is responsible for protecting the public health by making sure that human and veterinary drugs, vaccines and other biological products, medical devices, the Nation's food supply, cosmetics, dietary supplements, and products that give off radiation are safe, effective, and secure. \n*   Unknown A type of recruitment status. It identifies a study on ClinicalTrials.gov whose last known status was recruiting; not yet recruiting; or active, not recruiting but that has passed its completion date, and the status has not been verified within the past 2 years. Studies with an unknown status are considered closed studies. \n\n![Image 1](https://clinicaltrials.gov/assets/uswds/img/us_flag_small.png)\n\nAn official website of the United States government\n\nHere’s how you know\n\nHere’s how you know\n\n![Image 2](https://clinicaltrials.gov/assets/uswds/img/icon-dot-gov.svg)\n\n**Official websites use .gov**\n\nA **.gov** website belongs to an official government organization in the United States.\n\n![Image 3](https://clinicaltrials.gov/assets/uswds/img/icon-https.svg)\n\n**Secure .gov websites use HTTPS**\n\nA **lock** ( ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.\n\n[Skip to main page content](https://clinicaltrials.gov/#main-content)\n\n[![Image 4: NIH National Library of Medicine, National Center for Biotechnology Information (opens in a new tab)](https://clinicaltrials.gov/assets/main/img/AgencyLogo.svg)](https://ncbi.nlm.nih.gov/ \"NIH National Library of Medicine, National Center for Biotechnology Information (opens in a new tab)\")\n\n PRS Login \n\n[![Image 5: ClinicalTrials.gov return to the CTG homepage](https://clinicaltrials.gov/assets/images/ctg-header-logo.svg)](https://clinicaltrials.gov/ \"ClinicalTrials.gov return to the CTG homepage\")[![Image 6](https://clinicaltrials.gov/assets/images/nih-nlm-ncbi-logo.png)](https://clinicaltrials.gov/)\n\n Menu \n\n![Image 7: close](https://clinicaltrials.gov/assets/images/close.png)\n*   Find Studies\n    *   [Expert Search](https://clinicaltrials.gov/expert-search)\n    *   [How to Search](https://clinicaltrials.gov/find-studies/how-to-search)\n    *   [How to Use Search Results](https://clinicaltrials.gov/find-studies/how-to-use-search-results)\n    *   [How to Search for Studies with Results](https://clinicaltrials.gov/find-studies/how-to-search-for-studies-with-results)\n    *   [Constructing Complex Search Queries](https://clinicaltrials.gov/find-studies/constructing-complex-search-queries)\n    *   [RSS Feeds](https://clinicaltrials.gov/find-studies/rss)\n\n*   Study Basics\n    *   [Learn About Studies](https://clinicaltrials.gov/study-basics/learn-about-studies)\n    *   [How to Read a Study Record](https://clinicaltrials.gov/study-basics/how-to-read-study-record)\n    *   [How to Read Study Results](https://clinicaltrials.gov/study-basics/how-to-read-study-results)\n    *   [Glossary](https://clinicaltrials.gov/study-basics/glossary)\n    *   [Patient Resources](https://clinicaltrials.gov/study-basics/patient-resources)\n\n*   Submit Studies\n    *   [PRS Accounts](https://clinicaltrials.gov/submit-studies/prs-accounts)\n    *   [PRS Help Resources](https://clinicaltrials.gov/submit-studies/prs-help)\n\n*   Data and API\n    *   [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)\n    *   [About the API](https://clinicaltrials.gov/data-api/about-api)\n    *   [How to Download Study Records](https://clinicaltrials.gov/data-api/how-download-study-records)\n    *   [Access Data in FHIR](https://clinicaltrials.gov/data-api/fhir)\n\n*   Policy\n    *   [FAQs](https://clinicaltrials.gov/policy/faq)\n    *   [Clinical Trial Reporting Requirements](https://clinicaltrials.gov/policy/reporting-requirements)\n    *   [FDAAA 801 and the Final Rule](https://clinicaltrials.gov/policy/fdaaa-801-final-rule)\n    *   [Protocol Registration Definitions](https://clinicaltrials.gov/policy/protocol-definitions)\n    *   [Results Definitions](https://clinicaltrials.gov/policy/results-definitions)\n    *   [Expanded Access Definitions](https://clinicaltrials.gov/policy/expanded-access-definitions)\n\n*   About\n    *   [News and Updates](https://clinicaltrials.gov/about-site/news-and-updates)\n    *   [About ClinicalTrials.gov](https://clinicaltrials.gov/about-site/about-ctg)\n    *   [Trends and Charts](https://clinicaltrials.gov/about-site/trends-charts)\n    *   [Modernization](https://clinicaltrials.gov/about-site/modernization)\n    *   [Modernization Top Questions](https://clinicaltrials.gov/about-site/modernization-top-questions)\n    *   [Selected Publications](https://clinicaltrials.gov/about-site/selected-publications)\n    *   [Release Notes](https://clinicaltrials.gov/about-site/release-notes)\n    *   [Disclaimer](https://clinicaltrials.gov/about-site/disclaimer)\n    *   [Terms and Conditions](https://clinicaltrials.gov/about-site/terms-conditions)\n    *   [Linking to This Site](https://clinicaltrials.gov/about-site/linking-to)\n    *   [Accessibility](https://clinicaltrials.gov/about-site/accessibility)\n\n*   My Saved Studies (0)\n\n1.   [Home](https://clinicaltrials.gov/)\n2.   [Search Results](https://clinicaltrials.gov/search)\n3.   Study Record\n\n![Image 8: Disclaimer](https://clinicaltrials.gov/assets/images/warning.svg)\n\nThe U.S. government does not review or approve the safety and science of all studies listed on this website.\n\nRead our full  for details.\n\nClinicalTrials.gov is a website and online database of clinical research studies and information about their results. The National Library of Medicine (NLM) maintains the website. **The study sponsor or investigator submits information** about their study to ClinicalTrials.gov and **is responsible for the safety, science, and accuracy** of any study they list.\n\nBefore joining a study, talk to your health care professional about possible risks and benefits. To learn more about taking part in studies, read .\n\nClinicalTrials.gov ID \n\nSponsor \n\nInformation provided by \n\nLast Update Posted \n\nWhat would you like to download?\n--------------------------------\n\nFile Format\n\nStudy Details Researcher View No Results Posted Record History\n\nOn this page\n\n[Study Overview](https://clinicaltrials.gov/study/NCT06717347#study-overview)\n\n[Contacts and Locations](https://clinicaltrials.gov/study/NCT06717347#contacts-and-locations)\n\n[Participation Criteria](https://clinicaltrials.gov/study/NCT06717347#participation-criteria)\n\n[Study Plan](https://clinicaltrials.gov/study/NCT06717347#study-plan)\n\n[Collaborators and Investigators](https://clinicaltrials.gov/study/NCT06717347#collaborators-and-investigators)\n\n[Study Record Dates](https://clinicaltrials.gov/study/NCT06717347#study-record-dates)\n\n[More Information](https://clinicaltrials.gov/study/NCT06717347#more-information)\n\nStudy Overview\n--------------\n\nContacts and Locations\n----------------------\n\nThis section provides contact details for people who can answer questions about joining this study, and information on where this study is taking place.\n\nTo learn more, please see the [Contacts and Locations section in How to Read a Study Record](https://clinicaltrials.gov/study-basics/how-to-read-study-record#contacts-and-locations \"Contacts and Locations section in How to Read a Study Record\")(https://clinicaltrials.gov/study-basics/how-to-read-study-record#contacts-and-locations).\n\nStudy Contact \n\n**Name:**Toll Free Number\n\n**Phone Number:**1-888-577-8839\n\n**Email:**[Trialsites@msd.com](mailto:Trialsites@msd.com?subject=NCT06717347,%202140-010,%20A%20Study%20to%20Evaluate%20Zilovertamab%20Vedotin%20(MK-2140)%20Combination%20With%20Rituximab%20Plus%20Cyclophosphamide,%20Doxorubicin,%20and%20Prednisone%20(R-CHP)%20Versus%20Rituximab%20Plus%20Cyclophosphamide,%20Doxorubicin,%20Vincristine,%20and%20Prednisone%20(R-CHOP)%20in%20Participants%20With%20Previously%20Untreated%20DLBCL%20(MK-2140-010))\n\nThis study has 234 locations\n\nUnited States\n\nArizona Locations \n\n**Tucson, Arizona, United States, 85719**\n\nRecruiting\n\nThe University of Arizona Cancer Center - North Campus ( Site 0124)\n\nContact : \n\nStudy Coordinator\n\n520-621-5497\n\nCalifornia Locations \n\n**Los Alamitos, California, United States, 90720**\n\nRecruiting\n\nCancer Blood and Specialty Clinic ( Site 0109)\n\nContact : \n\nStudy Coordinator\n\n562-200-0203\n\n**Los Angeles, California, United States, 90048**\n\nRecruiting\n\nCedars-Sinai Medical Center ( Site 0115)\n\nContact : \n\nStudy Coordinator\n\n310-423-3277\n\n**San Francisco, California, United States, 94115**\n\nRecruiting\n\nPacific Hematology Oncology Associates ( Site 0131)\n\nContact : \n\nStudy Coordinator\n\n415-923-3012\n\nFlorida Locations \n\n**Hialeah, Florida, United States, 33013**\n\nRecruiting\n\nBioresearch Partner ( Site 0157)\n\nContact : \n\nStudy Coordinator\n\n833-489-4968\n\n**Orange City, Florida, United States, 32763**\n\nRecruiting\n\nMid Florida Hematology and Oncology Center ( Site 0172)\n\nContact : \n\nStudy Coordinator\n\n386-774-1223\n\nIllinois Locations \n\n**O'Fallon, Illinois, United States, 62269**\n\nRecruiting\n\nCancer Care Specialists of Illinois ( Site 0152)\n\nContact : \n\nStudy Coordinator\n\n618-416-7970\n\nIndiana Locations \n\n**Fort Wayne, Indiana, United States, 46804**\n\nRecruiting\n\nFort Wayne Medical Oncology and Hematology ( Site 0149)\n\nContact : \n\nStudy Coordinator\n\n260-436-0800\n\nKansas Locations \n\n**Topeka, Kansas, United States, 66606**\n\nRecruiting\n\nCotton O'Neil Cancer Center ( Site 0108)\n\nContact : \n\nStudy Coordinator\n\n785-478-9495\n\nKentucky Locations \n\n**Lexington, Kentucky, United States, 40536**\n\nRecruiting\n\nUniversity of Kentucky ( Site 0106)\n\nContact : \n\nStudy Coordinator\n\n859-257-6006\n\n**Louisville, Kentucky, United States, 40207**\n\nRecruiting\n\nNorton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0163)\n\nContact : \n\nStudy Coordinator\n\n502-899-3366\n\nMichigan Locations \n\n**Grand Rapids, Michigan, United States, 49503**\n\nRecruiting\n\nCorewell Health ( Site 0130)\n\nContact : \n\nStudy Coordinator\n\n616-486-6180\n\nMissouri Locations \n\n**Bridgeton, Missouri, United States, 63044**\n\nRecruiting\n\nCircuit Clinical - SSM Health Cancer Care DePaul ( Site 0166)\n\nContact : \n\nStudy Coordinator\n\n636-673-3083\n\n**Kansas City, Missouri, United States, 64108**\n\nRecruiting\n\nTruman Medical Center ( Site 0122)\n\nContact : \n\nStudy Coordinator\n\n816-404-4418\n\nNevada Locations \n\n**Las Vegas, Nevada, United States, 89102**\n\nRecruiting\n\nOptumCare Cancer Care ( Site 0121)\n\nContact : \n\nStudy Coordinator\n\n702-724-8787\n\n**Las Vegas, Nevada, United States, 89169**\n\nRecruiting\n\nComprehensive Cancer Centers of Nevada ( Site 0113)\n\nContact : \n\nStudy Coordinator\n\n702-622-9699\n\nNew York Locations \n\n**Albany, New York, United States, 12206**\n\nRecruiting\n\nNew York Oncology Hematology, P.C. ( Site 0129)\n\nContact : \n\nStudy Coordinator\n\n518-262-6696\n\nSouth Dakota Locations \n\n**Sioux Falls, South Dakota, United States, 57104**\n\nRecruiting\n\nSanford Cancer Center ( Site 0143)\n\nContact : \n\nStudy Coordinator\n\n605-328-8000\n\nTennessee Locations \n\n**Knoxville, Tennessee, United States, 37920**\n\nRecruiting\n\nThe University of Tennessee Medical Center ( Site 0142)\n\nContact : \n\nStudy Coordinator\n\n865-305-9000\n\nTexas Locations \n\n**Houston, Texas, United States, 77030**\n\nRecruiting\n\nCenter for Oncology and Blood Disorders ( Site 0153)\n\nContact : \n\nStudy Coordinator\n\n713-301-8964\n\n**Houston, Texas, United States, 77030**\n\nRecruiting\n\nHouston Methodist Cancer Center ( Site 0154)\n\nContact : \n\nStudy Coordinator\n\n713-363-8009\n\nVirginia Locations \n\n**Charlottesville, Virginia, United States, 22903**\n\nRecruiting\n\nUniversity of Virginia Cancer Center ( Site 0138)\n\nContact : \n\nStudy Coordinator\n\n434-243-7773\n\n**Richmond, Virginia, United States, 23229**\n\nRecruiting\n\nVirginia Cancer Institute ( Site 0148)\n\nContact : \n\nStudy Coordinator\n\n888-577-8839\n\n**Roanoke, Virginia, United States, 24014**\n\nRecruiting\n\nBlue Ridge Cancer Care ( Site 0132)\n\nContact : \n\nStudy Coordinator\n\n540-982-0237\n\nWisconsin Locations \n\n**Madison, Wisconsin, United States, 53715**\n\nRecruiting\n\nSSM Health Dean Medical Group ( Site 0140)\n\nContact : \n\nStudy Coordinator\n\n608-410-2700\n\nArgentina\n\n**CABA, Argentina, C1199ABB**\n\nRecruiting\n\nHospital Italiano de Buenos Aires ( Site 0304)\n\nContact : \n\nStudy Coordinator\n\n(011) 4959-0550\n\n**San Juan, Argentina, J5400ARW**\n\nRecruiting\n\nClinica EL Castaño ( Site 0312)\n\nContact : \n\nStudy Coordinator\n\n+542644277879\n\nBuenos Aires Locations \n\n**Caba., Buenos Aires, Argentina, C1430EGF**\n\nRecruiting\n\nClinica Adventista Belgrano ( Site 0309)\n\nContact : \n\nStudy Coordinator\n\n+5491140141500\n\n**Mar del Plata, Buenos Aires, Argentina, B7600FZO**\n\nRecruiting\n\nInstituto de Investigaciones Clinicas Mar del Plata ( Site 0306)\n\nContact : \n\nStudy Coordinator\n\n+542234963224\n\n**Pilar, Buenos Aires, Argentina, B1629AHJ**\n\nRecruiting\n\nHospital Universitario Austral ( Site 0307)\n\nContact : \n\nStudy Coordinator\n\n+541158239252\n\nBuenos Aires F.D. Locations \n\n**Buenos Aires, Buenos Aires F.D., Argentina, C1118AAT**\n\nRecruiting\n\nHospital Aleman ( Site 0301)\n\nContact : \n\nStudy Coordinator\n\n+541148232574\n\nSanta Fe Province Locations \n\n**Rosario, Santa Fe Province, Argentina, S2000CEJ**\n\nRecruiting\n\nFundacion Estudios Clinicos ( Site 0311)\n\nContact : \n\nStudy Coordinator\n\n+54 (0341) 2221472\n\nTucumán Province Locations \n\n**San Miguel de Tucumán, Tucumán Province, Argentina, T4000IKO**\n\nRecruiting\n\nC.I.C.E. 9 de Julio ( Site 0305)\n\nContact : \n\nStudy Coordinator\n\n0381 450-4512\n\nAustralia\n\nQueensland Locations \n\n**Douglas, Queensland, Australia, 4814**\n\nRecruiting\n\nTownsville University Hospital ( Site 3006)\n\nContact : \n\nStudy Coordinator\n\n+61744333549\n\nSouth Australia Locations \n\n**Adelaide, South Australia, Australia, 5000**\n\nRecruiting\n\nRoyal Adelaide Hospital ( Site 3001)\n\nContact : \n\nStudy Coordinator\n\n0870745898\n\nVictoria Locations \n\n**Ballarat, Victoria, Australia, 3350**\n\nRecruiting\n\nGrampians Health ( Site 3003)\n\nContact : \n\nStudy Coordinator\n\n+61353204000\n\n**Melbourne, Victoria, Australia, 3076**\n\nRecruiting\n\nNorthern Hospital ( Site 3002)\n\nContact : \n\nStudy Coordinator\n\n+61384058000\n\nWestern Australia Locations \n\n**Perth, Western Australia, Australia, 6000**\n\nRecruiting\n\nRoyal Perth Hospital-Haematology ( Site 3004)\n\nContact : \n\nStudy Coordinator\n\n+61864775013\n\nBelgium\n\nAntwerpen Locations \n\n**Mechelen, Antwerpen, Belgium, 2800**\n\nRecruiting\n\nAZ Sint-Maarten, Campus Leopoldstraat 2 ( Site 1102)\n\nContact : \n\nStudy Coordinator\n\n+32(0)15/89.10.10\n\nHainaut Locations \n\n**Mons, Hainaut, Belgium, 7000**\n\nRecruiting\n\nASBL CHU Helora - Hôpital de Mons - Site Kennedy ( Site 1103)\n\nContact : \n\nStudy Coordinator\n\n+3265413744\n\nBrazil\n\n**São Paulo, Brazil, 01321-001**\n\nRecruiting\n\nHospital Paulistano ( Site 0406)\n\nContact : \n\nStudy Coordinator\n\n+551131411083\n\n**São Paulo, Brazil, 05403-010**\n\nRecruiting\n\nHospital das Clinicas FMUSP ( Site 0402)\n\nContact : \n\nStudy Coordinator\n\n+5511975458304\n\nParaná Locations \n\n**Cascavel, Paraná, Brazil, 85802-080**\n\nRecruiting\n\nCEONC ( Site 0412)\n\nContact : \n\nStudy Coordinator\n\n049988422678\n\n**Curitiba, Paraná, Brazil, 82520-060**\n\nRecruiting\n\nHospital Erasto Gaertner ( Site 0401)\n\nContact : \n\nStudy Coordinator\n\n+5541999846033\n\nRio Grande do Norte Locations \n\n**Natal, Rio Grande do Norte, Brazil, 59062-000**\n\nRecruiting\n\nLiga Norte Riograndense Contra o Cancer ( Site 0407)\n\nContact : \n\nStudy Coordinator\n\n+5584999278442\n\nSanta Catarina Locations \n\n**Florianópolis, Santa Catarina, Brazil, 88020-210**\n\nRecruiting\n\nCEPEN - Centro de Pesquisa e Ensino em Oncologia de Santa Catarina ( Site 0403)\n\nContact : \n\nStudy Coordinator\n\n+554833804828\n\nSão Paulo Locations \n\n**Ribeirão Preto, São Paulo, Brazil, 14026-610**\n\nRecruiting\n\nHope ( Site 0413)\n\nContact : \n\nStudy Coordinator\n\n+55 16 98813-0059\n\n**São Carlos, São Paulo, Brazil, 13561-130**\n\nRecruiting\n\nClinica Advanze ( Site 0411)\n\nContact : \n\nStudy Coordinator\n\n55163371-1320\n\n**SJRP, São Paulo, Brazil, 15090-000**\n\nRecruiting\n\nF. F. R. M. São Jose do Rio Preto ( Site 0404)\n\nContact : \n\nStudy Coordinator\n\n+55 17 99788 6883\n\nCanada\n\nOntario Locations \n\n**Oshawa, Ontario, Canada, L1G 2B9**\n\nRecruiting\n\nLakeridge Health - The R.S. McLaughlin Durham Regional Cancer Centre (MDRCC) ( Site 0206)\n\nContact : \n\nStudy Coordinator\n\n9055768711\n\n**Toronto, Ontario, Canada, M4N 3M5**\n\nRecruiting\n\nSunnybrook Research Institute ( Site 0204)\n\nContact : \n\nStudy Coordinator\n\n4164804662\n\nChile\n\nCoquimbo Region Locations \n\n**La Serena, Coquimbo Region, Chile, 1720430**\n\nRecruiting\n\nIC La Serena Research ( Site 0504)\n\nContact : \n\nStudy Coordinator\n\n+56958646664\n\nLos Ríos Region Locations \n\n**Valdivia, Los Ríos Region, Chile, 5112129**\n\nRecruiting\n\nOncocentro Valdivia ( Site 0506)\n\nContact : \n\nStudy Coordinator\n\n+56632632200\n\nRegión de Valparaíso Locations \n\n**Viña del Mar, Región de Valparaíso, Chile, 2540488**\n\nRecruiting\n\nCentro de Investigaciones ( Site 0511)\n\nContact : \n\nStudy Coordinator\n\n+56323245375\n\nRegión del Biobío Locations \n\n**Concepción, Región del Biobío, Chile, 4070196**\n\nRecruiting\n\nBiocenter ( Site 0510)\n\nContact : \n\nStudy Coordinator\n\n+56412858421\n\nRegion M. de Santiago Locations \n\n**Santiago, Region M. de Santiago, Chile, 7500653**\n\nRecruiting\n\nCentro de Estudios Clínicos SAGA ( Site 0508)\n\nContact : \n\nStudy Coordinator\n\n+56991612199\n\n**Santiago, Region M. de Santiago, Chile, 7500921**\n\nRecruiting\n\nFALP ( Site 0501)\n\nContact : \n\nStudy Coordinator\n\n+5622712 8000\n\n**Santiago, Region M. de Santiago, Chile, 7580206**\n\nRecruiting\n\nClinica Inmunocel ( Site 0503)\n\nContact : \n\nStudy Coordinator\n\n+56224376600\n\n**Santiago, Region M. de Santiago, Chile, 7650018**\n\nRecruiting\n\nClínica RedSalud Vitacura ( Site 0512)\n\nContact : \n\nStudy Coordinator\n\n+56 223954046\n\n**Santiago, Region M. de Santiago, Chile, 8420383**\n\nRecruiting\n\nBradfordhill ( Site 0502)\n\nContact : \n\nStudy Coordinator\n\n+56229490970\n\nChina\n\nAnhui Locations \n\n**Hefei, Anhui, China, 230031**\n\nRecruiting\n\nAnhui Provincial Cancer Hospital ( Site 3124)\n\nContact : \n\nStudy Coordinator\n\n+8655165327666\n\nBeijing Municipality Locations \n\n**Beijing, Beijing Municipality, China, 100096**\n\nRecruiting\n\nPeking University Third Hospital ( Site 3102)\n\nContact : \n\nStudy Coordinator\n\n010-82266699\n\n**Beijing, Beijing Municipality, China, 100142**\n\nRecruiting\n\nBeijing Cancer Hospital ( Site 3101)\n\nContact : \n\nStudy Coordinator\n\n010-88121122\n\nChongqing Municipality Locations \n\n**Chongqing, Chongqing Municipality, China, 400030**\n\nRecruiting\n\nChongqing Cancer Hospital ( Site 3113)\n\nContact : \n\nStudy Coordinator\n\n023-65301682\n\nFujian Locations \n\n**Fuzhou, Fujian, China, 350014**\n\nRecruiting\n\nFujian Provincial Cancer Hospital. ( Site 3119)\n\nContact : \n\nStudy Coordinator\n\n059162752082\n\n**Xiamen, Fujian, China, 361003**\n\nRecruiting\n\nThe First Affiliated Hospital of Xiamen University ( Site 3120)\n\nContact : \n\nStudy Coordinator\n\n+8605922137255\n\nGuangdong Locations \n\n**Guangzhou, Guangdong, China, 510060**\n\nRecruiting\n\nSun Yat-sen University Cancer Center ( Site 3121)\n\nContact : \n\nStudy Coordinator\n\n020-87343765\n\n**Guangzhou, Guangdong, China, 510280**\n\nRecruiting\n\nZhujiang Hospital of Southern Medical University ( Site 3122)\n\nContact : \n\nStudy Coordinator\n\n020-62782020\n\nGuangxi Locations \n\n**Nanning, Guangxi, China, 530021**\n\nRecruiting\n\nAffiliated Cancer Hospital of Guangxi Medical University ( Site 3123)\n\nContact : \n\nStudy Coordinator\n\n0771-5323002\n\nGuizhou Locations \n\n**Guiyang, Guizhou, China, 550004**\n\nRecruiting\n\nThe Affiliated Hospital of Guizhou Medical University ( Site 3112)\n\nContact : \n\nStudy Coordinator\n\n0851-86740793\n\nHubei Locations \n\n**Wuhan, Hubei, China, 430079**\n\nRecruiting\n\nHubei Cancer Hospital ( Site 3125)\n\nContact : \n\nStudy Coordinator\n\n027-87670003\n\nJiangsu Locations \n\n**Nantong, Jiangsu, China, 226001**\n\nRecruiting\n\nAffiliated Hospital of Nantong University ( Site 3117)\n\nContact : \n\nStudy Coordinator\n\n+8618252100915\n\nJiangxi Locations \n\n**Nanchang, Jiangxi, China, 330029**\n\nRecruiting\n\nJiangxi Cancer Hospital ( Site 3118)\n\nContact : \n\nStudy Coordinator\n\n0791-88317256\n\nJilin Locations \n\n**Changchun, Jilin, China, 130021**\n\nRecruiting\n\nThe First Hospital Of Jilin University ( Site 3103)\n\nContact : \n\nStudy Coordinator\n\n0431-88782222\n\nShandong Locations \n\n**Jinan, Shandong, China, 250117**\n\nRecruiting\n\nShandong Cancer Hospital ( Site 3108)\n\nContact : \n\nStudy Coordinator\n\n053167626063\n\n**Linyi, Shandong, China, 276001**\n\nRecruiting\n\nLinYi Cancer Hospital ( Site 3104)\n\nContact : \n\nStudy Coordinator\n\n+865398127192\n\nShanghai Municipality Locations \n\n**Shanghai, Shanghai Municipality, China, 200032**\n\nRecruiting\n\nFudan University Shanghai Cancer Center ( Site 3115)\n\nContact : \n\nStudy Coordinator\n\n+862164175590\n\nShanxi Locations \n\n**Taiyuan, Shanxi, China, 030013**\n\nRecruiting\n\nShanxi Cancer Hospital ( Site 3106)\n\nContact : \n\nStudy Coordinator\n\n0351-4651606\n\n**Xi’an, Shanxi, China, 710061**\n\nRecruiting\n\n1st Affil Hosp of Med College of Xi'an Jiaotong University ( Site 3107)\n\nContact : \n\nStudy Coordinator\n\n029-85324094\n\nSichuan Locations \n\n**Chengdu, Sichuan, China, 610041**\n\nRecruiting\n\nSichuan Cancer Hospital. ( Site 3111)\n\nContact : \n\nStudy Coordinator\n\n02885420243\n\n**Chengdu, Sichuan, China, 610041**\n\nRecruiting\n\nWest China Hospital, Sichuan University ( Site 3110)\n\nContact : \n\nStudy Coordinator\n\n028-85422114\n\nTianjin Municipality Locations \n\n**Tianjin, Tianjin Municipality, China, 301617**\n\nRecruiting\n\nInstitute of Hematology and Blood Diseases Hosp CAMS&PUMC ( Site 3105)\n\nContact : \n\nStudy Coordinator\n\n022 23608030\n\nYunnan Locations \n\n**Kunming, Yunnan, China, 650118**\n\nRecruiting\n\nYunnan Province Cancer Hospital ( Site 3109)\n\nContact : \n\nStudy Coordinator\n\n0871-68185656\n\nZhejiang Locations \n\n**Hangzhou, Zhejiang, China, 310009**\n\nRecruiting\n\nThe First Affiliated Hospital, Zhejiang Medical University ( Site 3116)\n\nContact : \n\nStudy Coordinator\n\n0571-87236668\n\nColombia\n\nAntioquia Locations \n\n**Medellín, Antioquia, Colombia, 050034**\n\nRecruiting\n\nHospital Pablo Tobon Uribe ( Site 0604)\n\nContact : \n\nStudy Coordinator\n\n+57 604 4459753\n\nBogota D.C. Locations \n\n**Bogotá, Bogota D.C., Colombia, 110231**\n\nActive, not recruiting\n\nHospital Universitario San Ignacio ( Site 0607)\n\nDepartamento de Córdoba Locations \n\n**Montería, Departamento de Córdoba, Colombia, 230002**\n\nRecruiting\n\nIMAT S.A.S ( Site 0603)\n\nContact : \n\nStudy Coordinator\n\n+57 604 7832333\n\nRisaralda Department Locations \n\n**Pereira, Risaralda Department, Colombia, 660001**\n\nRecruiting\n\nOncologos del Occidente ( Site 0601)\n\nContact : \n\nStudy Coordinator\n\n573002558656\n\nValle del Cauca Department Locations \n\n**Cali, Valle del Cauca Department, Colombia, 760032**\n\nRecruiting\n\nFundación Valle del Lili ( Site 0602)\n\nContact : \n\nStudy Coordinator\n\n3158971414\n\nDenmark\n\nCentral Jutland Locations \n\n**Herning, Central Jutland, Denmark, 7400**\n\nRecruiting\n\nRegionshospitalet Gødstrup ( Site 1301)\n\nContact : \n\nStudy Coordinator\n\n+45 78430000\n\nNorth Denmark Locations \n\n**Aalborg, North Denmark, Denmark, 9000**\n\nRecruiting\n\nAalborg University Hospital ( Site 1302)\n\nContact : \n\nStudy Coordinator\n\n+4597662238\n\nFrance\n\nAlpes-Maritimes Locations \n\n**Nice, Alpes-Maritimes, France, 06189**\n\nRecruiting\n\nCentre Antoine-Lacassagne ( Site 1514)\n\nContact : \n\nStudy Coordinator\n\n+33492031000\n\nCharente-Maritime Locations \n\n**La Rochelle, Charente-Maritime, France, 17000**\n\nRecruiting\n\nHopital Saint Louis, Centre Hospitalier de La Rochelle ( Site 1511)\n\nContact : \n\nStudy Coordinator\n\n+33546458867.\n\nCote-d Or Locations \n\n**Dijon, Cote-d Or, France, 21000**\n\nRecruiting\n\nCHU Dijon Bourgogne ( Site 1516)\n\nContact : \n\nStudy Coordinator\n\n+33380669237\n\nHauts-de-Seine Locations \n\n**Saint-Cloud, Hauts-de-Seine, France, 92210**\n\nRecruiting\n\nInstitut Curie - site Saint-Cloud ( Site 1501)\n\nContact : \n\nStudy Coordinator\n\n01 47 11 17 92\n\nIsere Locations \n\n**La Tronche, Isere, France, 38700**\n\nRecruiting\n\nCHU GRENOBLE ALPES ( Site 1518)\n\nContact : \n\nStudy Coordinator\n\n+33476765755\n\nLimousin Locations \n\n**Limoges, Limousin, France, 87042**\n\nRecruiting\n\nCentre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 1512)\n\nContact : \n\nStudy Coordinator\n\n+33555056651\n\nMoselle Locations \n\n**Metz, Moselle, France, 57085**\n\nRecruiting\n\nCentre Hospitalier Régional Metz Thionville - Hôpital de Mercy ( Site 1515)\n\nContact : \n\nStudy Coordinator\n\n+33387553363\n\nNord Locations \n\n**Dunkirk, Nord, France, 59385**\n\nRecruiting\n\nCentre Hospitalier de Dunkerque ( Site 1513)\n\nContact : \n\nStudy Coordinator\n\n+330328285633\n\nPuy-de-Dome Locations \n\n**Clermont-Ferrand, Puy-de-Dome, France, 63100**\n\nRecruiting\n\nCentre Hospitalier Universitaire Estaing ( Site 1508)\n\nContact : \n\nStudy Coordinator\n\n33473752291\n\nPyrenees-Atlantiques Locations \n\n**Bayonne, Pyrenees-Atlantiques, France, 64100**\n\nRecruiting\n\nCentre Hospitalier de la Cote Basque ( Site 1509)\n\nContact : \n\nStudy Coordinator\n\n+33533788254\n\nSeine-Maritime Locations \n\n**Rouen, Seine-Maritime, France, 76038**\n\nRecruiting\n\nCentre Henri Becquerel ( Site 1517)\n\nContact : \n\nStudy Coordinator\n\n02.76.67.30.45\n\nVar Locations \n\n**Toulon, Var, France, 83800**\n\nRecruiting\n\nHIA Sainte Anne ( Site 1506)\n\nContact : \n\nStudy Coordinator\n\n+33483162506\n\nVaucluse Locations \n\n**Avignon, Vaucluse, France, 84000**\n\nRecruiting\n\nCentre Hospitalier d'Avignon ( Site 1505)\n\nContact : \n\nStudy Coordinator\n\n33432759330\n\nVendee Locations \n\n**La Roche-sur-Yon, Vendee, France, 85000**\n\nRecruiting\n\nCHD Vendee ( Site 1502)\n\nContact : \n\nStudy Coordinator\n\n+33251446173\n\nGreece\n\nAttica Locations \n\n**Athens, Attica, Greece, 106 76**\n\nRecruiting\n\nEvangelismos General Hospital of Athens ( Site 1602)\n\nContact : \n\nStudy Coordinator\n\n0030 2132041721\n\n**Athens, Attica, Greece, 115 26**\n\nRecruiting\n\nGeneral Hospital of Athens \"Laiko\"-Hematology Department ( Site 1603)\n\nContact : \n\nStudy Coordinator\n\n0030 2136060981\n\n**Athens, Attica, Greece, 124 62**\n\nRecruiting\n\nAttikon University General Hospital of Athens ( Site 1604)\n\nContact : \n\nStudy Coordinator\n\n0030 2105832318\n\nEvros Locations \n\n**Alexandroupoli, Evros, Greece, 681 00**\n\nRecruiting\n\nUniversity General Hospital of Alexandroupoli ( Site 1601)\n\nContact : \n\nStudy Coordinator\n\n0030 2551353739\n\nGuatemala\n\n**Guatemala City, Guatemala, 01009**\n\nRecruiting\n\nMEDI-K ( Site 0701)\n\nContact : \n\nStudy Coordinator\n\n+50222912323\n\n**Guatemala City, Guatemala, 01010**\n\nRecruiting\n\nCELAN,S.A ( Site 0702)\n\nContact : \n\nStudy Coordinator\n\n+502 55275016\n\n**Guatemala City, Guatemala, 01010**\n\nRecruiting\n\nCen Integral Onco Gastro y Hemato Onco Guatemala S.A. ( Site 0703)\n\nContact : \n\nStudy Coordinator\n\n+502 30147611\n\nHong Kong\n\n**Hong Kong, Hong Kong**\n\nRecruiting\n\nPrincess Margaret Hospital ( Site 3202)\n\nContact : \n\nStudy Coordinator\n\n85229901111\n\n**Hong Kong, Hong Kong**\n\nRecruiting\n\nQueen Mary Hospital ( Site 3201)\n\nContact : \n\nStudy Coordinator\n\n85222553838\n\nHungary\n\nHajdú-Bihar Locations \n\n**Debrecen, Hajdú-Bihar, Hungary, 4032**\n\nRecruiting\n\nDebreceni Egyetem Klinikai Kozpont ( Site 1702)\n\nContact : \n\nStudy Coordinator\n\n+3652255601\n\nSzabolcs-Szatmár-Bereg Locations \n\n**Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary, 4400**\n\nRecruiting\n\nSzabolcs Szatmár Bereg Vármegyei Oktatókórház ( Site 1704)\n\nContact : \n\nStudy Coordinator\n\n+3642599700/1060\n\nTolna County Locations \n\n**Szekszárd, Tolna County, Hungary, 7100**\n\nRecruiting\n\nTolna Vármegyei Balassa János Kórház ( Site 1710)\n\nContact : \n\nStudy Coordinator\n\n+36 74 501 603\n\nIsrael\n\n**Haifa, Israel, 3436212**\n\nRecruiting\n\nCarmel Hospital ( Site 1903)\n\nContact : \n\nStudy Coordinator\n\n04-8250844\n\n**Jerusalem, Israel, 9112001**\n\nRecruiting\n\nHadassah Medical Center ( Site 1901)\n\nContact : \n\nStudy Coordinator\n\n97226778180\n\n**Tel Aviv, Israel, 6423906**\n\nRecruiting\n\nSourasky Medical Center ( Site 1904)\n\nContact : \n\nStudy Coordinator\n\n9723-6973782\n\n**Tiberias, Israel, 15208**\n\nRecruiting\n\nPoria Medical Center ( Site 1902)\n\nContact : \n\nStudy Coordinator\n\n972-4-662759\n\nItaly\n\n**Ancona, Italy, 60126**\n\nRecruiting\n\nAOU delle Marche Ospedali Riuniti di Ancona ( Site 2011)\n\nContact : \n\nStudy Coordinator\n\n+390715964562\n\n**Brescia, Italy, 25123**\n\nRecruiting\n\nAzienda Ospedaliera Spedali Civili di Brescia-Hemathology ( Site 2001)\n\nContact : \n\nStudy Coordinator\n\n+390303995438\n\n**Milan, Italy, 20132**\n\nRecruiting\n\nIRCCS Ospedale San Raffaele ( Site 2012)\n\nContact : \n\nStudy Coordinator\n\n+39 02 2643 7649\n\n**Milan, Italy, 20141**\n\nRecruiting\n\nIEO Istituto Europeo di Oncologia ( Site 2009)\n\nContact : \n\nStudy Coordinator\n\n+39 02 94371079\n\n**Novara, Italy, 28100**\n\nRecruiting\n\nAzienda Ospedaliero Universitaria Maggiore della Carità ( Site 2004)\n\nContact : \n\nStudy Coordinator\n\n+3903213733127\n\n**Palermo, Italy, 90146**\n\nRecruiting\n\nAz. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO ( Site 2005)\n\nContact : \n\nStudy Coordinator\n\n+390916802773\n\n**Ravenna, Italy, 48121**\n\nRecruiting\n\nOspedale Santa Maria delle Croci ( Site 2006)\n\nContact : \n\nStudy Coordinator\n\n+390544285722\n\n**Roma, Italy, 00168**\n\nRecruiting\n\nFondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 2003)\n\nContact : \n\nStudy Coordinator\n\n00390630154180\n\nLombardy Locations \n\n**Monza, Lombardy, Italy, 20900**\n\nRecruiting\n\nFondazione IRCCS San Gerardo dei Tintori ( Site 2008)\n\nContact : \n\nStudy Coordinator\n\n+390392333539\n\nPotenza Locations \n\n**Rionero in Vulture, Potenza, Italy, 85028**\n\nRecruiting\n\nIRCCS Crob ( Site 2002)\n\nContact : \n\nStudy Coordinator\n\n+390972726685\n\nTorino Locations \n\n**Candiolo, Torino, Italy, 10060**\n\nRecruiting\n\nIstituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia ( Site 2010)\n\nContact : \n\nStudy Coordinator\n\n+390119933250\n\nJapan\n\n**Chiba, Japan, 260-8717**\n\nRecruiting\n\nChiba Cancer Center ( Site 3314)\n\nContact : \n\nStudy Coordinator\n\n+81-43-264-5431\n\n**Fukuoka, Japan, 812-8582**\n\nRecruiting\n\nKyushu University Hospital ( Site 3313)\n\nContact : \n\nStudy Coordinator\n\n+8192-641-1151\n\n**Hiroshima, Japan, 730-8619**\n\nRecruiting\n\nHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 3322)\n\nContact : \n\nStudy Coordinator\n\n+81-82-241-3111\n\n**Kyoto, Japan, 602-8566**\n\nRecruiting\n\nUniversity Hospital,Kyoto Prefectural University of Medicine ( Site 3315)\n\nContact : \n\nStudy Coordinator\n\n+81-75-251-5111\n\n**Miyazaki, Japan, 889-1692**\n\nRecruiting\n\nUniversity of Miyazaki Hospital ( Site 3319)\n\nContact : \n\nStudy Coordinator\n\n+81-985-85-1510\n\n**Okayama, Japan, 700-8558**\n\nRecruiting\n\nOkayama University Hospital ( Site 3311)\n\nContact : \n\nStudy Coordinator\n\n+81-86-223-7151\n\n**Osaka, Japan, 545-8586**\n\nRecruiting\n\nOsaka Metropolitan University Hospital ( Site 3317)\n\nContact : \n\nStudy Coordinator\n\n+81-6-6645-2121\n\n**Yamagata, Japan, 990-9585**\n\nRecruiting\n\nYamagata University Hospital ( Site 3312)\n\nContact : \n\nStudy Coordinator\n\n+81-23-633-1122\n\nAichi-ken Locations \n\n**Nagoya, Aichi-ken, Japan, 466-8560**\n\nRecruiting\n\nNagoya University Hospital ( Site 3309)\n\nContact : \n\nStudy Coordinator\n\n+81-52-741-2111\n\nEhime Locations \n\n**Matsuyama, Ehime, Japan, 791-0280**\n\nRecruiting\n\nNational Hospital Organization Shikoku Cancer Center ( Site 3321)\n\nContact : \n\nStudy Coordinator\n\n+81-89-999-1111\n\nHyōgo Locations \n\n**Kobe, Hyōgo, Japan, 650-0047**\n\nRecruiting\n\nKobe City Medical Center General Hospital ( Site 3318)\n\nContact : \n\nStudy Coordinator\n\n+81-78-302-4321\n\nIshikawa-ken Locations \n\n**Kanazawa, Ishikawa-ken, Japan, 920-8641**\n\nRecruiting\n\nKanazawa University Hospital ( Site 3308)\n\nContact : \n\nStudy Coordinator\n\n+81-76-265-2000\n\nKanagawa Locations \n\n**Isehara, Kanagawa, Japan, 259-1193**\n\nRecruiting\n\nTokai University Hospital ( Site 3302)\n\nContact : \n\nStudy Coordinator\n\n+81-463-93-1121\n\nMiyagi Locations \n\n**Sendai, Miyagi, Japan, 980-8574**\n\nRecruiting\n\nTohoku University Hospital ( Site 3301)\n\nContact : \n\nStudy Coordinator\n\n+81-22-717-7000\n\nOsaka Locations \n\n**Sakai, Osaka, Japan, 590-0197**\n\nRecruiting\n\nKindai University Hospital ( Site 3310)\n\nContact : \n\nStudy Coordinator\n\n+81-72-288-7222\n\nSaitama Locations \n\n**Iruma-gun, Saitama, Japan, 350-0495**\n\nRecruiting\n\nSaitama Medical University Hospital ( Site 3305)\n\nContact : \n\nStudy Coordinator\n\n+81-49-276-1111\n\nTokyo Locations \n\n**Bunkyo, Tokyo, Japan, 113-8431**\n\nRecruiting\n\nJuntendo University Hospital ( Site 3307)\n\nContact : \n\nStudy Coordinator\n\n+81-3-3813-3111\n\n**Bunkyo, Tokyo, Japan, 113-8677**\n\nRecruiting\n\nTokyo Metropolitan Komagome Hospital ( Site 3323)\n\nContact : \n\nStudy Coordinator\n\n+81-3-3823-2101\n\nYamanashi Locations \n\n**Chūō, Yamanashi, Japan, 409-3898**\n\nRecruiting\n\nUniversity of Yamanashi Hospital ( Site 3320)\n\nContact : \n\nStudy Coordinator\n\n+81-55-273-1111\n\nMalaysia\n\nSabah Locations \n\n**Kota Kinabalu, Sabah, Malaysia, 88586**\n\nRecruiting\n\nQueen Elizabeth Hospital ( Site 3405)\n\nContact : \n\nStudy Coordinator\n\n+6088517555\n\nSarawak Locations \n\n**Kuching, Sarawak, Malaysia, 93586**\n\nRecruiting\n\nSarawak General Hospital ( Site 3402)\n\nContact : \n\nStudy Coordinator\n\n+6082276666\n\n**Miri, Sarawak, Malaysia, 98000**\n\nRecruiting\n\nHospital Miri ( Site 3403)\n\nContact : \n\nStudy Coordinator\n\n+6085460600\n\nSelangor Locations \n\n**Petaling Jaya, Selangor, Malaysia, 47500**\n\nRecruiting\n\nSunway Medical Centre ( Site 3406)\n\nContact : \n\nStudy Coordinator\n\n+60386011080\n\n**Selangor Darul Ehsan, Selangor, Malaysia, 68000**\n\nRecruiting\n\nHospital Ampang ( Site 3404)\n\nContact : \n\nStudy Coordinator\n\n+60342896559\n\nMexico\n\n**Oaxaca City, Mexico, 68020**\n\nRecruiting\n\nCentro de Investigacion Clinica de Oaxaca ( Site 0805)\n\nContact : \n\nStudy Coordinator\n\n52 9515473137\n\nCoahuila Locations \n\n**Torreón, Coahuila, Mexico, 27000**\n\nRecruiting\n\nCIMAB SA de CV ( Site 0807)\n\nContact : \n\nStudy Coordinator\n\n+528717130315\n\nHidalgo Locations \n\n**Pachuca, Hidalgo, Mexico, 42000**\n\nRecruiting\n\nGrupo Ollin Care ( Site 0806)\n\nContact : \n\nStudy Coordinator\n\n52 7711996481\n\nMexico City Locations \n\n**Mexico City, Mexico City, Mexico, 03100**\n\nRecruiting\n\nHealth Pharma Professional Research S.A. de C.V. ( Site 0801)\n\nContact : \n\nStudy Coordinator\n\n+52 5575864856\n\n**Mexico City, Mexico City, Mexico, 03104**\n\nRecruiting\n\nCentro de Infusion Superare ( Site 0804)\n\nContact : \n\nStudy Coordinator\n\n52 5552646440\n\nMichoacán Locations \n\n**Morelia, Michoacán, Mexico, 58260**\n\nRecruiting\n\nCentro de Investigacion Clinica Chapultepec ( Site 0803)\n\nContact : \n\nStudy Coordinator\n\n52 4431478545\n\nNuevo León Locations \n\n**Monterrey, Nuevo León, Mexico, 64460**\n\nRecruiting\n\nHospital Universitario \"\"Dr. Jose Eleuterio Gonzalez\"\" ( Site 0802)\n\nContact : \n\nStudy Coordinator\n\n52 8183486136\n\nNetherlands\n\nSouth Holland Locations \n\n**Dordrecht, South Holland, Netherlands, 3318 AT**\n\nRecruiting\n\nAlbert Schweitzer Ziekenhuis ( Site 2103)\n\nContact : \n\nStudy Coordinator\n\n+31(0)786523013\n\nUtrecht Locations \n\n**Amersfoort, Utrecht, Netherlands, 3813 TZ**\n\nRecruiting\n\nMeander Medisch Centrum ( Site 2101)\n\nContact : \n\nStudy Coordinator\n\n+31(0)338502129\n\nPeru\n\n**Lima, Peru, 15072**\n\nRecruiting\n\nClínica San Felipe ( Site 0906)\n\nContact : \n\nStudy Coordinator\n\n511 2039900 Ext 131\n\n**Lima, Peru, 15072**\n\nRecruiting\n\nHospital Nacional Edgardo Rebagliati Martins ( Site 0903)\n\nContact : \n\nStudy Coordinator\n\n+51991895682\n\n**Lima, Peru, 15087**\n\nRecruiting\n\nHospital Nacional Dos De Mayo ( Site 0905)\n\nContact : \n\nStudy Coordinator\n\n+51944464618\n\nLambayeque Locations \n\n**Chiclayo, Lambayeque, Peru, 14001**\n\nRecruiting\n\nClínicas AUNA Sede Chiclayo ( Site 0904)\n\nContact : \n\nStudy Coordinator\n\n51 74748333 Ext 7832\n\nMuni Metro de Lima Locations \n\n**Surquillo, Muni Metro de Lima, Peru, 15038**\n\nRecruiting\n\nINSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 0901)\n\nContact : \n\nStudy Coordinator\n\n+512016500\n\nPoland\n\nMasovian Voivodeship Locations \n\n**Warsaw, Masovian Voivodeship, Poland, 02-781**\n\nRecruiting\n\nNarodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2201)\n\nContact : \n\nStudy Coordinator\n\n+48225462223\n\nPomeranian Voivodeship Locations \n\n**Słupsk, Pomeranian Voivodeship, Poland, 76-200**\n\nRecruiting\n\nWojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 2210)\n\nContact : \n\nStudy Coordinator\n\n59 84 60 390\n\nSilesian Voivodeship Locations \n\n**Gliwice, Silesian Voivodeship, Poland, 44-102**\n\nRecruiting\n\nNarodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2208)\n\nContact : \n\nStudy Coordinator\n\n+48322789794\n\n**Katowice, Silesian Voivodeship, Poland, 40-519**\n\nRecruiting\n\nPratia Onkologia Katowice ( Site 2204)\n\nContact : \n\nStudy Coordinator\n\n+48327462500\n\nWarmian-Masurian Voivodeship Locations \n\n**Olsztyn, Warmian-Masurian Voivodeship, Poland, 10-228**\n\nRecruiting\n\nSzpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko ( Site 2205)\n\nContact : \n\nStudy Coordinator\n\n+48895398428\n\nPortugal\n\n**Braga, Portugal, 4710-243**\n\nRecruiting\n\nUnidade Local de Saude de Braga - Hospital de Braga ( Site 2306)\n\nContact : \n\nStudy Coordinator\n\n+351253 027 249\n\n**Porto, Portugal, 4200-072**\n\nRecruiting\n\nInstituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 2302)\n\nContact : \n\nStudy Coordinator\n\n+351 22 508 4000\n\nPuerto Rico\n\n**Mayagüez, Puerto Rico, 00682**\n\nRecruiting\n\nBRCR Global - Mayaguez ( Site 1003)\n\nContact : \n\nStudy Coordinator\n\n1 561 437 6038\n\n**San Juan, Puerto Rico, 00918**\n\nRecruiting\n\nAuxilio Mutuo Cancer Center ( Site 1001)\n\nContact : \n\nStudy Coordinator\n\n787 758 2000\n\nRomania\n\n**Brasov, Romania, 500052**\n\nRecruiting\n\nCentrul de Diagnostic si Tratament Oncologic Brasov ( Site 2402)\n\nContact : \n\nStudy Coordinator\n\n+40268 960\n\n**Sibiu, Romania, 557260**\n\nRecruiting\n\nSpital Judetean Sibiu ( Site 2405)\n\nContact : \n\nStudy Coordinator\n\n+40269215050\n\nBucurești Locations \n\n**Bucharest, București, Romania, 030171**\n\nRecruiting\n\nSpitalul Clinic Colțea ( Site 2401)\n\nContact : \n\nStudy Coordinator\n\n+40213874100\n\nCluj Locations \n\n**Cluj-Napoca, Cluj, Romania, 4003437**\n\nRecruiting\n\nInstitutul Oncologic Cluj ( Site 2404)\n\nContact : \n\nStudy Coordinator\n\n+40264598362\n\nSingapore\n\nCentral Singapore Locations \n\n**Singapore, Central Singapore, Singapore, 119074**\n\nRecruiting\n\nNational University Hospital ( Site 3702)\n\nContact : \n\nStudy Coordinator\n\n6569082222\n\n**Singapore, Central Singapore, Singapore, 168583**\n\nRecruiting\n\nNational Cancer Centre Singapore ( Site 3701)\n\nContact : \n\nStudy Coordinator\n\n6564368000\n\nSouth Africa\n\nGauteng Locations \n\n**Pretoria, Gauteng, South Africa, 0181**\n\nRecruiting\n\nLIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 2506)\n\nContact : \n\nStudy Coordinator\n\n+27 (0)12 346 6701\n\n**Pretoria, Gauteng, South Africa, 0181**\n\nRecruiting\n\nNetcare Pretoria East Hospital ( Site 2502)\n\nContact : \n\nStudy Coordinator\n\n+27129932555\n\nWestern Cape Locations \n\n**Cape Town, Western Cape, South Africa, 7580**\n\nRecruiting\n\nHaemalife ( Site 2501)\n\nContact : \n\nStudy Coordinator\n\n+27 21 900 6277\n\n**Cape Town, Western Cape, South Africa, 7925**\n\nRecruiting\n\nGroote Schuur Hospital ( Site 2504)\n\nContact : \n\nStudy Coordinator\n\n+27214043077\n\nSouth Korea\n\n**Seoul, South Korea, 03722**\n\nCompleted\n\nSeverance Hospital, Yonsei University Health System ( Site 3802)\n\n**Seoul, South Korea, 05505**\n\nRecruiting\n\nAsan Medical Center ( Site 3803)\n\nContact : \n\nStudy Coordinator\n\n+82230105940\n\n**Seoul, South Korea, 06351**\n\nCompleted\n\nSamsung Medical Center ( Site 3807)\n\n**Seoul, South Korea, 07345**\n\nRecruiting\n\nSt.Mary's H., Youido ( Site 3805)\n\nContact : \n\nStudy Coordinator\n\n+82237791049\n\nKyonggi-do Locations \n\n**Goyang-si, Kyonggi-do, South Korea, 10408**\n\nRecruiting\n\nNational Cancer Center- Center for Hemotologic malignancy ( Site 3806)\n\nContact : \n\nStudy Coordinator\n\n8231-920-1505\n\nPusan-Kwangyokshi Locations \n\n**Busan, Pusan-Kwangyokshi, South Korea, 49241**\n\nRecruiting\n\nPusan National University Hospital ( Site 3804)\n\nContact : \n\nStudy Coordinator\n\n+8251-240-7839\n\nTaejon-Kwangyokshi Locations \n\n**Daejeon, Taejon-Kwangyokshi, South Korea, 35015**\n\nRecruiting\n\nChungnam National University Hospital ( Site 3801)\n\nContact : \n\nStudy Coordinator\n\n82422806922\n\nSpain\n\n**Barcelona, Spain, 08003**\n\nRecruiting\n\nHospital del Mar ( Site 2610)\n\nContact : \n\nStudy Coordinator\n\n34932483343\n\n**Madrid, Spain, 28041**\n\nRecruiting\n\nHospital General Universitario 12 de Octubre ( Site 2605)\n\nContact : \n\nStudy Coordinator\n\n+34605532453\n\n**Madrid, Spain, 28046**\n\nRecruiting\n\nHospital Universitario La Paz ( Site 2611)\n\nContact : \n\nStudy Coordinator\n\n34912071518\n\n**Málaga, Spain, 29010**\n\nRecruiting\n\nHospital Virgen de la Victoria ( Site 2609)\n\nContact : \n\nStudy Coordinator\n\n0034951032508\n\n**Zaragoza, Spain, 50009**\n\nRecruiting\n\nHospital Universitario Miguel Servet ( Site 2607)\n\nContact : \n\nStudy Coordinator\n\n34976765500\n\nAndalusia Locations \n\n**Seville, Andalusia, Spain, 41009**\n\nRecruiting\n\nHospital Universitario Virgen Macarena ( Site 2608)\n\nContact : \n\nStudy Coordinator\n\n34955054993\n\nBarcelona Locations \n\n**L'Hospitalet de Llobregat, Barcelona, Spain, 08908**\n\nRecruiting\n\nICO L Hospitalet ( Site 2601)\n\nContact : \n\nStudy Coordinator\n\n932607750\n\nLas Palmas Locations \n\n**Las Palmas de Gran Canaria, Las Palmas, Spain, 35016**\n\nRecruiting\n\nH. Insular de Gran Canaria ( Site 2606)\n\nContact : \n\nStudy Coordinator\n\n0034928441738\n\nValenciana, Comunitat Locations \n\n**Alicante, Valenciana, Comunitat, Spain, 03010**\n\nRecruiting\n\nHospital General Universitario Dr. Balmis ( Site 2604)\n\nContact : \n\nStudy Coordinator\n\n34965913727\n\nSwitzerland\n\nCanton of Aargau Locations \n\n**Baden, Canton of Aargau, Switzerland, 5404**\n\nRecruiting\n\nKantonspital Baden ( Site 2703)\n\nContact : \n\nStudy Coordinator\n\n0041564862111\n\nCanton of St. Gallen Locations \n\n**Sankt Gallen, Canton of St. Gallen, Switzerland, 9000**\n\nRecruiting\n\nCantonal Hospital St.Gallen-Oncology & Hematology ( Site 2702)\n\nContact : \n\nStudy Coordinator\n\n41714941111\n\nCanton Ticino Locations \n\n**Bellinzona, Canton Ticino, Switzerland, 6501**\n\nRecruiting\n\nOspedale Regionale Bellinzona e Valli ( Site 2701)\n\nContact : \n\nStudy Coordinator\n\n1-888-577-8839\n\n**Lugano, Canton Ticino, Switzerland, 6900**\n\nRecruiting\n\nOspedale Italiano Lugano (OIL) ( Site 2705)\n\nContact : \n\nStudy Coordinator\n\n0041918118612\n\nTaiwan\n\n**Kaohsiung City, Taiwan, 83301**\n\nRecruiting\n\nChang Gung Memorial Hospital at Kaohsiung ( Site 3905)\n\nContact : \n\nStudy Coordinator\n\n886-7-7317123\n\n**Tainan, Taiwan, 704**\n\nRecruiting\n\nNational Cheng Kung University Hospital ( Site 3902)\n\nContact : \n\nStudy Coordinator\n\n+88662353535x4620\n\n**Taipei, Taiwan, 10002**\n\nRecruiting\n\nNational Taiwan University Hospital ( Site 3901)\n\nContact : \n\nStudy Coordinator\n\n+88623123456\n\n**Taipei, Taiwan, 10449**\n\nRecruiting\n\nMackay Memorial Hospital ( Site 3908)\n\nContact : \n\nStudy Coordinator\n\n+886225433535\n\n**Taipei, Taiwan, 114**\n\nRecruiting\n\nTri-Service General Hospital ( Site 3906)\n\nContact : \n\nStudy Coordinator\n\n+886287927208x12903\n\nTaoyuan Locations \n\n**Taoyuan, Taoyuan, Taiwan, 333**\n\nRecruiting\n\nChang Gung Memorial Hospital - Linkou Branch ( Site 3903)\n\nContact : \n\nStudy Coordinator\n\n+88633281200x2555\n\nThailand\n\nBangkok Locations \n\n**Bangkoknoi, Bangkok, Thailand, 10700**\n\nRecruiting\n\nFaculty of Medicine Siriraj Hospital ( Site 4001)\n\nContact : \n\nStudy Coordinator\n\n+6624194448\n\n**Pathumwan, Bangkok, Thailand, 10330**\n\nRecruiting\n\nChulalongkorn University ( Site 4003)\n\nContact : \n\nStudy Coordinator\n\n+6622564000\n\nChiang Mai Locations \n\n**Muang, Chiang Mai, Thailand, 50200**\n\nRecruiting\n\nMaharaj Nakorn Chiang Mai Hospital ( Site 4002)\n\nContact : \n\nStudy Coordinator\n\n+6653935488\n\nTurkey (Türkiye)\n\n**Adana, Turkey (Türkiye), 01120**\n\nRecruiting\n\nBaskent Universitesi Adana Dr. Turgut Noyan UAM ( Site 2809)\n\nContact : \n\nStudy Coordinator\n\n+90 322 344 44 44\n\n**Ankara, Turkey (Türkiye), 06200**\n\nRecruiting\n\nDr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 2803)\n\nContact : \n\nStudy Coordinator\n\n+90 (0312) 336 09 09\n\n**Ankara, Turkey (Türkiye), 06230**\n\nRecruiting\n\nHacettepe Universite Hastaneleri ( Site 2810)\n\nContact : \n\nStudy Coordinator\n\n05322276104\n\n**Ankara, Turkey (Türkiye), 06620**\n\nRecruiting\n\nAnkara University Faculty of Medicine ( Site 2801)\n\nContact : \n\nStudy Coordinator\n\n+903125956593\n\n**Antalya, Turkey (Türkiye), 7100**\n\nRecruiting\n\nAntalya Egitim ve Arastirma Hastanesi ( Site 2805)\n\nContact : \n\nStudy Coordinator\n\n0090 505 765 6778\n\n**Istanbul, Turkey (Türkiye), 34722**\n\nRecruiting\n\nGöztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi ( Site 2804)\n\nContact : \n\nStudy Coordinator\n\n0090 532 408 9525\n\nSamsun Locations \n\n**Korfez Mahallesi, Samsun, Turkey (Türkiye), 55270**\n\nRecruiting\n\nOndokuz Mayıs Universitesi ( Site 2806)\n\nContact : \n\nStudy Coordinator\n\n+905052722289\n\nTekirdas Locations \n\n**Suleymanpasa, Tekirdas, Turkey (Türkiye), 59030**\n\nRecruiting\n\nNamık Kemal University Medical Faculty ( Site 2807)\n\nContact : \n\nStudy Coordinator\n\n+905326347632\n\nUkraine\n\n**Kyiv, Ukraine, 03022**\n\nRecruiting\n\nSNPE National Cancer Institute ( Site 2902)\n\nContact : \n\nStudy Coordinator\n\n380443346418\n\n**Kyiv, Ukraine, 03057**\n\nRecruiting\n\nUniversal Clinic Oberig ( Site 2908)\n\nContact : \n\nStudy Coordinator\n\n+380445213003\n\n**Kyiv, Ukraine, 03115**\n\nRecruiting\n\nSI National Research Center of Radiation Medicine, Hematology, Oncology ( Site 2901)\n\nContact : \n\nStudy Coordinator\n\n+38 044 4502329\n\n**Kyiv, Ukraine, 04112**\n\nRecruiting\n\nPublic Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co ( Site 2905)\n\nContact : \n\nStudy Coordinator\n\n+38 044 4671989\n\nCherkasy Oblast Locations \n\n**Cherkasy, Cherkasy Oblast, Ukraine, 18009**\n\nRecruiting\n\nMNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2904)\n\nContact : \n\nStudy Coordinator\n\n+38 047 2370025\n\nIvano-Frankivsk Oblast Locations \n\n**Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine, 76008**\n\nRecruiting\n\nCommunal non-profit enterprise \"Regional clinical hospital of Ivano-Frankivsk Regional Council\" ( Site 2906)\n\nContact : \n\nStudy Coordinator\n\n+380342 528029\n\nKhmelnytskyi Oblast Locations \n\n**Khmelnytskiy, Khmelnytskyi Oblast, Ukraine, 29000**\n\nRecruiting\n\nKhmelnytskyi Regional Hospital ( Site 2907)\n\nContact : \n\nStudy Coordinator\n\n+380382649001\n\nLviv Oblast Locations \n\n**Lviv, Lviv Oblast, Ukraine, 79057**\n\nRecruiting\n\nInstitute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2903)\n\nContact : \n\nStudy Coordinator\n\n+380322373917\n\nClick to view interactive map\n\nParticipation Criteria\n----------------------\n\nResearchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.\n\n For general information about clinical research, read [Learn About Studies(https://clinicaltrials.gov/study-basics/learn-about-studies)](https://clinicaltrials.gov/study-basics/learn-about-studies).\n\nEligibility Criteria\n\nDescription\n\nInclusion Criteria:\n\n*   Has histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL), by prior biopsy, based on local testing according to the WHO classification of neoplasms of the hematopoietic and lymphoid tissues\n*   Has positron emission tomography (PET) positive disease at screening, defined as 4 to 5 on the Lugano 5-point scale\n*   Has received no prior treatment for their DLBCL\n*   Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 assessed within 7 days before randomization\n*   Has an ejection fraction ≥45% as determined by either echocardiogram (ECHO) or multigated acquisition (MUGA)\n*   Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART)\n*   Who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load prior to randomization\n*   Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n\nExclusion Criteria:\n\n*   Has a history of transformation of indolent disease to DLBCL\n*   Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) or Grey zone lymphoma\n*   Has Ann Arbor Stage I DLBCL\n*   Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), or serious cardiac arrhythmia requiring medication\n*   Has clinically significant pericardial or pleural effusion\n*   Has ongoing Grade >1 peripheral neuropathy\n*   Has a demyelinating form of Charcot-Marie-Tooth disease\n*   HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease\n*   Has ongoing corticosteroid therapy\n*   Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed\n*   Known additional malignancy that is progressing or has required active treatment within the past 2 years\n*   Known active central nervous system (CNS) lymphoma\n*   Has active autoimmune disease that has required systemic treatment in the past 2 years\n*   Has active infection requiring systemic therapy\n*   Has concurrent active HBV (defined as HBsAg positive and detectable HBV DNA) and HCV (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid (RNA)) infection\n*   Has history of allogeneic tissue/solid organ transplant\n\nAges Eligible for Study \n\n18 Years and older (Adult,Older Adult) \n\nSexes Eligible for Study \n\nAll\n\nAccepts Healthy Volunteers \n\nNo\n\nStudy Plan\n----------\n\nThis section provides details of the study plan, including how the study is designed and what the study is measuring.\n\nExpand all / Collapse all\n\n How is the study designed? \n\nDesign Details\n\n**Primary Purpose  :**Treatment\n\n**Allocation  :**Non-Randomized\n\n**Interventional Model  :**Parallel Assignment\n\n**Masking  :**None (Open Label)\n\nArms and Interventions\n\n| Participant Group/Arm | Intervention/Treatment |\n| --- | --- |\n| Participant Group/Arm | Experimental: Zilovertamab vedotin + Rituximab + Cyclophosphamide, Doxorubicin, Prednisone (R-CHP) Participants receive a dose of zilovertamab vedotin (1.75 mg/kg) plus 750 mg/m^2 cyclophosphamide, 50 mg/m^2 doxorubicin, and 375 mg/m^2 rituximab or rituximab biosimilar administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months) plus 2 cycles of rituximab or biosimilar for participants with high risk DLBCL. Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). | Intervention/Treatment | Biological: Zilovertamab vedotin * IV infusion * Other Names: * MK-2140 * VLS-101 Biological: Rituximab * IV infusion * Other Names: * RITUXAN® Drug: Cyclophosphamide * IV infusion * Other Names: * CYTOXAN® * NEOSAR® Drug: Doxorubicin * IV infusion * Other Names: * ADRIAMYCIN® Biological: Rituximab Biosimilar * IV infusion * Other Names: * TRUXIMA® * RUXIENCE® * RIABNI® Drug: Prednisone * Per Approved Product Label Drug: Prednisolone * Oral administration Drug: Rescue medication * Participants receive rescue medication at the investigator's discretion, per approved product label. The recommended rescue medication is granulocyte colony-stimulating factor (G-CSF). |\n| Participant Group/Arm | Active Comparator: Rituximab + Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) Participants receive 750 mg/m^2 cyclophosphamide, 50 mg/m^2 doxorubicin, and 375 mg/m^2 rituximab or rituximab biosimilar, 1.4 mg/m^2 vincristine administered by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 6 cycles (up to approximately 4 months) plus 2 cycles of rituximab or biosimilar for participants with high risk DLBCL. Participants also receive 100 mg prednisone or prednisolone via oral tablet per day during Days 1-5 of each 21-day cycle for up to 6 cycles (up to approximately 4 months). | Intervention/Treatment | Biological: Rituximab * IV infusion * Other Names: * RITUXAN® Drug: Cyclophosphamide * IV infusion * Other Names: * CYTOXAN® * NEOSAR® Drug: Doxorubicin * IV infusion * Other Names: * ADRIAMYCIN® Biological: Rituximab Biosimilar * IV infusion * Other Names: * TRUXIMA® * RUXIENCE® * RIABNI® Drug: Prednisone * Per Approved Product Label Drug: Prednisolone * Oral administration Drug: Vincristine * IV infusion |\n\n What is the study measuring? \n\n Primary Outcome Measures \n\n| Outcome Measure | Measure Description | Time Frame |\n| --- | --- | --- |\n| Progression-free survival (PFS) | PFS is defined as the time from randomization to the first documented disease progression per Lugano response criteria by blinded independent central review (BICR) or death due to any cause, whichever occurs first. | Up to ~ 50 months |\n\n Secondary Outcome Measures \n\n| Outcome Measure | Measure Description | Time Frame |\n| --- | --- | --- |\n| Complete Response at End of Treatment (CR at EOT) | CR at EOT is defined as a CR per Lugano response criteria as assessed by BICR at end of treatment. Participants with missing data or who discontinue treatment or study prior to reaching EOT will be considered non-responders and included in the total number of participants. | Up to ~ 32 months |\n| Overall Survival (OS) | OS is defined as the time from randomization to death due to any cause. | Up to ~ 74 months |\n| Event-free Survival (EFS) | EFS is defined as the time from randomization to any of the following events: progressive disease that precludes surgery, local or distant recurrence, second primary malignancy or death due to any cause. The EFS for all participants will be presented. | Up to ~ 74 months |\n| Duration of Complete Response (DurCR) | For participants who demonstrate CR at EOT per Lugano response criteria by BICR, duration of complete response is defined as the time from the first documented evidence of CR at or before EOT until disease progression or death due to any cause, whichever occurs first. | Up to ~ 74 months |\n| Number of Participants Who Experience an Adverse Event (AE) | An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience at least one AE will be presented. | Up to ~ 9 months |\n| Number of Participants Who Discontinue Study Treatment Due to an AE | An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented. | Up to ~ 6 months |\n| Change From Baseline in Health-Related Quality Of Life (HRQoL) on Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Trial Outcome Index (TOI) Score | The FACT-Lym is a 42-item questionnaire designed to measure HRQoL and cancer-specific symptoms in non-Hodgkin lymphoma patients. Subscales include FACT-General (FACT-G), FACT-Trial Outcome Index (FACT-TOI), FACT-Lym total score (FACT-Lym TS), and the Lymphoma subscale (Lym S). The Lym S has a single domain consisting of 15 items specific to lymphoma burden with a score ranging from 0 to 60. FACT-G has 4 well-being domains, physical (7 items), social/family (7), emotional (6), and functional (7), with scores ranging from 0 to 108. FACT-TOI combines FACT-G's physical and functional domains with Lym S, with scores ranging from 0 to 116. FACT-Lym TS combines FACT-G with Lym S, with scores ranging from 0 to 168. The scoring of FACT-Lym is on a 5-point Likert scale from 0 to 4, with 0= not at all, 1= a little bit, 2= somewhat, 3=quite a bit, 4=very much. The higher the score the better the quality of life. | Baseline and Week 25 |\n| Change From Baseline in HRQoL on FACT-Lym Total Score | The FACT-Lym is a 42-item questionnaire designed to measure HRQoL and cancer-specific symptoms in non-Hodgkin lymphoma patients. Subscales include FACT-General (FACT-G), FACT-Trial Outcome Index (FACT-TOI), FACT-Lym total score (FACT-Lym TS), and the Lymphoma subscale (Lym S). The Lym S has a single domain consisting of 15 items specific to lymphoma burden with a score ranging from 0 to 60. FACT-G has 4 well-being domains, physical (7 items), social/family (7), emotional (6), and functional (7), with scores ranging from 0 to 108. FACT-TOI combines FACT-G's physical and functional domains with Lym S, with scores ranging from 0 to 116. FACT-Lym TS combines FACT-G with Lym S, with scores ranging from 0 to 168. The scoring of FACT-Lym is on a 5-point Likert scale from 0 to 4, with 0= not at all, 1= a little bit, 2= somewhat, 3=quite a bit, 4=very much. The higher the score the better the quality of life. | Baseline and Week 25 |\n| Change From Baseline in HRQoL on FACT-Lym Physical Wellbeing (PWB) Score | The FACT-Lym is a 42-item questionnaire designed to measure HRQoL and cancer-specific symptoms in non-Hodgkin lymphoma patients. Subscales include FACT-General (FACT-G), FACT-Trial Outcome Index (FACT-TOI), FACT-Lym total score (FACT-Lym TS), and the Lymphoma subscale (Lym S). The Lym S has a single domain consisting of 15 items specific to lymphoma burden with a score ranging from 0 to 60. FACT-G has 4 well-being domains, physical (7 items), social/family (7), emotional (6), and functional (7), with scores ranging from 0 to 108. FACT-TOI combines FACT-G's physical and functional domains with Lym S, with scores ranging from 0 to 116. FACT-Lym TS combines FACT-G with Lym S, with scores ranging from 0 to 168. The scoring of FACT-Lym is on a 5-point Likert scale from 0 to 4, with 0= not at all, 1= a little bit, 2= somewhat, 3=quite a bit, 4=very much. The higher the score the better the quality of life. | Baseline and Week 25 |\n| Change From Baseline in HRQoL on Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) Neurotoxicity Subscale Score | The FACT GOG-NTX provides a targeted assessment of symptoms of peripheral neuropathy, including sensory, motor, and auditory problems and cold sensitivity. It is an 11-item questionnaire designed to measure the neurotoxicity subscale. The scoring of FACT GOG-NTX is on a 5-point Likert scale from 0 to 4, with 0= not at all, 1= a little bit, 2= somewhat, 3=quite a bit, 4=very much. To produce a Neurotoxicity Subscale score (range 0-44), multiply the sum of the item scores by the number of items in the subscale, then divide by the number of items answered. | Baseline and Week 25 |\n\nCollaborators and Investigators\n-------------------------------\n\nThis is where you will find people and organizations involved with this study. \n\nSponsor \n\nMerck Sharp & Dohme LLC\n\nInvestigators \n\n*   Study Director:Medical Director,Merck Sharp & Dohme LLC \n\nStudy Record Dates\n------------------\n\n These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website. \n\nMore Information\n----------------\n\n[Record History](https://clinicaltrials.gov/#)\n\nExpand all / Collapse all\n\nTerms related to this study\n---------------------------\n\n Keywords Provided by Merck Sharp & Dohme LLC\n\nLymphoma, Large B-Cell, Diffuse \n\nAdditional Relevant MeSH Terms\n\nLymphoma, B-Cell \n\nLymphoma, Non-Hodgkin \n\nLymphoma \n\nNeoplasms by Histologic Type \n\nNeoplasms \n\nLymphoproliferative Disorders \n\nLymphatic Diseases \n\nHemic and Lymphatic Diseases \n\nImmunoproliferative Disorders \n\nImmune System Diseases \n\nLymphoma, Large B-Cell, Diffuse \n\nAntibodies, Monoclonal, Murine-Derived \n\nAntibodies, Monoclonal \n\nAntibodies \n\nImmunoglobulins \n\nImmunoproteins \n\nBlood Proteins \n\nProteins \n\nAmino Acids, Peptides, and Proteins \n\nSerum Globulins \n\nGlobulins \n\nPhosphoramide Mustards \n\nNitrogen Mustard Compounds \n\nMustard Compounds \n\nHydrocarbons, Halogenated \n\nHydrocarbons \n\nOrganic Chemicals \n\nPhosphoramides \n\nOrganophosphorus Compounds \n\nDaunorubicin \n\nAnthracyclines \n\nNaphthacenes \n\nPolycyclic Aromatic Hydrocarbons \n\nHydrocarbons, Aromatic \n\nHydrocarbons, Cyclic \n\nPolycyclic Compounds \n\nAminoglycosides \n\nGlycosides \n\nCarbohydrates \n\nPregnadienediols \n\nPregnadienes \n\nPregnanes \n\nSteroids \n\nFused-Ring Compounds \n\nPregnadienetriols \n\nVinca Alkaloids \n\nSecologanin Tryptamine Alkaloids \n\nIndole Alkaloids \n\nAlkaloids \n\nHeterocyclic Compounds \n\nIndoles \n\nHeterocyclic Compounds, 2-Ring \n\nHeterocyclic Compounds, Fused-Ring \n\nIndolizidines \n\nIndolizines \n\nRituximab \n\nCyclophosphamide \n\nDoxorubicin \n\nPrednisone \n\nPrednisolone \n\nVincristine \n\nPlan for Individual Participant Data (IPD)\n------------------------------------------\n\nPlan to Share Individual Participant Data (IPD)?\n\nYes\n\nIPD Plan Description\n\nhttps://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf\n\nIPD Sharing Url\n\n[https://externaldatasharing-msd.com/](https://externaldatasharing-msd.com/ \"https://externaldatasharing-msd.com/ (opens in a new tab)\")(https://externaldatasharing-msd.com/)\n\nDrug and device information, study documents, and helpful links\n---------------------------------------------------------------\n\nStudies a U.S. FDA-Regulated Drug Product\n\nYes\n\nStudies a U.S. FDA-Regulated Device Product\n\nNo\n\nHelpful Links Provided by Merck Sharp & Dohme LLC\n\n[Merck Clinical Trials Information](https://www.merckclinicaltrials.com/ \"Merck Clinical Trials Information (opens in a new tab)\")(https://www.merckclinicaltrials.com/)\n\nAbout\n\n[About ClinicalTrials.gov](https://clinicaltrials.gov/about-site/about-ctg \"About ClinicalTrials.gov (opens in a new tab)\")\n\n[Release Notes](https://clinicaltrials.gov/about-site/release-notes \"Release Notes (opens in a new tab)\")\n\n[Site Map](https://clinicaltrials.gov/site-map \"Site Map (opens in a new tab)\")\n\nHelp\n\n[Give us feedback](https://nlmenterprise.co1.qualtrics.com/jfe/form/SV_5iL6W3r2A7vY52R?ncbi_app=ctgov2&CurrentPage=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06717347)\n\n[Glossary](https://clinicaltrials.gov/study-basics/glossary \"Glossary (opens in a new tab)\")\n\n[Customer Support](https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01242&category=clinicaltrials.gov&hd_url=https%3A%2F%2Fclinicaltrials.gov)\n\nLegal\n\n[Disclaimer](https://clinicaltrials.gov/about-site/disclaimer \"Disclaimer (opens in a new tab)\")\n\n[Terms and Conditions](https://clinicaltrials.gov/about-site/terms-conditions \"Terms and Conditions (opens in a new tab)\")\n\nAbout\n\n*   [About ClinicalTrials.gov](https://clinicaltrials.gov/about-site/about-ctg)\n*   [Release Notes](https://clinicaltrials.gov/about-site/release-notes)\n*   [Site Map](https://clinicaltrials.gov/site-map)\n\nHelp\n\n*   [Give us feedback](https://nlmenterprise.co1.qualtrics.com/jfe/form/SV_5iL6W3r2A7vY52R?ncbi_app=ctgov2&CurrentPage=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06717347)\n*   [Glossary](https://clinicaltrials.gov/study-basics/glossary)\n*   [Customer Support](https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01242&category=clinicaltrials.gov&hd_url=https%3A%2F%2Fclinicaltrials.gov)\n\nLegal\n\n*   [Disclaimer](https://clinicaltrials.gov/about-site/disclaimer)\n*   [Terms and Conditions](https://clinicaltrials.gov/about-site/terms-conditions)\n\n![Image 9: ClinicalTrials.gov logo](https://clinicaltrials.gov/assets/images/ctg-footer-logo.svg)\n\n National Library of Medicine\n\n 8600 Rockville Pike, Bethesda, MD 20894 \n\n[![Image 10: NIH National Library of Medicine, National Center for Biotechnology Information (opens in a new tab)](https://clinicaltrials.gov/assets/main/img/AgencyLogo.svg)](https://ncbi.nlm.nih.gov/ \"NIH National Library of Medicine, National Center for Biotechnology Information (opens in a new tab)\")\n\nClinicalTrials.gov\n\nAn official website of the [U.S. Department of Health and Human Services](https://www.hhs.gov/ \"U.S. Department of Health and Human Services (opens in a new tab)\")(https://www.hhs.gov), [National Institutes of Health](https://www.nih.gov/ \"National Institutes of Health (opens in a new tab)\")(https://www.nih.gov), [National Library of Medicine](https://www.nlm.nih.gov/ \"National Library of Medicine (opens in a new tab)\")(https://www.nlm.nih.gov), and [National Center for Biotechnology Information](https://www.ncbi.nlm.nih.gov/ \"National Center for Biotechnology Information (opens in a new tab)\")(https://www.ncbi.nlm.nih.gov).\n\n*   [About HHS](https://www.hhs.gov/about/index.html \"About HHS (opens in a new tab)\")\n*   [About NIH](https://www.nih.gov/about-nih \"About NIH (opens in a new tab)\")\n*   [About NLM](https://www.nlm.nih.gov/about \"About NLM (opens in a new tab)\")\n*   [About NCBI](https://www.ncbi.nlm.nih.gov/home/about \"About NCBI (opens in a new tab)\")\n*   [Accessibility support](https://www.nlm.nih.gov/accessibility.html \"Accessibility support (opens in a new tab)\")\n*   [FOIA requests](https://www.nih.gov/icd/od/foia/index.htm \"FOIA requests (opens in a new tab)\")\n*   [No FEAR Act data](https://www.edi.nih.gov/no-fear-act \"No FEAR Act data (opens in a new tab)\")\n*   [Office of the Inspector General](https://oig.hhs.gov/ \"Office of the Inspector General (opens in a new tab)\")\n*   [Privacy policy](https://www.nlm.nih.gov/privacy.html \"Privacy policy (opens in a new tab)\")\n*   [HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html \"HHS Vulnerability Disclosure (opens in a new tab)\")\n\nLooking for U.S. government information and services?\n\n[Visit USA.gov](https://www.usa.gov/ \"Visit USA.gov (opens in a new tab)\")(https://www.usa.gov/)\n\nRevision: v3.3.4\n\n![Image 11: Tell us what you think!](https://iad1.qualtrics.com/WRQualtricsSiteIntercept/Graphic.php?IM=IM_3xWqwNkIHc7cA0S)\n\n![Image 12: Close](https://siteintercept.qualtrics.com/WRQualtricsShared/Graphics/siteintercept/wr-dialog-close-btn-black.png)"
        }
      ]
    }
  }
}